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1 Introduction 
 
1.1 The Family of the STAT Transcription Factors 
Over 50 years ago, interferon has been described as a founder of the cytokine 
family [1]. In 1990, the first signal transducer and activator of transcription (STAT) 
protein was discovered in the course of research on interferon (IFN) signal 
transduction. The stimulation with IFN-alpha/beta resulted in the formation of a 
complex of transcription factors also known as ISGF-3 [2, 3], which consists of 
STAT1, STAT2 and IRF9, formerly termed p48 [4]. Subsequently, five more 
STAT proteins have been identified. So far, the STAT protein family consists of 
seven family members namely STAT1, STAT2, STAT3, STAT4, STAT5A and 5B, 
and STAT6 [5, 6]. Moreover, up to 11 additional splicing isoforms have been 
discovered, but a physiologic function is still unclear [7-9]. The STAT factors 
range in size from 750 – 900 amino acids and contain six conserved domains 
[10]. 
STATs Ligands Phenotype of STAT deficient mice 
STAT1 IFN-α/β/γ, EGF Loss of IFN-dependent immune response 
Increased susceptibility for bacterial and viral 
infections 
STAT2 IFN-α/β Defect in type-I-IFN dependent immune 
response 
STAT3 IL-2, IL-6, IL-7, IL-9, IL-10, IL-
11, IL-15, IL-19, IL-20  IL-21, IL-
23, IL-27, IL-31, EGF, HGF, 
OSM, CNTF, CT-1, Leptin, G-
CSF, TPO, LIF, FLT3L 
Embryonic lethality 
 
STAT4 IL-12, IL-23 Defect in TH1 cell-differentiation 
STAT5A and 
STAT5B 
IL-2, IL-3, IL-5, IL-7, IL-9, IL-15, 
G-CSF, GM-CSF, EPO, TPO, 
GH, Prolactin, OSM 
Infertility 
Defect in NK-cell development  
Defect in T-cell proliferation 
Impaired hematopoiesis 
Defect in development of mammary glands 
and lactation 
STAT6 IL-4, IL-13 Impaired differentiation of TH2 cells 
 
 
Studies with genetically manipulated mice, lacking one or more Stat genes, have 
shown a relevance of STAT factors in fundamental cellular processes such as 
proliferation, differentiation, apoptosis, and inflammation [11-13] (Table 1). 
Activation of the STAT signal transduction is a result of cytokine- or  growth 
factor- binding at their specific receptors such as cytokine receptors (i.e. IL-
Table 1: STATs are activated by the listed ligands. Genetic knock-out of STAT factors results in 
described phenotype (modified from [6, 9, 12, 13]). 
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6Rα/gp130, OSMR), receptor tyrosine kinases (i.e. EGFR, PDGFR) and G-
protein coupled receptors (i.e. S1P receptor) [14-17]. Ligand binding to the 
receptor leads to the activation of receptor associated kinases such as the Janus 
kinases (JAKs) [18], intrinsic receptor tyrosine kinases [14-16], or Src family 
kinases (SFKs) [19] which is followed by the phosphorylation of specific tyrosine 
motives at a cytoplasmic receptor domain. The phosphorylated receptor 
complexes direct SH-2-dependent recruitment of STAT proteins resulting in 
phosphorylation of a single tyrosine residue. Non-receptor tyrosine kinases such 
as the oncoproteins v-Src and BCR-Abl are able to phosphorylate STAT factors 
independently of receptors [20, 21]. The phosphorylated STAT factors dimerize 
through intermolecular SH2 domain/phosphotyrosine interactions resulting in 
nuclear translocation and DNA-binding to promote target gene induction [22-24]. 
Nuclear translocation has been described as a diffusion-driven process as well as 
a process in which STAT factors are associated with endocytotic vesicles [25]. 
Especially STAT3 has been shown to be activated by cytokine or growth factor 
receptors that were internalized upon ligand binding and continued signaling 
along the endocytotic pathway [26]. 
While STAT activation is usually transient and tightly regulated, persistent 
activation of cytokine receptors, receptor tyrosine kinases and non-receptor 
tyrosine kinases in cancer cells leads to a constitutive activation of STAT 
molecules, particularly of STAT3 and STAT5. Constitutive STAT activity results in 
an enduring change of gene expression [27]. 
Posttranslational modifications besides the tyrosine phosphorylation critical for 
activation have been characterized including serine phosphorylations which are 
important for an improved gene induction (Ser727 in STAT1 and STAT3; Ser721 
in STAT4; Ser725 in STAT5A; Ser730 in STAT5B) [28]. Moreover, modifications 
such as acetylation of STAT3 at lysine 685 [29] and STAT6 [30], methylation at 
arginine residues [31], ubiquitination [32], and sumoylation [33] have been 
described.  
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1.1.1 Function of STAT3. 
STAT3 was initially identified as an IL-6 dependent acute phase response factor 
(APRF) that binds to enhancer elements in the promoter of acute phase genes 
upon interleukin-6 (IL-6) stimulation in hepatocytes [34].  
Unlike other STAT factors, STAT3 knock-out revealed early embryonic lethality 
and therefore shows the most serious phenotype. STAT3 deficient murine 
embryos died before gastrulation, of about 6.5 – 7.5 days post coitum [35]. 
STAT3 knock-out by conditional gene ablation revealed severe defects in 
targeted tissues. Affected functions upon loss of STAT3 involve impaired acute 
phase response (liver), migration (keratinocytes), survival (thymic epithelium, 
sensory-/moto-neurons, and T-lymphocytes), proliferation (T-lymphocytes) and 
apoptosis (mammary epithelium) [36-40] (Table 2).   
 
STAT3 deficient tissue Phenotype 
Keratinocytes Defect wound healing by impaired migration of keratinocytes 
impaired hair cycle  
Thymic epithelium Hypersensitivity to stress 
Age-dependent thymic hypoplasia 
Mammary epithelium Impaired involution due to defect apoptosis of epithelial cells 
Impaired activation of mammary macrophages and number of mast 
cells during involution 
Liver Impaired acute-phase response 
Lung Impaired homeostasis 
Increased inflammation 
Fibroblasts IL-6 mediated IFN-γ-like response by extended STAT1 activity 
T lymphocytes Impaired IL-6 dependent survival 
Impaired IL-2Rα expression 
Defect TH17 cell-development 
Monocytes/Neutrophils Enhanced Th1 differentiation  and activity 
Increased inflammatory response 
Development of chronic colitis 
Granulocytes Enhanced proliferation due to impaired negative feeedback 
Impaired acute neutrophil mobilization 
Neurons Enhanced neuronal apoptosis 
Astrocytes Impaired astrocyte hypertrophy 
Defect inflammatory response 
 
 
 
So far, 4 isoforms of STAT3 have been identified (STAT3α, β, γ, δ). STAT3β (82 
kDa) is a splicing variant of STAT3α ( 89 kDa). It is C-terminally truncated by 55 
amino acids, which are replaced by 7 unique amino acids (FIDAVWK). Thus, 
STAT3β lacks the transactivation domain which implies no role in gene 
Table 2: Role of STAT3 in different tissues revealed by conditional gene silencing in mice. 
(modified from [36-40]). 
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expression, and therefore reveals dominant negative potential [41]. However, 
recent studies using specific gene ablation of either STAT3α or STAT3β indicated 
that STAT3β can rescue embryonic lethality induced by lack of STAT3α [42]. 
Moreover, STAT3β seems to be an important negative regulator of STAT3α by 
induction of specific target genes related to acute phase response [43, 44]. 
STAT3γ (72 kDa) and STAT3δ (64 kDa) are proteolytically truncated at the 
carboxy-terminus of STAT3α. So far, no function has been described for these 
isoforms [7, 45]. 
Mutations in one of the STAT3 alleles, which had dominant-negative effects, 
have been described in the context of the IgE-syndrome. The mutations were 
mainly located in the SH2-domain and the DNA binding domain [46]. 
1.1.2 The IL-6/gp130/STAT3 signaling pathway. 
The IL-6-type cytokines interleukin-6 (IL-6), oncostatin M (OSM), leukemia 
inhibitory factor (LIF), IL-11, IL-27, cardiotrophin-1 (CT-1), Neuropoietin, ciliary 
neutrophic factor (CNTF) and cardiotrophin-like cytokine (CLC) are polypeptides 
of about 15 – 25 kDa that form a subfamily of the helix bundle cytokines 
consisting of four α-helices. IL-6-type cytokines feature pleiotropic functions and 
stimulate cells in an autocrine or paracrine manner [24, 47-49]. All these 
cytokines signal through the transmembrane protein gp130 (glycoprotein 130), 
whereby gp130 forms either homodimers or heterodimers with LIF-R, OSM-R or 
WSX-1. IL-6, IL-11, CT-1 and CNTF recruit additional specific α-receptors [23]. 
In the event of the IL-6/gp130/STAT3 signaling pathway, IL-6 binds to IL-6Rα 
resulting in the recruitment of gp130. The extracellular part of the IL-6Rα consists 
of three domains, whereby an Ig-like domain (D1) is followed by two FNIII 
(fibronectin type III)-like domains (D2, D3) which form the cytokine binding 
module (CBM). The extracellular part of gp130 consists of six domains (D1 – D6). 
Domain D1 represents an Ig-like domain which is followed by five FNIII domains 
(D2 – D6). The CBM is formed by domains D2 and D3 [50]. 
Binding of IL-6-type cytokines to plasma membrane receptor complexes results in 
the activation of two signaling pathways, the JAK/STAT pathway and the MAPK 
(mitogen-activated protein kinase) cascade [23].  
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Since cytokine receptors lack an intrinsic kinase activity, receptor engagement 
leads to the activation of intracellular, receptor associated Janus kinases (JAK). 
  
                        
 
 
 
 
 
 
The family of Janus kinases comprises JAK1, JAK2, JAK3 and TYK2. Janus 
kinases consist of two kinase domains of which only the carboxy terminus shows 
enzymatic activity [51, 52]. Upon activation JAKs phosphorylate collectively five 
tyrosine residues of the gp130 receptors. Tyrosine phosphorylation results in the 
Figure 1: IL-6/gp130/STAT3 signaling pathway. Stimulation with IL-6 results in the activation 
of an intrinsic signaling cascade, in which receptor associated JAKs phosphorylate the receptor 
resulting in the recruitment of STAT3 to the receptor. Receptor bound STAT3 gets 
phosphorylated by the JAKs which leads to the dissociation of STAT3 from the receptor, 
followed by dimerization and nuclear translocation. In the nucleus, STAT3 promotes gene 
expression upon which dephosphorylated STAT3 leaves the nucleus. Termination can be 
mediated by STAT3 induced SOCS proteins, PIAS or phosphatases. Abbreviations: IL-6-
interleukin-6; gp130-glycoprotein 130; JAK-Janus Kinase; SOCS-suppressor of cytokine 
signaling; PIAS-protein inhibitor of activated STAT; PTPase-protein tyrosine phosphatase. 
(modified from [24, 50]). 
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recruitment of STAT3 which binds with its SH-2-domain (src-homology-2-domain) 
at amino acid motives YXPQ or YXXQ [53-56]. Binding of STAT3 to the receptor 
leads to the phosphorylation at tyrosine 705 by JAKs [3, 57], which is followed by 
the dissociation of STAT3 from the receptor. Phosphorylated tyrosine 705 
interacts with the SH-2 domain of another STAT3 molecule. Dimerized STAT3 
translocates to the nucleus where it binds to enhancer elements of the DNA to 
promote induction of target genes [22, 29, 58]. One of many STAT3 target genes 
is SOCS3 (suppressor of cytokine signaling 3). This negative regulator can bind 
with its SH2 domain at Tyr759 of gp130 and inhibit JAK activity by direct 
interaction [59, 60]. Additional proteins for the negative regulation of IL-
6/gp130/STAT3 signal transduction have been characterized. PIAS (protein 
inhibitors of activated STATs) binds to activated STAT factors and prevents DNA 
binding possibly by recruitment of co-repressor proteins or by modulation of 
STAT functionality through their SUMO ligase activity [61]. Moreover, STAT 
signaling can be regulated by tyrosine phosphatases such as SHP2 and TC-PTP 
which are able to dephosphorylate and inactivate STAT3. Similar to SOCS3, 
SHP2 binds to a phosphotyrosine motif (Tyr759) of the gp130 receptor and is 
able to dephosphorylate JAKs [62, 63]. Furthermore, nuclear translocation of 
STAT3 has been found to be inhibited by Grim-19 [64]. 
The IL-6/gp130/STAT3 signaling pathway is a transient process of about one 
hour (Figure 1). 
1.1.3 Dysregulation of STAT3 signal transduction in tumorigenesis. 
In the early 90s, the importance of STAT3 in oncogenesis was recognized. In 
contrast to benign cells, STAT3 has been found constitutively active in v-Src 
transformed cells [20]. Inhibition of STAT3 signal transduction reversed 
transformation of murine fibroblasts by the v-Src oncoprotein and resulted in 
impaired proliferation or apoptosis [65, 66]. Moreover, a constitutively active 
mutant of STAT3 (STAT3C) transformed murine fibroblasts in culture which 
allowed them to form tumors in mice [67]. Aberrant signaling by STAT3 has been 
detected in a wide variety of human tumor specimens and tumor cell lines 
including multiple myeloma, leukemias, lymphomas, and a variety of solid tumors 
such as, breast, melanoma, head and neck, lung, ovarian, pancreatic and 
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prostate cancer. Besides STAT3, other STAT factors such as STAT1 and STAT5 
have been described to play a role in tumorigenesis as well [68]. 
In the scope of STAT3 several upstream activators have been identified to be 
responsible for aberrant activation of STAT3 in tumor cells such as cytokines [69] 
or growth factor [70, 71]. Constitutive active kinases such as v-Src, TEL-JAK, 
JAK2-V617F, BCR-Abl, v-Abl, NPM-Alk, v-Ros and v-Eyk can function 
independently of extracellular stimuli and persistently phosphorylate STAT3 at 
Tyr705 [27]. Insufficient induction or gene silencing of negative regulators such 
as PIAS3, SOCS proteins or phosphatases like SHP-2 might result in constitutive 
activation of STAT3 as well [72, 73]. In addition, a constitutive phosphorylation of 
STAT3 is mediated by some tumor viruses such as the human-T-lymphotrophic 
virus-1 (HTLV-1) [74], polyomaviruses [75], Epstein-Barr virus (EBV) [76] and 
Herpes virus samiri [77], which activate JAKs or tyrosine kinases of the Src family 
directly or indirectly.  
 
Genes induced by STAT3   
Acute-phase Oncogenesis  
α2-Macroglobuline (α2M) 
Antichymotrypsine (ACT) 
Serum amyloid A (SAA) 
SOCS3 
C-reactive protein (CRP) 
Fibrinogen 
c-myc 
c-fos 
Transformation 
Cyclin D1 
Cyclin D2 
Proliferation 
Bcl-2 
Bcl-xL 
Mcl-1 
Survivin 
p53↓ 
Anti-apoptotic signals 
VEGF 
HIF1α 
FGF2 
Angiogenesis 
MMP2 
MMP9 
Metastasis 
 
 
In contrast to the transient activation of STAT3 in inflammation, signal 
transduction of STAT3 is dysregulated in cancer and results in constitutive 
activation, which is followed by altered regulation of STAT3 target genes. 
While inflammation results in the upregulation of acute phase proteins, 
continuous gene expression of proliferative, angiogenetic, and anti-apoptotic 
proteins is induced in oncogenesis [27]. STAT3 has been shown to contribute to 
the transformation of cells in vitro, the induction of Cyclin D1 and D2 
(proliferation) [78, 79], c-myc (transformation) [80], Bcl-xL, Mcl-1, Survivin (anti-
Table 3: Differences of STAT3 regulated genes in inflammation and oncogenesis.  (modified 
from [27, 58]). 
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apoptotic signals) [81], MMP2, MMP9 (metastasis) [82, 83], VEGF, FGF2 and 
HIF1α (angiogenesis) [84] (Table 3).  
Processes in cancer cells such as uncontrollable proliferation, resistance to 
apoptosis, angiogenesis and metastasis are necessary for the formation and 
progression of tumors. Thereby, tumor cells interact with the microenvironment or 
tumor stroma which consists of the basement membrane, extracellular matrix, 
vasculature, fibroblasts and immune cells. The communication is mediated by the 
expression, secretion and autocrine or paracrine action of soluble factors such as 
cytokines and growth factors. In this context STAT3 plays an important role [85]. 
On the one hand, activated STAT3 promotes proliferation and survival in tumor 
cells. On the other hand, STAT3 drives the production of cytokines and growth 
factors by tumor cells that activate STAT3 in non-transformed cells of the 
microenvironment.  
STAT3 is involved in the tumor induced immunosuppression by induction of 
cytokines. In the presence of IL-6, IL-21 and IL-23, STAT3 promotes the 
differentiation of TH17 cells. In the tumor microenvironment, TH17 cells secrete IL-
17 in a STAT3 dependent manner [86]. IL-17 production results in TH17 cell 
expansion and the activation of STAT3 in other stromal cells, which can further 
enhance tumor growth [87]. The soluble factors IL-6, IL-10 and VEGF stimulate 
STAT3 activation in dendritic cells (DC) which inhibits their maturation and results 
in the inactivation of effector T-cells [85, 88]. Negative regulation of effector T 
cells results in reduced cytotoxicity. Moreover, activated STAT3 favors the 
emergence of regulatory T cells (Treg), which suppress activity of cytotoxic CD8+ 
T cells in the tumor [89, 90].  
It has been shown that STAT1 is involved in the immune evasion regulated by 
STAT3. STAT1 is thought to be a tumor suppressor which counter-regulates 
STAT3. While STAT1 is overexpressed in STAT3 knock-out cells, minor 
expression of STAT1 was observed in cells with constitutive active STAT3. 
Contrary to STAT3, STAT1 is essential in signal transduction upon IFNγ 
stimulation and therefore regulates cell cycle arrest, pro-apoptotic pathways and 
immune surveillance [91]. 
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1.1.4 STAT3 as a target for cancer therapy. 
A limited number of transcription factors are constitutively active in human 
cancers. Since transcription factors play a central role as mediators between 
oncogenic kinases and aberrant gene regulation, they are promising targets for 
therapeutic intervention [92]. In the context of STAT3, several indirect and direct 
approaches have been emphasized in diminishing constitutive activation or 
protein expression to prevent malignant transformation and are summarized in 
figure 2. On protein level, one promising strategy is the application of antisense 
oligonucleotides [93] and small interfering RNA [94]. Other direct approaches 
involve the development of specific STAT3 inhibitors that prevent receptor 
recruitment, dimerization or DNA binding. Peptides, peptidomimetics, peptide-
aptamers, non-peptide analogs, and platin (IV)-complexes have been studied 
regarding STAT3 inhibition [95].  
 
  
 
 
Moreover, engineered oligonucleotides such as guanine-rich G-quartets and 
alcylators have been identified to bind at phosphorylated STAT3 to prevent 
binding of STAT3 on target gene promoters [91]. An indirect strategy is the 
Figure 2: Strategies for STAT3 inhibition. These include the inhibition of STAT3- gene 
expression, dimerization, DNA-binding and the inhibition of tyrosine kinases (modified from [91]). 
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application of small molecule inhibitors to diminish the activity of dysregulated 
kinases upstream of STAT3. AG490 [96], AZD1480 [97], and JSI-1 (cucurbitacin-
1) [98] are inhibitors of the Janus kinases and prevent activation of down-stream 
effectors including STAT3, leading to growth arrest and apoptosis of tumor cells. 
Additional inhibitors of tyrosine kinases involve the BCR-Abl inhibitor Imatinib 
(gleevec, Novartis, USA) [91], the Src-inhibitor Dasatinib and the VEGFR/EGFR 
inhibitor Sorafenib [99]. All these inhibitors target intracellular proteins which is 
problematic, since they have to pass the hydrophobic cell membrane. Therefore, 
another strategy to prevent STAT3 activation is the inhibition of extracellular 
binding of cytokines or growth factors to their cognate receptor. This can be 
achieved by the application of recombinant proteins such as monoclonal 
antibodies, cytokine antagonists, soluble receptors, or engineered receptor fusion 
proteins.  
 
 
 
 
The receptor fusion proteins were developed for the inhibition of cytokine 
receptor signaling like the IL-6/STAT3 signal transduction [100]. The human IL-6 
receptor fusion protein (hIL-6RFP) consists of the three extracellular domains of 
human gp130 and two domains D2-D3 located in the N-terminus of human IL-
6Rα fused by a linker (33 – 49 Aa). The linker provides flexibility and stability for 
optimal ligand-binding [101] (Figure 3A). It has been implicated that IL-6 and the 
IL-6RFP form a tetrameric complex, similar to the hexameric IL-6 receptor 
complex, consisting of two molecules IL-6 bound to two receptor fusion proteins 
(Figure 3B). The IL-6RFP has been shown to prevent IL-6 induced STAT3 
phosphorylation in vitro and does not interact with other IL-6 type cytokines such 
as OSM, LIF, and IL-11 [101, 102].   
Figure 3: The IL-6
RFP
. A: Domain structure of the human IL-6 receptor fusion protein (left), and 
bound to IL-6 (right) B: hexameric structure of IL-6
RFP
 bound to IL-6. (modified from [100]). 
A B 
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1.2 Initiation of Prostate Cancer 
The normal human prostate is a tubular–alveolar gland consisting of an 
epithelium surrounded by a stromal compartment. The adult prostate is located at 
the base of the bladder and its function is the secretion of proteins to the seminal 
fluid consisting of organic solutes, lipids, and cholesterol [103]. The prostate is 
described by three distinct morphological regions: the peripheral zone, the 
transition zone, and the central zone. Benign prostate hyperplasia (BPH), which 
is a non-cancerous enlargement, occurs in the transition zone. Prostatic 
intraepithelial neoplasia (PIN) is a precursor of invasive carcinoma and most 
commonly found in the peripheral zone (Figure 4A) [104, 105]. Histologically, the 
prostate gland consists of an epithelial and a stromal compartment, separated by 
the basement membrane. The prostatic epithelium is composed of three different 
cell types including luminal cells, basal cells and neuroendocrine cells. Luminal 
cells are terminally differentiated cells with limited proliferative activity. They 
express the androgen receptor (AR) and secrete prostate fluid containing fatty 
acids such as prostaglandins and proteins including prostate specific antigen 
(PSA), prostate specific acid phosphatase (PAP) androgen dependently [106].  
 
 
 
 
 
 
 
 
 
 
 
Basal cells rarely express AR, do not require androgens for survival, and are 
highly proliferative. The basal layer is less differentiated and defined as the 
precursor compartment of luminal cells [107, 108]. The role of neuroendocrine 
cells in the prostatic epithelium is considered to produce soluble factors that 
paracrine supports the growth of luminal cells. Neuroendocrine cells are 
A B 
Figure 4: Schematic structure of the prostate. A: Schematic illustration of the human prostate 
with its different zones. B: Graphic of the cell-types within a prostatic duct (modified from [104]). 
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androgen independent [109, 110] (Figure 4B). The stromal compartment contains 
nerves, fibroblasts, infiltrating lymphocytes and macrophages, endothelial cells 
and smooth muscle cells. 
Chronic inflammation might facilitate prostate cancer initiation. Infections by 
bacteria and viruses, toxins or uric acid can cause prostate inflammation and 
might lead to DNA-damage or cell death in epithelial cells. Defective DNA-repair 
results in enhanced risk of mutations or chromosomal alterations [111]. 
Amplification of Myc [112] and AR [113] has been emphasized to play a role in 
prostate cancer initiation. Moreover, inflammation leads to up-regulation of 
cytokines that promote epithelial cell proliferation [114].  
In 1940 it has been demonstrated that the prostate is androgen dependent [115]. 
Presumably, another possibility for the initiation of prostate cancer is the up-
regulation of androgens followed by the constitutive activation of the androgen 
receptor. This hypothesis has been supported by studies showing that eunuchs 
do not develop prostate cancer and that men who use anabolic steroids have a 
higher risk of prostate cancer initiation [116, 117]. 
1.2.1 Function of AR. 
As a member of the nuclear hormone receptor superfamily, the androgen 
receptor (AR) is a hormone dependent transcription factor [118]. In the absence 
of androgens, AR is primarily localized in the cytoplasm of stromal and secretory 
luminal cells, bound to heat shock proteins (HSPs) which stabilize the tertiary 
structure of inactive AR and protect AR from proteolysis [119]. Activation of AR is 
initiated by androgens. Androgens are important for sexual differentiation, 
development and maintenance in males. Testosterone is an androgen, which like 
other steroid hormones is derived from cholesterol. Testosterone is primarily 
synthesized in the Leydig cells of the testis, and to a lesser extent by the adrenal 
glands. In serum, testosterone is bound to the sex-hormone-binding globulin 
(SHBG) and albumin. Only 2 % of total testosterone is unbound in serum [120]. 
As a hydrophobic steroid hormone free testosterone passes the cell membrane. 
In the cytoplasm, testosterone gets reduced to 5α-dihydrotestosterone (DHT) by 
the 5α-reductase [119, 121]. Binding of DHT to AR results in dissociation from 
HSPs, causing homo-dimerization, subsequent phosphorylation and nuclear 
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translocation of AR [122-124]. In the nucleus, AR binds to androgen responsive 
elements (AREs) of target genes resulting in recruitment of co-regulatory proteins 
such as SRC-1 (steroid receptor coactivator), p160, ARA (androgen receptor 
activator), CBP (CREB-binding protein), and p300 to form an active transcription 
complex [125] (Figure 5). 
 
         
 
 
 
 
 
Posttranslational modifications have been characterized and include eight serine 
phosphorylations (Ser16, 81, 213, 256, 308, 424, 515 and 650) and two tyrosine 
phosphorylations (Tyr267, 543) [124, 126-128]. Among other kinases, AKT 
(Ser213) and MAP kinases have been suggested to phosphorylate AR [128]. The 
Src kinase has been implicated to phosphorylate AR at Tyr543 [127]. Serine and 
tyrosine phosphorylations of the androgen receptor are important for improved 
gene induction [129, 130]. 
AR driven target gene expression is involved in diverse biological processes such 
as proliferation, differentiation and secretion. In prostate cancer the androgen 
receptor regulates genes involved in differentiation and prostate function (e.g. 
PSA, kallikrein 2, PAP) [131, 132], cell cycle (Cyclin A, B1, D1, CDK2, 4, p27, 
Figure 5: The androgen receptor signaling pathway. The androgen receptor (AR) is bound to 
heat-shock protein 90 (HSP90) in a confirmation that prevents DNA binding. Free testosterone 
passes the cell membrane and is converted to dihydrotestosterone (DHT) by the 5α-reductase. 
DHT binding to AR induces a conformational change in AR which leads to the dissociation of 
HSP90. Then, AR homo-dimerizes, gets phosphorylated and translocates to the nucleus. 
Phosphorylated, DNA-bound AR homodimer recruits co-regulators such as steroid receptor 
coactivator 1 (SRC-1), ARA (Androgen receptor activator), or CBP (CREB-binding protein) 
(modified from [119]) 
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p21, p16,) [133, 134], metastasis (MMP-2) [135] and angiogenesis (VEGF-C, 
FGF2) [136, 137] (Table 4).  
 
AR gene regulation   
PSA  
kallikrein 2 (hK2)  
prostatic acid phosphatase (PAP) 
Secretion 
Cyclin A, cyclin B1, cyclin D1 
CDK2, CDK4 
p27, p21, p16↓ 
Proliferation/Apoptosis 
MMP-2 Metastasis 
VEGF-C 
FGF2 
Angiogenesis 
 
 
The androgen receptor is predominantly expressed in the male sexual organs. 
Other tissues including bone, skin, thyroid, hepatic, pancreatic, gastrointestinal, 
neuronal, muscular, and female reproductive system show weak expression of 
AR [138]. Studies of conditional AR knock-out in mice demonstrated 80 % 
smaller testes associated with decreased serum testosterone concentrations, 
arrested spermatogenesis, and decreased bone volume [139, 140].  
1.2.2 Targeting the androgen receptor – Hormone deprivation therapy. 
Early stage prostate cancer has been emphasized to be a hormone-dependent 
cancer requiring androgens as well as AR for cell growth and oncogenic 
progression. So far, hormone deprivation therapy is considered a typical 
treatment either by surgical or chemical means resulting in tumor regression in 
most patients [141]. However, most prostate cancers escape hormone ablation 
therapy after a limited duration of one to three years which is called androgen 
independent prostate cancer (AIPC) or hormone refractory prostate cancer 
(HRPC) [142, 143].  
Androgen independence defines a clinical stage in which prostate cancer cells 
have developed different mechanisms which enables them to survive and 
proliferate in an androgen-poor microenvironment. This development occurs in 
late stage prostate cancer and in HRPC. Numerous mechanisms that lead to 
HRPC have been proposed including the hypersensitive, promiscuous, outlaw, 
bypass, and cancer stem cell pathways [142]. In most cases, AR is suggested to 
remain functional, either in a ligand-dependent or ligand-independent manner.  
Table 4: AR regulated genes in prostate cancer.  (modified from [131-137]). 
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In the hypersensitive pathway, prostate cancer cells adapt to low levels of 
androgens by clonal selection of cells with amplified AR-gene, or by local 
increases in androgen levels in the tumor tissue due to up-regulation of enzymes 
involved in the conversion of adrenal precursors to testosterone [113, 144, 145]. 
         
          
 
 
 
 
 
 
The promiscuous pathway involves mutations in AR that effect structure and 
function, i.e. the T877A mutation in the ligand binding domain of AR. This 
mutation broadens ligand specificity of AR to other steroid hormones such as 
progestin and estrogen, as well as anti-androgens like flutamide. Flutamide 
Figure 6: Possible mechanisms leading to HRPC. 1. One mechanism in the hypersensitive 
pathway is the amplification of the AR-gene. 2. In the promiscuous pathway, AR-specificity to its 
cognate ligand is widened to the stimulation by non-androgenic ligands due to mutations. 3. In 
the outlaw pathway, AR can be phosphorylated by RTKs resulting in a ligand-independent 
activation of AR. 4. AR signaling can be bypassed by other signaling pathways e.g. the Map 
kinase, AKT, and STAT3 signal transduction. 5. Due to clonal selection, epithelial cancer stem 
cells survive and promote proliferation and anti-apoptosis. Abbreviations: GF – growth factors; 
CR – cytokine receptor; RTK - receptor tyrosine kinase, (modified from [142]). 
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action changes from antagonistic to an agonistic resulting in activation of AR 
[146]. 
In the outlaw pathway it has been suggested that the androgen receptor can be 
activated by cytokines (IL-4, IL-6) and growth factors (KGF, EGF, IGF-1, FGF2, 
HGF, and TGFβ) in the presence of low level androgens [147, 148]. Elevated IL-6 
serum concentrations are associated with higher prostate-specific antigen (PSA) 
levels and tumor metastasis [149]. IL-6 stimulation leads to synergistic activation 
of AR in the presence of low androgen concentrations [150]. In this context, it has 
been implicated that STAT3 interacts with AR at the DNA to promote AR-target-
gene expression [151]. Other signaling pathways that have been emphasized to 
play an important role in the ligand-independent activation of the androgen 
receptor are the MAP kinase and the AKT/PI3-kinase signal transduction [152, 
153].  
The bypass pathway encompasses signaling pathways that are up-regulated in 
HRPC and promote oncogenic target gene induction such as the STAT3, MAP 
kinase and the AKT/PI3-kinase pathways. These alternative signaling pathways 
are capable of bypassing AR.  In this context, IL-6 has been suggested to 
participate in malignant progression of prostate cancer. Bypass of AR signaling 
pathway in the absence of androgens and AR may occur due to selection of 
cancer clones during hormone ablation therapy [154-156].  
The prostate cancer stem cell model suggests that the failure of HRPC is a result 
of the survival of a subpopulation of androgen independent cancer cells. These 
epithelial stem cells or progenitor cells remain viable upon HRPC and continue to 
proliferate and differentiate into either androgen-dependent or –independent cells 
[157, 158] (Figure 6).  
1.2.3 Therapeutic intervention in prostate cancer. 
Primary or local prostate cancer is usually treated by radical prostatectomy, 
radiation or bilateral orchiectomy combined with hormone deprivation therapy 
using either anti-androgens or androgen lowering agents. Hormone deprivation 
therapy is the standard therapy in metastatic prostate cancer as well. Beside the 
possibility of existent androgen independent cancer clones many cancer cells 
seem to remain dependent on the AR signaling pathway in HRPC. Thus, 
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treatment of HRPC encompasses a second-line hormone deprivation therapy and 
the inhibition of receptor tyrosine kinases such as EGFR, VEGFR, or the non-
receptor tyrosine kinase Src [159]. Chemotherapeutical agents of the androgen 
receptor signaling pathway include anti-androgens, HSP90 inhibitors, HDAC 
inhibitors, and androgen lowering agents [160].  
 
Inhibitor Function 
HSP90 inhibitors: 
Geldanamycin 
Tanespimycin 
Celastrol 
Gedunin 
Inhibition of HSP90 to prevent proper 
conformation of AR and others 
AR siRNA Downregulation using small antisense 
oligonucleotides 
Anti-androgens: 
Flutamide 
Bicalutamide (CasodeX) 
Nilutamide 
MDV-3100 
Inhibition of AR transcriptional engagement 
Androgen lowering agents: 
Ketoconazole 
Abiraterone 
Finasteride 
Dutasteride 
Inhibition of androgen synthesis and 
processing by targeting enzymes such as 
p450, 5α-reductase, or using 
Gonadotropin-releasing hormone (GnRH) 
antagonists  
HDAC inhibitors: 
Trichostatin A 
Depsipeptide 
Suber-oylanilide hydroxamic acid (SAHA) 
LBH589 
Downregulation of approximately 50 % AR 
target-genes  
Preventing HSP90 binding to AR resulting 
in destabilized AR 
EGFR/ErbB2 inhibitors: 
Small molecule inhibitors (Gefitinib, Erlotinib, 
Lapatinib) 
Monoclonal antibodies (Trastzumab (Herceptin), 
Pertuzamab) 
Among others, inhibition of EGFR results 
in down regulation of the MAP kinase and 
AKT/PI3 kinase pathways 
Src inhibitors: 
Dasatinib 
Down regulation of the MAP kinase and 
AKT/PI3 kinase and STAT3 pathways 
VEGFR inhibitors 
Sunitinib 
Bevacizumab 
Inhibition of neo-vascularization 
 
 
Anti-androgens compete with testosterone at the ligand binding domain to 
prevent AR activity [161]. However, mutations in AR result in the conversion of 
the antagonistic to an agonistic action of anti-androgens [162].  
HSP90 is required for accurate folding and stabilization of proteins. Inhibitors of 
HSP90 compete with ATP for N-terminal binding. In addition to AR, kinases such 
as ErbB2, and AKT as well as p53 are inhibited by HSP90 targeting [163]. 
Table 5: Chemotherapeutical agents used in prostate cancer therapy.  (modified from [159]). 
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Histone deacetylases (HDACs) remove acetyl groups from acetylated lysines. 
Deacetylated lysins of histone proteins interact with the negatively charged DNA 
and therefore down-regulate transcription. Moreover, HDAC inhibitors seem to 
destabilize AR by deacetylizing HSP90 which interferes with the binding of 
HSP90 to AR [164]. Androgen lowering agents target androgen synthesis or 
antagonize soluble factors that stimulate androgen synthesis such as GnRH 
(Gonadotropin-releasing hormone) [165]. Moreover, antisense oligonucleotides 
have been developed to downregulate AR protein. However, delivery of these 
siRNAs still needs to be addressed [166]. Agents that are in pre-clinical 
investigations or clinical studies are summarized in table 5. 
 
1.3 Cancer Cell Differentiation and Cancer Stem Cells (CSCs) in Prostate 
Cancer 
1.3.1 The cancer stem cell theory.   
Tissue regeneration is regulated by a subset of cells called ‘somatic stem cells'. 
The stem cell population possesses properties of self-renewal and differentiation. 
Stem cells can either divide into one or two daughter cells with the same stem 
cell characteristics (self-renewal) or they can generate transit amplifying or 
progenitor cells that differentiate into specialized, less proliferative cells with 
defined life-spans (differentiation) [167].  
The first connection between stem cells and cancer was proposed in the 19th 
century. Due to similarities between tumor and embryonic tissue, Rudolf Virchow 
hypothesized that cancer arises from activation of embryonic stem like cells that 
are present in mature tissue [168].  
It has been suggested that cancer stem cells or cancer stem-like cells can arise 
from normal stem cells, progenitor cells, and differentiated cells by genetic 
alterations and influences of the microenvironment. In this context, progenitor and 
mature cells de-differentiate to regain stem-like properties [169]. Clonal selection 
by mutations or microenvironmental changes may result in some cancer stem cell 
clones with growth and survival advantages and therefore drive tumor 
malignancy  (Figure 7). 
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Moreover, the cancer stem cell model proposes that tumorigenic CSCs may 
generate tumors through the stem cell processes of self-renewal and 
differentiation into multiple cell types. Cancer stem cells are described as the 
tumor initiating population that drives tumor growth [169]. This observation was 
supported by analysis of neuroblastomas. Highly differentiated neuroblastomas 
are usually locally confined and therefore generally curable by surgery [170]. In 
contrast, less differentiated tumors are often more aggressive and have fatal 
results despite intensive therapeutical intervention [171].  
The first subpopulation of cancer cells with tumorigenic potential was isolated by 
flow cytometry. This technique made it possible to distinguish between 
phenotypically distinct cells. The CSC subpopulation, which expressed CD34, but 
lacked CD38, was capable of initiating an acute myeloid leukemia (AML) in 
immunocompromised NSGNOD mice [172]. Other studies were able to provide 
evidences about the existence of a cancer stem cell population that is able to 
initiate tumor growth, including colon, pancreatic, brain, ovarian and breast 
cancer. These subpopulations were characterized by distinct protein expression 
profiles called cancer stem cell markers. Some of the stem-like cell indicating 
markers that have been identified in prostate CSCs are summarized in table 6. 
The most prominent cell-surface proteins that have been used for the isolation of 
prostate CSCs are CD44, integrin α2β1 and CD133 (Prominin 1). Among others, 
Sox2, Musashi-1 (MSI-1), Nanog and the Aldehyde dehydrogenase 1 (ALDH1) 
are expressed in prostate CSCs [158, 173-176]. Since these stem-like cell 
indicating markers comprise multi-functional proteins, it is necessary to analyze 
Figure 7: Cancer stem cell 
development. Shown are normal 
stem cells, progenitor and 
differentiated cells. Internal factors 
such as genetic alterations and 
external factors such as the secretion 
of soluble factors by the 
microenvironment (indicated by the 
bolt of lightning) can result in 
conversion, or de-differentiation, into 
cancer stem cells. Cancer stem cells 
then drive tumor progression, 
(modified from [169]). 
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and confirm the up-regulation of several markers to identify cancer cells with 
stem-like properties.  
 
CSC marker Function Tumor type 
CD44 Cell-surface glycoprotein involved in cell-adhesion, 
cell-cell interaction, migration and homing 
Receptor for hyaluronic acid 
Breast, Head and 
Neck, Prostate 
Integrin α2β1 Extracellular matrix receptor for collagen and laminin. Prostate 
CD133  
(Prominin-1) 
Five-transmembrane glycoprotein involved in plasma 
membrane topology 
Expressed in fetal neural stem cells, progenitor cells 
in fetal liver, endothelial precursor and developing 
epithelium 
Prostate, Breast, 
Brain, Colon, 
Pancreas, Lung, 
Liver 
Sox2 Transcription factor essential for stem cell 
maintenance and self-renewal of embryonic stem 
cells 
Prostate, Breast, 
Brain 
Musashi-1 (MSI-1) RNA binding protein that is important for post-
transcriptional gene regulation 
Plays a role in normal stem cell maintenance and 
differentiation 
Regulates Notch signaling during asymmetric cell 
division 
Breast, Colon, 
Prostate, Brain 
Nanog Transcription factor with roles in self-renewal and 
maintenance of pluripotency of embryonic stem cells 
by target gene regulation (upregulation of ALDH1 
and CD133) 
Interactions with other stem cell regulators such as 
Sox2 and Oct3/4 
Breast, Prostate, 
Brain 
Aldehyde 
dehydrogenase1  
(ALDH1) 
Cytoplasmic enzyme involved in oxidation of 
aldehydes, and conversion of retinol to retinoic acid 
in normal stem cells 
Bladder, Lung, 
Head and Neck, 
Breast, Prostate 
 
 
 
1.3.2 Implications for prostate cancer therapy. 
Tumors consist of phenotypically and functionally heterogeneous cancer cells. In 
prostate cancer, CSCs comprise only a small subset (0.1 – 1 %) of tumor cells. 
Since CSCs have been shown to be highly drug- and radiation- resistant, failure 
to eliminate this cell-population might result in tumor relapse  
Drug-resistance might be a result of up-regulated ABC transporters which 
decrease intracellular drug concentration by pumping substrate drugs out of the 
cell [177]. The overexpression of anti-apoptotic proteins such as Bcl-2 and 
survivin as well as the up-regulation of DNA-repair apparatuses have been 
implicated to play a role in CSC drug resistance [178, 179]. Furthermore, the slow 
proliferation rate of CSCs in the context of self-renewal (symmetric divison) 
Table 6: Prostate cancer stem-like cell markers. Listed are identified CSC indicating markers 
for prostate cancer stem cells, their function and tissues in which they have been noted to be 
upregulated in CSCs (modified from [158,173-176]). 
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results in escape from chemotherapeutics that preferentially target high 
proliferative cells [180]. Conventional therapies transiently reduce tumors by 
targeting the tumor bulk, but survival of CSCs leads to recurring tumor growth. In 
order to prevent recurrence it is important to target all heterogenous cell 
populations. Therapies targeting the CSCs can be designed by inhibiting the 
maintenance of pluripotency or by inducing differentiation of these cells. 
Strategies to eliminate CSCs involve targeting ABC-transporters, transcription 
factors that induce anti-apoptotic proteins, and signaling pathways which regulate 
self-renewal [181].  
One of the signaling pathways that has been suggested to play a role in CSC 
phenotype development is the IL-6/STAT3 signal transduction. Gene signatures 
of prostate CSCs revealed activation of JAK/STAT3 signal transduction in this 
cell population [182]. Moreover, STAT3 has been emphasized to play a role in 
maintaining pluripotency [183] and self-renewing processes [184] in embryonic 
stem cells and glioblastoma stem cells [185].  
 
1.4 Scientific goals 
Prostate cancer is initially androgen dependent. Androgen deprivation therapy, as 
the standard therapy for progressive tumor growth, targets the androgen receptor 
signaling pathway. Despite initial regression of androgen dependent tumors, 
hormone refractory prostate cancer recurs. HRPC might be a result of cancer 
stem cells that survive targeted therapy. Most often, HRPC is a lethal form of 
prostate cancer that progresses and metastasizes. 
The transcription factor STAT3 plays an important role in tumorigenesis by 
enhancing gene-induction of proteins involved in proliferation, angiogenesis, 
metastasis, anti-apoptosis and immune evasion [27, 186]. In prostate cancer, the 
IL-6/STAT3 signaling pathway has been suggested to correlate with malignancy 
and metastatic behavior of tumor cells [155, 187]. Elevated levels of IL-6 have 
been noted in patients with metastatic disease or HRPC [188-190]. Activated 
STAT3 has been found in several metastatic cancer cells e.g. DU145 and PC-3 
cells [191]. So far, no connection between STAT3 activity and the development of 
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a CSC phenotype as a potential reason for aggressive tumor growth and HRPC 
has been established.  
In this study, a murine epithelial prostate cancer cell line was used to establish 
and to verify the suggested role of IL-6/STAT3 signaling pathway in the transition 
to hormone refractory prostate cancer. It was planned to evaluate the oncogenic 
potential of STAT3 and the androgen receptor by comparing tumor cells gene 
silenced for STAT3 and AR by determining proliferative, angiogenic and apoptotic 
activity. A gene-expression profile gave more insights into the genetic alterations 
induced by genetic knock-down of STAT3 and AR. The impact of STAT3 on 
angiogenic and metastatic processes in prostate cancer was evaluated by using 
cells stably expressing the fusion proteins STAT3α-YFP or the dominant-negative 
form STAT3β-YFP.  
It was planned to characterize the IL-6 receptor fusion protein (IL-6RFP) in order to 
evaluate its functionality in vitro and in vivo. The impact of IL-6RFP on inhibiting IL-
6/STAT3 signaling was investigated by determining tumor growth and connected 
to proliferation, apoptosis and vascularization.  
The role of STAT3 dependent CSC phenotype development was evaluated in 
primary, metastatic, recurring, and targeted prostate cancer by IL-6RFP. It was 
planned to determine the correlation of STAT3 or AR and CSC phenotype 
development in murine and human prostate cancer samples. Moreover, the 
impact of a combined therapy using IL-6RFP and the anti-androgen bicalutamide 
on tumor growth and CSC phenotype development was compared to the 
respective mono-therapies. 
 The aim of this study was to evaluate the impact of the IL-6/STAT3 and 
the androgen receptor signaling on the development of a CSC phenotype in the 
progression and recurrence of prostate cancer upon hormone ablation therapy, 
and to introduce the IL-6 receptor fusion protein as a potential therapy to target 
the CSC population in prostate cancer. 
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2 Materials and Methods  
 
2.1 Materials 
2.1.1 Chemicals 
Chemicals were used in pro analysis quality. Buffers and media were preapared 
with double destilled water.  
2.1.2 Cytokines, inhibitors and enzymes 
Recombinant murine and human IL-6 were supplied from R+D systems and its 
median effective dose was 0.02 – 0.06 ng/ml, Flutamide with an IC50 of 1.3 µM 
and bicalutamide with an IC50 of 0.16 μM were supplied from Sigma (Saint 
Louis, USA). The IC50 represents the molar concentration of an antagonist, 
which produces 50% of the maximal possible inhibitory response for that 
antagonist. The murine IL-6 receptor fusion protein (IL-6RFP) as an inhibitor of the 
IL-6/Stat3 signaling pathway was produced and secreted in HekIL-6RFP cells. 80 – 
100 % confluent Hek cells stably expressing IL-6RFP were plated with 4 ml 
medium without FBS and antibiotics for 48 h. Afterwards, conditioned medium 
was sterile filtered with a filter containing a PVDF membrane with 0.45 µm pores 
(Millipore, Billerica, USA) and stored at 4oC for 2 – 3 days. The neutralizing anti-
IL-6 antibody (MP5-20F3) was obtained from BD bioscience. 
If not indicated differently enzymes were used by Roche or New England 
Biolabs. 
2.1.3 Antibodies 
Antibodies Reactivity Isotype Source Application 
α-STAT3 N-Terminus (Aa 50-
240) of STAT3 
mouse St. Cruz Biotechnology, 
St. Cruz, USA (F-2) 
WB 
α-STAT3 C-terminus  rabbit St. Cruz Biotechnology, 
St. Cruz, USA (C-20) 
EMSA 
α-pY-STAT3 p-tyrosine-motive of 
STAT3 
mouse St. Cruz Biotechnology, 
St. Cruz, USA (B-7) 
WB, IF 
α-pY-STAT3 p-tyrosine-motive of 
STAT3 
rabbit St. Cruz Biotechnology, 
St. Cruz, USA (Tyr705)-R 
 IF 
α-AR C-terminus of AR rabbit St. Cruz Biotechnology, 
St. Cruz, USA (C-19) 
WB 
α-AR N-terminus of AR rabbit St. Cruz Biotechnology, 
St. Cruz, USA (N-20) 
WB 
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α-AR Internal residues of 
AR 
rabbit Epitomics, Burlingame, 
USA (3165-1) 
WB, IF 
α-β-Actin N-terminus of the 
actin β-isoform  
mouse Sigma, St. Louis, USA WB 
α-GAPDH C-terminus of 
GAPDH 
rabbit Cell signaling, Danvers, 
USA (#2118) 
WB 
α-IL-6  rabbit Millipore, Billerica, USA 
(ab1423) 
WB 
α-IL-6 C-terminus of IL-6 goat St. Cruz Biotechnology, 
St. Cruz, USA (M-19) 
IF 
α-IL-6  mouse ABCAM,Cambridge, USA 
(ab9324) 
IF 
α-His 6x His epitope rabbit Cell signaling, Danvers, 
USA (#2365) 
WB, IF 
α-His 6x His epitope goat ABCAM (ab9136) IF 
α-Ki-67 Internal residues of 
KI-67 (1200 – 1300) 
rabbit ABCAM, Cambridge, 
USA, (ab15580) 
IF 
α-CD31 Internal residues of 
CD31 
rat BD Bioscience, San Jose, 
USA (#550274) 
IF 
α-cleaved 
Caspase 3 
N-terminus of 
Caspase-3 
rabbit Cell signaling, Danvers, 
USA (#9664) 
WB 
α-cleaved PARP C-terminus of PARP rabbit Cell signaling, Danvers, 
USA (#9544) 
WB 
α-Bcl-2 C-terminus of Bcl-2 rabbit Cell signaling, Danvers, 
USA (#2876) 
WB 
α-Bcl-xL Residues 
surrounding Asp61 
rabbit Cell signaling, Danvers, 
USA (#2764) 
WB 
α-Sox2 C-terminus of Sox2 rabbit ABCAM, Cambridge, 
USA (ab97959) 
WB, IF 
α-Sox2 C-terminus of Sox2 mouse ABCAM, Cambridge, 
USA (ab79351) 
IF 
α-MSI-1 N-terminus of MSI-1 rabbit ABCAM, Cambridge, 
USA (ab52865) 
WB, IF 
α-MSI-1  rat Ebioscience, San Diego, 
USA (14-9896-82) 
IF 
α-CD44 Internal residues of 
CD44 
rabbit Epitomics, Burlingame, 
USA (3381-1) 
IF 
α-CD44  mouse ABCAM, Cambridge, 
USA (ab6124) 
IF 
α-CD44-FiTC Internal residues of 
CD44 
 Biolegend, London, UK IVMPM 
α-Nanog N-terminus of Nanog rabbit Epitomics, Burlingame, 
USA (3369-1) 
IF 
α-Nanog  mouse ABCAM, Cambridge, 
USA (ab62734) 
IF 
α-integrinα2β1  mouse ABCAM, Cambridge, 
USA (ab30483) 
IF 
AF647-
conjugated 
Galectin3 
  Ebioscience, San Diego, 
USA, (515301-80) 
FACS 
APC-conjugated 
integrin β1 
  Ebioscience, San Diego, 
USA (17-0291-80) 
FACS 
APC-conjugated 
CD44 
  BD Biosciences, San 
Jose, USA (559942) 
FACS, LCI 
AF488 
conjugated α-
mouse 
Heavy chain of 
mouse Ig 
goat Invitrogen, Grand Island, 
USA (A-11001) 
IF 
AF488 
conjugated α-
rabbit 
Heavy chain of rabbit 
Ig 
goat Invitrogen, Grand Island, 
USA (A11008) 
IF 
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AF546 
conjugated α-
rabbit 
Heavy chain of rabbit 
Ig 
goat Invitrogen, Grand Island, 
USA (A11035) 
IF 
AF546 
conjugated α-
goat 
Heavy chain of goat 
Ig 
donkey Invitrogen, Grand Island, 
USA (A11056) 
IF 
AF555 
conjugated α-rat 
Heavy chain of rat Ig goat Invitrogen, Grand Island, 
USA (A20346) 
IF 
Cy2 conjugated 
α-rabbit 
Heavy chain of rabbit 
Ig 
donkey Jackson-
ImmunoResearch, 
Baltimore, USA 
IF 
Cy2 conjugated 
α-mouse 
Heavy chain of 
mouse Ig 
donkey Jackson-
ImmunoResearch, 
Baltimore, USA 
IF 
HRP-conjugated 
α-mouse 
Constant area of 
mouse-Ig 
donkey GE Healthcare, 
Buckinghamshire, UK 
WB 
HRP-conjugated 
α-rabbit 
Constant area of 
rabbit-Ig 
donkey GE Healthcare, 
Buckinghamshire, UK 
WB 
 
2.1.4 Plasmids 
Vector Insert Source 
pcDNA5/FRT/TO 
Stat3-YFP Andreas Herrmann, CITI Duarte, 
USA 
pcDNA5/FRT/TO Stat3-YFP  
pSVL 
Stat3β Andreas Herrmann, CITI Duarte, 
USA 
pcDNA3.1 
mIL-6
RFP
 V5-His Gerhard Müller-Newen, Institut für 
Biochemie, Uniklinikum Aachen 
pcDNA5/FRT/TO mIL-6
RFP
 V5-His  
pLKO.1-puro Stat3-shRNA Sigma, Saint Louis, USA 
pLKO.1-puro AR-shRNA Sigma, Saint Louis, USA 
pLKO.1-puro Non-silencing control-shRNA Sigma, Saint Louis, USA 
 
2.1.5 Oligonucleotides 
The used olugonucleotides were supplied from IDT (Integrated DNS 
Technologies, Coralville, USA). GAPDH primers were used of the universal 
probe library mouse GAPDH assay (Roche Applied Science, USA) 
 
Oligonucleotide Forward primer Reverse primer 
IL-6  5’-gctaccaaactggatataatcagga 5’-ccaggtagctatggtactccagaa 
OSM  5’-ctgctccaactcttcctctca 5’-caggttttggaggcggata 
VEGF  5’-actggaccctggctttactg 5’-tctgctctccttctgtcgtg 
EGF  5’-catgccccacaggatttg 5’-gggcaggaaacaagttcgt 
AR  5’-ccagtcccaattgtgtcaaa 5’-tccctggtactgtccaaacg 
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2.2 Methods of Molecular Biology 
2.2.1 Growth and storage of bacteria 
One-shot-TOP-10 E. coli bacteria (Invitrogen, Carlsbad, USA) were either 
cultured in LB-medium, supplemented with a selection marker such as ampicillin 
(50 µg/ml) and incubated rocking with 250 rpm or on LB-agar (1,5%) at 37oC. 
Storage of bacteria followed at – 80oC in LB-Medium with 20%Glycerol. 
 
LB-Medium: 10 g/l  Tryptone 
   5 g/l   Yeastextract 
   10 g/l   NaCl 
 
LB-Agar: 15 g/l   Agar (in LB-Medium) 
 
2.2.2 Isolation of plasmid-DNA 
Small scale isolation of plasmid-DNA 
To control cloning procedures plasmid-DNA was isolated of 5 ml bacterial over 
night culture by means of Mini Plasmid Kit (Qiagen, Maryland, USA) according to 
manufacturer’s recommendations. 
 
Large scale isolation of plasmid-DNA 
For transfection of eucaryotic cells as well as sequencing of plasmid-DNA in a 
preparative manner, DNA (50-500 µg) was purified of 250 ml bacterial overnight 
culture by means of the Plasmid Maxi Kit (Qiagen, Maryland, USA) according to 
manufacturer’s recommendations. Purified DNA was solved in Nuklease free 
water. 
2.2.3 Quantitative analysis of nucleic acids 
Quantities of DNA were determined by photometric measurement of the 
absorption at 260 nm (A260). An absorption-value of A260=1.0 is equal to an 
amount of 50 µg double stranded DNA. Purity of preparated nucleic acids was 
analyzed by measuring absorption at 280 nm (A280) additionally. For pure DNA 
the quotient of A260/A280 should correspond to 1.8 – 2.0.  
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2.2.4 DNA digest with restriction endonucleases 
Enzymatic restriction of DNA was performed according to manufacturer’s 
recommendations.  
2.2.5 Fractionation of nucleic acids by agarose gel electrophoresis 
To verify clonings and for preparations, digested DNA fragments were separated 
via gel electrophoresis and compared with a marker to determine their size. 
Digested DNA was compounded with 5x DNA probe mixture (Bio-Rad, 
Hercules, USA) and subjected to a 0.7-2% (w/v) Agarose gel. To display DNA 
at a UV transilluminator (λ=366 nm) ethidium bromide was added to the gel 
as well as the TAE running buffer.  
TAE (1x): 242 g  Tris base 
   57.1 ml glacial acetic acid 
   100 ml  0.5 M EDTA (pH 8.0) 
   in 1000 ml ddH2O 
2.2.6 Isolation of DNA-fragments from agarose gels  
Gel electrophoretic separated DNA-fragments were cut of the agarose gel, then 
purified according to manufacturer’s recommendations by means of the Qiaquick 
gel extraction kit (Qiagen, Maryland, USA) and finally dissolved in 20 µl 
nuclease-free water. 
2.2.7 DNA ligation 
The DNA rapid ligase (Roche, Mannheim, Germany) was used to ligate double 
stranded DNA fragments. According to strength and the supposed size of the 
DNA band in the agarose gel, 10 - 100 ng of linearized vector was incubated 
with a 2 - 10 molar excess of the insert for 30 - 60 min at room temperature. 
Then ligation preparations were transformed into competent bacteria. 
2.2.8 Transformation of competent bacteria 
For transformation purposes One-shot-TOP-10 E.coli (Invitrogen, Carlsbad, 
USA) were mixed with either 0.5 - 2 µl plasmid or with 10 µl ligated product, and 
incubated for 25 min on ice. Afterwards bacteria were heat shocked for 30 s at 
42oC. After heat shock 250 µl SOC-Medium was added to bacteria-DNA mixture 
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and subsequently rocked with 250 rpm for 1 h at 37oC. Up to 100 µl of the 
bacterial suspension was plated on agar plates containing ampicillin (50 µg/ml). 
Agar plates were incubated over night at 37oC and subsequently grown bacterial 
colonies were analyzed. 
2.2.9 Cloning of mIL-6RFP and STAT3-YFP 
mIL-6RFP: 
The expression vector pcDNA3.1-mIL-6RFP V5/his as well as pcDNA5/FRT/TO 
were digested with restriction endonucleases Nhe I and Pme I. Afterwards the 
DNA fragment mIL-6-RFP was integrated into the pcDNA5/FRT/TO vector. 
Stat3-YFP:  
Expression vectors pSVL-STAT3and pcDNA5/FRT/TO-STAT3α-YFP were 
digested with endonucleases Xho I and Age I. Then STAT3 was ligated with the 
pcDNA5/FRT/TO backbone vector.  
2.2.10 QRT-PCR and QPCR-array 
QRT-PCR: 
Total RNA was isolated using the RNeasy 96 kit (Qiagen, Valencia, CA). The 
qScript One-Step Fast qRT-PCR kit (Quanta, Gaithersburg, MD) was used to 
reverse transcribe and amplify 25 ng of total RNA per reaction, according to the 
manufacturer's protocol. ProbeFinder software (Roche Applied Science, 
Indianapolis, Indiana, USA) was used to design primer sets for IL-6, OSM, 
VEGF, EGF, STAT3 and AR and to select the respective probes from the 
Universal Probe Library (Roche Applied Science). All samples were run in 
triplicates. Amplifications were performed on a Bio-Rad iCycler iQ5 Multiple-
Color Real-time PCR Detection System (Bio-Rad Laboratories, Hercules, 
California, USA). Data were normalized to the GAPDH expression. Expression 
levels were calculated with the 2 DDCt method.  
QPCR arrays: 
Total RNA was isolated using the RNeasy 96 Kit (Qiagen, Valencia, CA). 500 ng 
of each RNA sample were converted to cDNA with the RT² First Strand Kit 
(Qiagen) and then combined with the RT2 SYBR Green qPCR Mastermix 
(Qiagen) according to the manufacturer's instructions. Equal volumes (25 µl) of 
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this mixture were loaded into each well of the mouse JAK-STAT or angiogenesis 
RT² Profiler PCR array plates (Qiagen). The qPCR was performed on an iQ5 
Real-time PCR Detection System (Bio-Rad, Hercules, CA). Relative gene 
expression levels were calculated using the ΔΔCt method. 
   
2.3 Culture and Transfection of eukaryotic cells  
2.3.1 Culture of eucaryotic cells 
Murine epithelial prostate cancer cells TRAMP-C1 (TC1), TRAMP-C2 (TC2) 
(American Type Culture Collection (ATCC), Manassas, USA), TC1- control-, 
STAT3-, or AR-shRNA cell lines, as well as TC1 Stat3α-YFP and TC1 Stat3β-
YFP cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco, Grand island, USA) medium supplemented with 5 % FBS, 5 % Nu-Serum 
IV, 0.005 mg/ml bovine insulin, and 10 nM Dehydroisoandrosterone (SIGMA, 
Saint Louis, USA). EC line, derived from prostate, was kindly provided by S. 
Huang and J. Fidler (M.D. Anderson Cancer Center, Houston, Texas). This cell 
line was maintained in RPMI medium (Gibco, Grand island, USA) supplemented 
with 10 % FBS. Parental Hek293 and Hek293-mIL-6RFP cells were cultured in 
DMEM containing 10 % FBS. Additionally, all media were supplemented with 
100U/ml penicillin, 0.1 mg/ml streptomycin (Gibco, Grand island, USA). Cells 
were incubated at 37oC and 5 % CO2 in a water-saturated atmosphere. For 
subculture adherent growing cells were detached from cell culture plates with a 
trypsin/EDTA solution. 
 
Cell line Description 
TC1 adherent murine prostate cancer cells 
TC2 adherent murine prostate cancer cells 
TC1 Stat3α-YFP adherent murine prostate cancer cells 
TC1 Stat3β-YFP adherent murine prostate cancer cells 
TC1 Stat3
shRNA
 adherent murine prostate cancer cells 
TC1 AR
shRNA
 adherent murine prostate cancer cells 
TC1 nt-control
shRNA
 adherent murine prostate cancer cells 
EC adherent murine endothelial cell derived from prostate 
Hek293 adherent human embryonic kidney cells 
Hek293
IL-6RFP
 adherent human embryonic kidney cells 
MFib adherent murine fibrosarcoma cells 
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DMEM Medium supplemented with 4,5 g Glukose/l, L-Glutamin und 
110 mg/l Natrium-Pyruvat (Gibco, Paisley, UK) 
RPMI 1640 Medium with L-Gutamin (Gibco, Paisley, UK) 
OPTIMEM Medium (Gibco, Paisley, UK) 
FBS  mycoplasma free fetal bovine serum (Sigma, Saint Louis, 
USA) 
HBSS-/- Medium without Ca2+ and Mg2+ and Phenolrot (Gibco, 
Paisley, UK) 
HBSS+/+ Medium with Ca2+ and Mg2+ 
 
Trypsin (0.05%)/ EDTA (0.02%) (Gibco, Paisley, UK) 
Penicillin/Streptomycin/Amphotericin (Gibco, Paisley, UK) 
  
PBS  200 mM NaCl 
   2.5 mM KCl 
   8.0 mM Na2HPO4 
   1.5 mM KH2PO4 
2.3.2 Storage of eucaryotic cells 
Eucaryotic cells were stored in media containing 3.3 % FBS and 10 % DMSO 
(freezing medium). Cells were detached from cell culture plate using 
Trypsin/EDTA, affiliated in media and then spinned down at 4oC. Sedimented 
cells were resuspended with cold freezing medium, frozen for a couple of days at 
– 80oC and subsequently stored in liquid nitrogen at – 196oC. 
2.3.3 Transfection and preparation of stable expression cell lines 
Transfection with Lipofectamine 2000: 
One day before transfection, cells were plated on 6-well plates and cultured to a 
confluency of 50 - 70 %. For transfection, complexes were prepared as follows: 
A. 4 µg DNA was diluted in 250 µl OPTIMEM (Gibco, Grand island, USA) without 
FBS. B. 250 µl OPTIMEM lacking FBS were mixed with 10 µl Lipofectamine. 
Upon an incubation of complexes A and B at RT for 5 min, they were mixed, and 
then incubated for another 20 - 30 min at RT. Afterwards complexes were added 
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to cells grown in medium without antibiotics. 24 h later, transfection-mixture was 
aspirated and replaced with new medium. 
 
Generating Flp-In host cell lines and stable expression cells: 
To generate Flp-In Host Cell Lines cells of interest were transfected with 
pFRT/lacZeo plasmid. Maintenance and Zeocin selection of transfected cells 
were performed according to manufacturer’s recommendations (Invitrogen, 
Carlsbad, USA). Once, the Flp-In Host cell line was generated, cells were co-
transfected with pOG44 vector that expresses the Flp recombinase as well as 
the pcDNA5/FRT/TO vector containing the insert of interest in a ratio of 9:1. 
Maintenance and selection of stable expressing cells by Hygromycin was 
performed according to manufacturer’s recommendations (Invitrogen, Carlsbad, 
USA). 
2.3.4 Development of shRNA cells 
293T cells were plated at a density of 4 × 106 cells per 10-cm dish. Cells were 
co-transfected by calcium phosphate co-precipitation with 10 mg of pPACK 
packaging plasmid mix (SBI, Mountain View, USA) and 15 mg of the respective 
transfer plasmid (pLKO1-mouse Stat3 shRNA (TRCN0000071456, Sigma, St. 
Louis, USA), pLKO1-AR mouse shRNA (TRCN0000026189), pLKO1-human 
Stat3 shRNA (TRCN0000020840) or pLKO1-non-silencing shRNA (Sigma)). The 
culture medium was replaced with fresh medium after 6 h. Supernatants were 
collected 24 h and 48 h after transfection. To determine the viral titers, 105 
HT1080 cells were seeded in a six-well plate and transduced with various 
dilutions of the vectors in the presence of 4 mg of Polybrene/ml (Sigma). The 
culture medium was replaced 48 h later with fresh medium containing puromycin 
(Sigma) at a concentration of 1.5 mg/ml. Puromycin-resistant colonies were 
counted 10 days after transduction. TC1 cells or DU145 cells were transduced 
with the viral vectors at an MOI of 0.5. Transduced cells were selected by adding 
1.5 mg/ml puromycin to the culture medium. 
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2.3.5 Preparation of cells for injection in mice 
For injection of mice designated cells were amplified in vitro and counted by 
means of trypan-blue staining in a hemacytometer. Between 0.5 x 106 and 2.5 x 
106 cells were diluted in HBSS-/-, and 100 µl cell-suspension was implanted in 
mice ventral, subcutaneously. TC1, TC2, TC1 cells expressing control-, STAT3-, 
or AR-shRNA, TC1 cells stably expressing STAT3α-YFP, or STAT3β-YFP were 
implanted in immunocompromised mice.  
To analyze metastatic potential of tumor cells, 5 x 104 cells were injected retro-
orbitally into mice. Lungs of mice were excised every other day after injection for 
7 days, stored in HBSS-/- and analyzed by IVMPM ex vivo shortly after excision. 
 
2.4 Biochemical Methods 
2.4.1 Preparation of cell-lysates 
All following preparations were performed at 4oC with pre-chilled buffers. Cells 
were washed with PBS once, then scratched from cell-culture dish in 300 µl 
Lysis-buffer, and transferred to an Eppendorf Tube. Upon an incubation of 30 
min cell lysates were vortexed for about 10 s and then centrifuged at 13.000 rpm 
for 15 min and 4oC. The supernatant (=lysate) was transeferred to a new 
Eppendorf tube. Protein concentration was determined by Bradford. Lysates 
were stored at -20oC.    
2.4.2 Preparation of tissue-lysates  
For preparation of lysates, tumors were excised, transferred to an eppendorf 
tube, and frozen in liquid nitrogen immediately. Frozen tissue was grinded with 
mortar and pestle while adding liquid nitrogen continously. When tissue was 
homogenized, 1 ml pre-chilled RIPA-lysisbuffer was added and mixed carefully. 
Then, lysate was transferred to an eppendorf tube and incubated for 30 min on 
ice. Upon vortexing, lysates were centrifuged for 20 min at 13,000 rpm and 4oC. 
Supernatant was transferred to a new eppendorf tube and stored at -20oC.   
 
 RIPA-Lysis-buffer: 50 mM Tris-HCl, pH=7.4 
    150 mM NaCl 
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    1 mM  EDTA 
    0.5 %  Nonidet P-40 
    1 mM  NaF 
    15 %  Glycerol 
    20 mM b-Glycerophosphat 
 
Protease- and Phosphatase-Inhibitors (Pierce, Rockford, USA) were added 
fresh: 
 
 Protease-Phosphatase-Inhibitor-Cocktail: 
    1 mM  AEBSF-HCl 
    0.8 µM Aprotinin 
    5 µM  Bestatin 
    15 µM  E-64 
    5 mM  EDTA 
    20 µM  Leupeptin 
    10 µM  Pepstatin A         
    1 mM  Na-Vanadat                
2.4.3 Quantitative protein determination 
The Bradford-reagent (Bio-Rad, Hercules, USA) was used to assess quantities 
of soluble proteins. 5 µl of a protein-solution was dissolved in 200 µl of the 
Bradford-reagent mixed with 800 µl water and incubated for 5 min at RT upon 
the sample was vortexed shortly. The absorption was evaluated with a 
phtometer at 595 nm. By means of a calibration curve which was determined for 
BSA the factor for an exact calculation of protein concentrations could be 
assessed. 
2.4.4 Discontinuous SDS polyacrylamide gel electrophoresis  
The discontinuous SDS polyacrylamide gel electrophoresis involves the 
separation of proteins based on their size. Lysates were mixed with 4x Laemmli-
sample buffer containing -mercaptoethanol to reduce possibly existing disulfide 
bonds. Additionally, proteins were dentaurated by heating at 95 oC for 10 min. 
Therefore the size of negatively charged proteins defines their electrophoretic 
mobility which is about to be proportional to the molecular weight. The gel 
electrophoresis was performed in a vertical gel chamber (Invitrogen, Carlsbad, 
USA) at 190 V for approximately 45 min. The Rainbow-Marker (Amersham, 
Buckinghamshire, UK) was applied as a size standard. 
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 SDS-running buffer: 
    1.5 %  Tris-Base, pH=8.3 
    7.2 %  Glycin 
    0.5 %  SDS 
 
 4x Laemmli-sample buffer: 
    40 %  Glycerin 
    8 %  SDS 
    250 mM Tris-HCl, pH=6.8 
    0.4 %  Bromphenolblau 
    120 %  β-Mercaptoethanol 
2.4.5 Western blot and immunodetection 
Gel electrophoretic separated proteins were transferred to a nitrocellulose-
membrane (Amersham, Buckinghamshire, UK) by use of a tank blot chamber. 
For that the gel as well as the nitrocellulose membrane were dipped in water 
first, and afterwards incubated with two whatman paper and two sponges in 
transfer-buffer for 10 min. Gel and membrane were layered in the blotting 
cassette, air bubble-free, in between the two sponges and whatman paper, and 
then placed in the tank blot chamber which contained transfer-buffer and ice. 
Transfer of proteins from the gel to the membrane was performed at 110 V for 75 
min or 30 V over night, and at 4oC.  
To suppress unspecific bindings the membrane was blocked with 5 % 
milkpowder-solution in TBS-T for 1 h upon transfer. Afterwards the membrane 
was incubated with a solution containing the antibody of interest (1 µg/ml in TBS-
T) over night by rocking evenly at 4oC. The other day the membrane was 
washed once for 15 min and twice for 5 min with TBS-T. Then TBS-T was 
replaced with a corresponding solution of a HRP-conjugated secondary antibody 
for 1 h upon which the three-step washing procedure followed once again. The 
detection is based on Horseradish Peroxidase (HRP) labelled secondary 
antibodies. Solutions for detection contain a substrate, luminol, which in its 
oxifdated form results in exposition of chemiluminescence. Thus, occuring 
antibody-protein complexes could be visualized on autoradiography films.  
 
 Transfer-buffer: 14.4 g/l Glycerin 
    3.03 g/l Tris-HCl 
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    20 %  Methanol 
 
 TBS-T:  50 mM Tris-HCl 
    150 mM NaCl 
    0.1 %  Tween20  
 
For counterstainings the nitrocellulose membrane was covered with stripping 
buffer (Pierce, Rockford, USA), rocked for 10 min at RT, and then washed with 
TBS-T twice for 10 min. After a block with 5 % milkpowder solution for 1 h follow 
up procedures were performed as described above. 
2.4.6 Protein crosslinking 
To detect ligand-protein interaction, proteins were crosslinked to the ligand by 
using DSS or DTSSP. Both crosslinkers form covalent amide bonds between 
primary amino groups of lysine residues or the N-terminus of polypeptides and 
NHS-esters. The reaction results in the release of N-hydroxysuccinimide. While 
DSS binds ligand to protein covalently, DTSSP contains a disulfide bond and is 
therefore cleavable by β-mercaptoethanol or Dithiothreitol (DTT). 90 µl CM of 
HekIL-6RFP cells was mixed with 10 µl IL-6 representing a final concentration of 20 
ng/ml interleukin-6. DSS or DTSSP were added to a final concentration of 5 mM 
and whole mixture was incubated for 2 h at RT. Then, samples were mixed with 
4x Laemmli-sample buffer containing β-mercaptoethanol and subjected to SDS-
polyacrylamide gel electrophoresis and subsequent western blot. 
2.4.7 Preparation of nuclear extracts 
All following procedures were performed at 4oC with pre-chilled buffers. Cells 
were washed with PBS/Vanadate (0.1 mM) twice, detached from the cell culture 
dish and then transfered to an eppendorf tube. Upon centrifugation at 1500 rpm 
for 2 min sedimented cells were resuspended in 400 µl hypotonic Buffer A and 
incubated for 10 min. Then, cells were mechanically lysed by vortexing for 10 s 
followed by another centrifugation upon which the sediment was resuspended in 
100 µl Buffer C and incubated for 20 min.  The nuclear fraction encompassed 
the supernatant after centrifugation at 14000 rpm for 2 min.  
 
 Buffer A:  10 mM Hepes-KOH pH=7.9 
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    1.5 mM MgCl2 
    10 mM KCl 
 
 Buffer C:  20 mM Hepes-KOH pH=7.9 
    420 mM NaCl 
    1.5 mM MgCl2 
    0.2 mM EDTA 
    25 % (v/v) Glycerin 
 
Protease-Inhibitors were added freshly: 
    0.2 mM PMSF 
    0.5 mM DTT 
    1 mM  Na-Vanadate 
2.4.8 Electrophoretic-Mobility-Shift-Assay (EMSA) 
EMSA was performed to determine binding of proteins to specific DNA-
sequences. For that nuclear extracts were incubated with radioactive labelled 
DNA-oligonucleotides and electrophorestic separated.  
Up to 10 µg of nuclear extract were mixed with 9.5 µl probe mixture and 
radioactive probe with 10000 cpm and incubated for 10 min at RT. The probe 
mixture consists of 10 mM HEPES, 10 % Glycerol, 1 mM DTT, 0.1 µg/µl poly 
(dI:dC), 0.5 µg/µl BSA, and 0.2 pmols radiolabeled probe. For supershift controls 
STAT-specific antibodies were added additionally. The antibodies bind the 
examined protein whereby a complex of protein, DNA and antibody emerged. 
This complex should migrate slower in a native gel than DNA-protein complexes, 
what enables the identification of STAT-proteins. The separation of complexes 
was performed in 5.5 % native polyacrylamide gels at 220 V. Upon 
electrophooresis gels were fixed in 10 % methanol/10 % acetic acid for 30 min, 
and dried by vacuum at 80oC. Protein-DNA-complexes were visualized by 
autoradiography.  
 
 Gel:   6.75 ml Acrylamide (40/2 %) 
    4.5 ml  99 % glycerol 
    3 ml  5X TBE 
    43.5 ml Water 
    400 µl  10 % APS 
    40 µl  TEMED 
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 Running-buffer: 54 g  Tris-HCl 
    27.5 g  boric acid 
    20 ml  0.5 M EDTA 
 
To measure DNA binding of STAT3 a radioactive labeled double stranded 
m67SIE-DNA-oligonucleotide was used, which is a synthetic DNA sequence 
containing the sis inducible element (SIE) of the c-fos promoter. The DNA 
sequence contains a mutation (m67) which allows STAT1 and STAT3 to bind.  
   
 m67SIE: 5’-GAT TGA CGG GAA CTG-3’ 
(STAT binding site is underlined) 
2.4.9 Gelatin Zymography 
Zymography was performed in order to detect secreted matrix metallo 
proteinases (MMP) 2 and MMP-9. MMP-2 and MMP-9 are gelatinases. 
Conditioned medium of cells was mixed with an equal amount of Tris-Glycine 
sample buffer for 10 min at RT. Then, samples were applied to a Ready Gel 
Zymogram Gel with 10 % gelatin (Bio Rad Hercules, USA). The gel 
electrophoresis was performed in a vertical gel chamber with 1x Tris-Glycine 
Running Buffer at 125 V for approximately 80 min. After running, gel was 
incubated with Zymogramm Renaturing Buffer with gentle agitation for at RT. 30 
min later, Renaturing Buffer was replaced with Zymogramm Developing Buffer. 
Gel was equilibrated with gentle agitation for 24 h at 37oC. After washing thrice 
with ddH2O to remove SDS and buffer salts, which interfere with binding of the 
dye to the protein, gel was incubated with Simply Blue Safe Stain (Invitrogen, 
Grand island, USA) for 60 min at RT with gentle shaking. Then, gel was washed 
with ddH2O for 60 min and subsequently photographed at the α-imager. 
 
Sample-Buffer (2x): 2.5 ml  0.5 M Tris-HCl, pH = 6.8 
    2 ml  Glycerol 
    4 ml  10 % SDS 
    0.5 ml  0.1 % Bromphenol Blue 
    1 ml  ddH2O 
 
Running-Buffer: 2.9 g  Tris Base 
    14.4 g  Glycine 
    1 g  SDS 
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    To 1 L  ddH2O 
 
Renaturing-Buffer: 25 %  Triton X-100 
     
Developing-Buffer: 50 mM Tris-HCl, pH = 7.5 
    0.2 M  NaCl 
    5 mM  CaCl2 
    0.2 %  Brij 35 
     
2.4.10 Preparation of single cell from tissue 
Excised tumors were washed with HBSS+/+ (Ca2+, Mg2+) and treated with a 
homogenizing-buffer in which tissue was fragmented manually. Afterwards, 
homogenized tissue was incubated for 30 min at 37 oC and then filtered by a cell 
strainer (BD bioscience, Durham, USA). Interfering erythrocyte contaminations 
were removed by Lysis. For this prupose, cellsuspension was sedimented at 4oC 
with 1500 rpm for 5 min, resuspended in ACS, and incubated for 3 min at RT. By 
adding an excess of HBSS-/- Lysis was finalized. Upon a centrifugation with 1500 
rpm for 5 min cell sediment was resuspended in 10 ml HBSS-/-.  
For analysis of apoptosis by flow cytometry 1 ml of cell-suspension was 
transferred to FACS-tube and following a further centrifugation with 1500 rpm for 
5 min at 4oC cells were resuspended in 500 µl Binding-buffer containing 5 µl 
AnnexinV-FiTC (Biovision, Milpitas, USA. Samples were analyzed within 30 min 
after staining at the Accuri C6 of Accuri Cytometers (Ann Arbor, USA). 
Evaluation was performed with C-plus.  
For analysis requiring living cells 5 ml pre warmed Histopaque (Sigma, Saint 
Louis, USA) were pipetted below the cell-suspension, and centrifuged at 600 x g, 
no acceleration nor deceleration for 20 min. After density-gradient centrifugation 
opaque phase containing living cells was transferred to a new tube and washed 
with HBSS-/- thrice. Then cells were subjected to either flow cytometry or RT-
PCR. 
Homogenizing-buffer: 
    DNase  100 U/ml 
    Collagenase  400 U/ml 
    in HBSS+/+  
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ACS:  NH4Cl   9 g/l 
    KHCO3  1 g/l 
EDTA   37 mg/l 
 
2.5 Methods of Cell Biology 
2.5.1 Migration assay 
To analyze migration of cells a Boyden chamber assay was performed. A 
Boyden chamber consists of a transwell insert, with a porous filter (pore size: 8 
µm), that is set inside a culture plate. Migratory cells then move from the apical 
area of the transwell through the filter towards the lower compartment below, 
where they can be quantified.  
For this purpose, Collagen was diluted with medium to a final concentration of 
1.2 mg/ml, and was added to the cell culture insert (Corning, Tewksbury, USA). 
To harden the collagen, Boyden Chamber was incubated for approximately 30 
min at 37oC. Then, 150 µl of 2 x 105 cells were plated on collagen. 48 h later, 
cells that migrated to the lower compartment were collected, centrifuged for 5 
min at 1500 rpm, and counted by trypan-blue staining in a hemacytometer.  
2.5.2 Tube formation assay 
Angiogenesis is defined as the formation of new blood vessels from existing 
vasculature. Endothelial cells are the key cell type involved in this process. 
During angiogenesis, endothelial cell migrate toward angiogenic stimuli such as 
FGF or VEGF, proliferate, and differentiate into new capillaries. In order to 
determine the formation of three-dimensional vessels the tube formation assay is 
used as a model for studying endothelial differentiation into vasculature. For this 
purpose, ECs were stained with Cell Tracker Orange (CMTMR) (Invitrogen, 
Grand island, USA). 5 µM CMTMR was pre-warmed in serum-free medium to 
37oC. Afterwards, culture medium of ECs was replaced by medium containing 
CMTMR, incubated for 30 min at 37oC, and washed twice with medium 
containing FBS and antibiotics. Meanwhile, 1 ml collagen that was diluted with 
conditioned medium to a final concentration of 1.2 mg/ml was plated on a 6-well 
plate to achieve a nautral cellular environment and to enhance tube formation. 
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After collagen hardened at 37oC for approximately 30 min, 1.5 x 105 cells diluted 
in 150 µl were plated on collagen. Then, additional 2 ml collagen was diluted to a 
final concentration of 1.2 mg/ml and added to the 6-well plate. 24 h later, cell 
formation was analyzed at the confocal microscope LSM510. 
2.5.3 Tumor sphere formation assay 
Normal proliferating tissues are maintained by a stem cell population. Recent 
studies suggest that tumors as well are derived from a similar self-renewing 
subpopulation of undifferentiated cancer stem cells. The tumor sphere formation 
assay measures the ability to form stem cell colonies. These non-adherent 
spheres termed tumor spheres are enriched with cells containing stem cell-like 
properties. To evaluate the capability of cells forming tumor spheres, cells were 
resuspended, singularized by using a 40 µm cell strainer, and then counted by 
trypan blue staining with a hepacytometer. To remove remaining serum, cells 
were washed thrice with Hank’s balanced salt solution (HBSS, Invitrogen, Grand 
island, USA). Then, 5 x 104 cells were plated in 3 ml tumor sphere medium on a 
6-well plate. 20 ng/ml FGF-2 and EGF were added freshly. Formed tumor 
spheres with at least 20 cells per sphere were counted every other day using a 
transmitted light microscope for six days.  
 Tumor sphere medium: 
500 ml DMEM F-12 50:50 (1X) w/o Glutamine             
5 ml         200 mM L-Glutamine: (1%) 
13.7 ml      1M Hepes: (2.5%) 
10 ml        B-27 supplement (50X) 
420 ul       Heparin Sodium(1,000 U/ml) 
5 ml          Pen/Strep (10,000 U Pen/ml, 10,000 ug Strep/ml) 
                              
2.5.4 Flow cytometry 
Flow cytometry is a technology that measures multiple physical characteristics 
such as light scattering, light excitation, and emission of single particles, usually 
cells, in the size range of 0.5 μm to 150 μm diameter. The measured 
characteristics describe relative size, granularity, and fluorescence intensity of 
particles. For this purpose, particles are transported under pressure in a fluid 
stream through a beam of light with constant velocity to record how the particle 
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scatters incident laser light and emits fluorescence. The forward scatter (FSC) is 
used as a measure for particle’s size, while the side scatter (SSC) describes the 
granularity of particles. Fluorescence emission is processed by appropriate 
optical filters. The electronic system converts the detected light signals into 
electronic signals that can be processed by the computer.  
For analysis of cell surface proteins, cells were washed with HBSS once, 
detached from cell culture dish with 1 ml PBS/EDTA (10 mM) and transferred to 
a pre-chilled FACS tube. Cells were centrifuged at 1500 rpm (600 x g) for 5 min 
at 4oC, and sediment was resuspended with 500 μl FACS Buffer twice. 
Afterwards, cells were blocked with Fcγ antibodies diluted 1:100 in FACS Buffer 
for 10 min at 4oC. Then, cells were washed with 4 ml FACS Buffer twice and 
stained with fluorophore conjugated antibodies diluted 1:50 to 1:100 in FACS 
Buffer for 30 min on ice. Subsequently, cells were washed twice with 4 ml FACS 
Buffer. Sediment was resuspended in 300 µl FACS Buffer. The measurement 
was performed at the Accuri C6 (BD Accuri cytometers, Ann Arbor, USA) and 
analysis was performed with C plus.  
 
 FACS-Puffer: 5%  FBS 
    0,1%   NaN3 
    in PBS 
 
2.5.5 Enzyme-linked immunosorbent assay (ELISA) 
The sandwich ELISA is a method for detecting and quantifying a specific protein 
in a complex mixture. It involves the attachment of a capture antibody to a solid 
phase, like polystyrene microplate wells. Afterwards, samples containing known 
or unknown antigen, and then enzyme-labeled antibodies are added.  The 
detection antibody is either directly labeled with a signal-generating enzyme or 
fluorophore or it is probed with an enzyme- or fluor-labeled secondary antibody. 
For enzymatic detection, the appropriate enzyme substrate is added. The 
observed signal is proportional to the amount of antigen in the sample (Figure 8). 
In order to quantify a protein, the 100 μl capture antibody (goat anti mouse IL-
6Rα) was coated on a 96-well microplate and incubated over night at RT. The 
 
Materials and Methods 
 
42 
 
other day, plate was washed with 400 μl Wash Buffer twice and then blocked by 
adding 300 μl Blocking Buffer for 1 h at RT. 
 
 
After another wash 100 μl sample was added per well and incubated for 2 h at 
RT. Afterwards plate was washed and incubated with 100 μl Detection antibody 
at RT. 20 min later, plate was washed again and incubated with 50 μl substrate 
solution for 20 min at RT. The substrate solution consists of a 1:1 mixture ofH2O2 
and tetramethylbenzidine. After adding Stop solution to each well, the optical 
density was measured with λ = 450 nm using a microplate reader. All reagents 
were supplied from R&D Systems (Minneapolis, USA) and stored according to 
manufacturer’s recommendations. 
 
2.6 Handling and Treatment of Mice 
2.6.1 Mice 
The following mouse strains were used: 
B6.129S7-Rag1tm1Mom/J mice have a C57BL/6J background and lack B- 
and T- cells.  
Il2-rg(ko)/NOD-SCID mice are IL2 receptor gamma negative and 
therefore lack mature B-, T- and natural killer cells (NK). 
 
Treatment of mice with putative tumor growth inhibitors:  
Flutamide was diluted in 10 % EtOH and 90 % neobee oil and injected 
into mice in a concentration of 25 mg/kg. 
Secreted IL-6RFP was gathered in blank DMEM medium and injected in a 
concentration of 3.5 µg/kg. 
Figure 8: Principle of a 
sandwich ELISA. Capture 
antibodies are attached to a 
solid phase. After addition of 
antigens, biotinylated 
antibodies were added. For 
detection, Streptavidin-HRP 
was incubated first, and then 
TMB was added. 
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Bicalutamide was diluted in 10 % EtOH and 90 % corn oil and injected 
into mice with a concentration of 50 mg/kg. 
2.6.2 Observation of tumor growth 
Tumorgrowth was observed every 2 to 3 days using a vernier caliper (size = 
length x width x height) starting after a tumor volume of about 50 mm3 and until 
tumors reached sizes up to 1400 mm3. Growth curves were depicted by 
averaged values of 6 to 8 mice per group. Tumors of interest were excised and 
supplied to necroptic analysis. 
 
2.7 Microscopic Methods 
2.7.1 Indirect Immunofluorescence 
Indirect immunofluorescence in cells: 
Cells were plated on cover slips and washed with PBS++ after 24 h or 48 h. 
Fixation of cells was performed with 2 - 4 % paraformaldehyde at RT for 20 min. 
Afterwards, cells were washed with PBS++ and permeabilized with PBST++ for 5 
min at RT. To prevent unspecific bindings of antibodies, remaining aldehyde 
groups of permeabilized cells were saturated with 50 mM NH4Cl (dissolved in 
PBST++). Then, specimens were blocked with blocking-buffer for 60 min at RT. 
About 30 µl primary antibody, diluted 1:100 in 0.2 % BSA/PBST++ were pipetted 
on parafilm in a prepared wet chamber, cover slips were placed with cells upside 
down on antibody solution, and then incubated over night at 4oC. After washing 
with 0.2 % BSA/PBST++, cells were incubated with a secondary, fluorophore-
conjugated antibody (1:100 in 0.2 %BSA/PBST++) and Hoechst33342 to stain the 
nuclei for 1 h at RT. Then, specimens were washed thrice, whereby coverslips 
were dipped in 0.2 % BSA/PBST++ first, then in PBST++, followed by a dip in 
water. Finally, coverslips were mounted with Mowiol (Calbiochem, La Jolla, USA) 
on slides. Immunofluorescent stainings were analyzed by confocal microscopy 
(LSM510Meta, Carl Zeiss, Jena, Germany). 
 
 PBS++:  1 mM  MgCl2 
    0.1 mM CaCl2 
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    In PBS 
 
 PBST++:  0.1 %  Trton X-100 
    In PBS++ 
 
 Block-Puffer:  1 %  BSA 
    In PBST++ 
 
Indirect immunofluorescence in OCT frozen sections: 
For immunofluorescent staining of tumors, excised tissue was mounted with 
OCT and frozen at -80oC. Sections of frozen tissue were prepared at the 
Cryostat (Leica CM 3050S, Germany). After air drying at RT for 30 min, tissue 
sections of 10 µm were fixed with 2% paraformaldehyde for 15 min, 
permeabilized in ice cold methanol for 10 min, and washed thrice in PBS for 5 
min at RT. Then, sections were incubated with Image Enhancer (Invitrogen, 
Carlsbad, USA) for 30 min followed by a block in PBS supplemented with 10% 
goat serum/ 2.5% mouse serum (Sigma, Saint Louis, USA) for 1 h at RT. 
Incubation with primary antibodies diluted 1:50 – 1:100 in PBS containing 10% 
goat and 2.5% mouse sera was performed over night at 4 oC. The other day, 
sections were washed with PBS thrice for 5 min, and incubated for 1 h with 
fluorophore-conjugated secondary antibodies in PBS and Hoechst33342, 
followed by another wash with PBS thrice. Afterwards, tissue sections were 
mounted with Mowiol, covered with a coverslip and analyzed by confocal 
microscopy.   
 
Indirect Immunofluorescence in paraffin embedded slides: 
Archival human prostate carcinoma tissues from an anonymous group of 
patients were provided by the Pathology Core of City of Hope Comprehensive 
Cancer Center. Tumor tissues were formalin fixed and paraffin embedded. To 
soften paraffin slides of 3 μm were heated for 30 min at 42oC on a heating plate. 
Sections were deparaffinized in xylene thrice for 10 min, in 100 % ethanol for 10 
min, once in 100 % ethanol for 5 min, twice in 95 % ethanol for 5 min, then in 70 
% ethanol for 5 min, and finally in 50 % ethanol for 5 min. Afterwards sections 
were rinsed in water for 5 min and then boiled in 1x Antigen Unmasking Solution 
(Vector, Burlingame, USA) at 121oC for 10 min to retrieve antigens. Upon a 
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PBS-wash for 10 min sections were processed as described above (Indirect 
immunofluorescence of OCT frozen sections).  
 
Live cell imaging: 
For the upregulation of CD44 in tumor spheres, cells were incubated with APC 
conjugated CD44 antibodies 30 min before imaging. Plates were transferred to 
the confocal microscope and images were acquired within 10 min to avoid 
influences on cells by temperature changes. 
 
Instructions and settings: 
Hoechst33342 diluted (Invitrogen, Carlsbad, USA) to a final concentration of 100 
ng/ml was added to secondary antibody solution and used to stain DNA. It binds 
preferably at AT-rich regions in the small groove of DNA and it has an emission 
maximum at 460 nm. The excitation of the fluorophore was performed by means 
of a 2-photon-laser at 790 nm. With 2-photon-technique fluorescent molecules 
were excited by effectively simultaneous absorption of two almost infrared 
photons. Detection of fluorophores was performed employing different filters. In 
case of Hoechst33342 fluorescence a bandpassfilter with λ = 390 - 465 nm was 
applied. 
In proof of YFP-fusionproteins an argon laser with λ = 514 nm was chosen. 
Detection of YFP emission was performed by a bandpassfilter, λ = 535 - 590 nm. 
AlexaFluor488, Cy2, or FiTC conjugated secondary antibodies were excited with 
λ = 488, and emissions were detected by a bandpassfilter with λ = 500 - 530. 
Secondary antibodies conjugated to AlexaFluor546, AlexaFluor555, as well as 
CellTracker Orange -CMTMR (Invitrogen, Carlsbad, USA) were excited with λ = 
543 nm, and detected between λ = 565 - 615 nm.  
Mean fluorescence intensities were used for quantifications of fluorescence 
intensities. For this purpose single fluorescence intensities of fluorophore-
conjugated secondary antibodies in regions of interest were recorded in 12 bit 
mode and arbitrary units were quantified and averaged. Microscopic settings for 
optimal fluorescence intensities were adapted for each experiment. Among each 
experiment, microscopic settings were kept consistently to achieve comparable 
results. Moreover, nuclear fluorescence intensity profiles were generated at the 
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confocal microscope in which Hoechst staining was used as a marker for the 
nuclei.  
Recording of fluorescence intensities was performed at the confocal laser 
scanning microscope LSM 510 (Carl Zeiss, Jena, Germany) with objectives such 
as 10x (Fluar 10x/0.5), 20x (Plan-Apochromat  20x/0.8), 40x (C-Apochromat 
 40x/1.20 W corr), or a 63x (C Apochromat  63x/1.20 W corr) and a constant 
slice thickness (1 µm).  
2.7.2 Intravital Multi Photon Microscopy (IVMPM) 
Background:  
In conventional linear (i.e. single-photon) fluorescence imaging, short 
wavelength light is used to excite fluorophores. After relaxation (NR) excited 
electrons drop from an energetic higher state (S1) back to default (S0). The 
resulting energy or emission at a slightly longer wavelength due to the Stokes 
shift is used to form the image. For this purpose, the excitation light is focused 
into the specimen. The fluorescence from the focal plane passes through the 
pinhole and arrives at the detector.  
Since single photons are used for the excitation of the fluorophore, light is 
emitted along the laser-beam (Figure 9A). This results in several disadvantages 
of which one general problem is that the short (high-energy) excitation 
wavelengths enhance phototoxicity resulting in fluorophore bleaching. To 
exclude light scattering confocal microscopy utilizes a pinhole. Thus, this 
technique allows 3D sectioning (x,y,z) into thicker tissue. However, high-energy 
wavelength causes tissue damage and therefore decreases penetration depth. 
The application of non-linear multiphoton microscopy provides 3D optical 
sectioning without phototoxicity below and above the focal plane, because two-
photon excitation occurs only at the focal spot. Thus, depth of tissue penetration 
is improved compared to single-photon microscopy (500 µm vs 80 µm). The 
principle of intravital multiphoton microscopy (IVMPM) is that an atom or 
molecule can absorb near-simultaneous energy from two photons, each of which 
contributes one half of the energy required to induce fluorescence. The electrons 
of a fluorophore are transferred from default (S0) to a higher energy state (S2). 
The following relaxation results in energy loss (NR), and upon drop of electrons 
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from S1 to default (S0), light of longer wavelength is emitted (Stokes shift). The 
resulting fluorescence emission varies with the square of the excitation intensity. 
Due to this quadratic relationship between excitation and emission, fluorescence 
is constrained to a focal spot formed by the microscope objective. Typically, 
each pulse lasts of about 100 fs, with intervening gaps of 10 ns compared to a 
continuous laser as used in single photon microscopy (Figure 9B). 
 
                  
 
 
 
 
 
 
 
 
 
 
 
For intravital Multi Photon Microscopy tumor bearing mice were anesthetized 
with a 2 % isoflurane/oxygen gas, and prepared for surgery. Then, mice were 
injected with dextran-rhodamine (100 µg/200 µl HBSS-/-) (Invitrogen, Carlsbad, 
USA) to visualize the vasculature, AnnexinV-FiTC (BioVision), or CD44-FiTC (50 
 
A B 
Figure 9: Comparison of single- and multi-photon microscopy. A: Schematic beam path of 
linear one photon, confocal microscopy (Top). Single photons of a high energetic laser (λ = 488 
nm) excite fluorophores. Electrons in the fluorophore drop after relaxation (NR) from S1 to 
Default (S0). Emission occurs along the laser beam (bottom). B: Schematic beam path of non-
linear two-photon microscopy (top). Near-simultan photons excite fluorophores. Due to the 
quadratic relationship betwenn excitation and emission, light is emitted at a focal point (bottom). 
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μg/200 μl) (Biolegend, USA) in complex with an equal amount of an iRGD 
peptide with the sequence: CRGDKGPDC (synthesized by Piotr Swiderski at the 
City of Hope), and/or Hoechst33342 (250 µg/200 µl HBSS-/-) intravenously. 
Anesthesized mice were opened ventrally and the subcutan growing tumor was 
exposed. Afterwards, the region of interest was coated with a coverslip and 
analyzed by IVMPM. Tumor bearing mice continued to receive 2 % 
isofluorane/oxygene anesthesia while imaging was performed using the Prairie 
Technologies Ultima microscope (Middleton, USA). To record rhodamine- and 
YFP- emission, fluorophores were excited with λ = 860 nm. Emission was 
recorded by a filter with λ = 500 nm – 550 nm (YFP), and 565 nm - 615 nm 
(rhodamine). For recording Hoechst33342 emission signals were recorded at λ = 
730 nm with emission between 435 nm – 485 nm. Extracellular matrix (ECM) 
emission was given by second harmonic generation at λ = 890 nm (Coherent 
Chameleon Ultra II Ti:Sa laser). Images were acquired using an Ultima 
Multiphoton Microscopy System (Prairie Technologies) equipped with Prairie 
View software and non-descanned Hamamatsu PhotoMultiplier Tubes, and 
objectives such as 40x (Olympus LUMPlanFL/IR 40x/0.80W) or 10x (Olympus U 
PLanFLN 10x/0.30). Images were collected in a 512x512 pixels, 16-bit 
resolution. TIFF formatted images were analyzed by Image Pro Plus 
professional imaging software (Media Cybernetics, Bethesda, MD). 
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3 Results 
 
3.1 Critical Role of STAT3 in Prostate Tumorigenesis  
3.1.1 IL-6-STAT3 signaling pathway is important for prostate cancer progression 
upon hormone deprivation. 
In primary prostate cancer oncogenic cells expressing the androgen receptor 
(AR) depend on androgens to survive. Therefore, in this androgen-sensitive 
state treatment with anti-androgens is one of the standard therapies. Among 
others, flutamide is an anti-androgen that competes with testosterone for the 
ligand-binding domain of AR, inhibiting its transcriptional activity. As such, 
flutamide is used for hormone deprivation therapy. However, after one to three 
years cancer frequently recurs even more aggressively and is considered to be 
androgen-independent [142].  
To investigate the role of STAT3 in the transition from androgen-sensitive to 
androgen-independent prostate cancer upon hormone deprivation therapy, 
TRAMP-C1 (TC1) cells were engrafted in immunocompromised Rag1-/- mice. 
Murine TC1 cells are epithelial prostate cancer cells of luminal origin and 
represent the primary tumor site. Rag1-/- mice lack B- and T-cells and were used 
to avoid immune responses that could impact tumor growth. 
Once the TC1-tumors were palpable and reached a volume of 200 – 300 mm3, 
mice were injected intraperitoneally with either 25 mg/kg flutamide or a vehicle 
control. Relative to the control-vehicle treated group, flutamide administration 
resulted in significantly delayed tumor growth initially. However, subsequent 
treatment with flutamide was insufficient to reduce growth kinetics, but rather 
resulted in tumor growth progression. On day 36, eight days after start of 
treatment, the vehicle treated mice (V) reached a tumor volume of 885 mm3, 
while flutamide injected mice (Fl1) obtained mean tumor sizes of 372 mm3.  
Subsequent continuing flutamide administration of group Fl2 resulted in tumor 
sizes of 856 mm3 after day 46 (Figure 10A). On the 36th day, tumor-bearing mice 
from group V and Fl1 were euthanized to perform necroptic analysis. The 
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remaining mice treated with flutamide were resected 46 days after tumor cell 
engraftment (Fl2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The excised tumors were prepared for western blot analysis, indirect 
immunofluorescence and RT-PCR.  
In order to determine patterns in AR and STAT3 protein expression upon 
flutamide treatment, lysates were subjected to western blot and analyzed with 
antibodies as indicated.  
 
MFI – AR 
V Fl1 Fl2 
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B 
Figure 10: Impact of anti-androgen therapy on tumor growth, AR expression and STAT3 
activity. A: 3 groups of Rag1-/- mice (V, Fl1 and Fl2, with n = 8) were injected with 2.5 x 10
6
 
TC1 cells subcutaneously (s.c.). Treatment with 25 mg/kg flutamide or vehicle started on day 28 
(indicated by the black arrow) and was performed  intraperitoneally (i.p.) every other day. Mean 
tumor volumes are shown in graph (n = 6 – 7). On days 36 and 46 tumors were harvested 2 
hours after last treatment (indicated by red boxes). B: Lysates of excised tumors were analyzed 
by western blot with antibodies raised against indicated proteins. C: Frozen sections of isolated 
tumors were prepared and stained with primary antibodies raised against pYSTAT3 or AR. 
Secondary antibodies conjugated to AF488 were used for immunodetection. pYSTAT3 and AR 
are depicted in green. Hoechst dye was added for nuclear staining and is depicted in blue. 
(Scale: 100 µm) D: Shown are fluorescence intensities of tyrosine phosphorylated STAT3 or AR 
from 3 different tumors. Bar graphs show quantified mean fluorescence intensities (MFI) (n = 3). 
Error bars represent standard deviation. 
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Since AR binds to its own promoter to induce AR expression [192], anti-
androgen treatment resulted in decreased AR protein-level (Fl1 and Fl2) 
compared to vehicle control. Conversely, flutamide administration led to elevated 
STAT3 total protein. Moreover, tyrosine phosphorylation of STAT3 was 
increased in Fl2 relative to vehicle control. No significant change in STAT3 
phosphorylation was detectable when comparing V and Fl1. Since 
phosphorylated STAT3 was elevated in Fl2 but not in Fl1, it seemed that STAT3 
activity might be critical for anti-androgen escape. Staining with antibodies 
against β-actin was performed as a loading control (Figure 10B). To confirm this 
result, tumor sections were immunostained for pYSTAT3 or AR. Relative to 
vehicle control, images showed decreased fluorescence intensities in Fl1 and 
Fl2 sections stained for AR, while fluorescence of pYSTAT3 was elevated upon 
flutamide treatment, especially in Fl2. Moreover, immunofluorescent staining 
revealed that tyrosine phosphorylated STAT3 was predominantly localized in the 
nucleus. AR was co-localized with the nuclear staining as well, suggesting AR 
activity (Figure 10C). Mean fluorescence intensities (MFIs) of obtained images 
were calculated to quantify protein expressions of AR and pYSTAT3. The bar 
graph showed a steady increase of tyrosine-phosphorylated STAT3 during 
flutamide treatment. In contrast, MFIs revealed decreases of AR expression in 
samples Fl1 and Fl2 compared to vehicle control (Figure 10D).  
    
 
  
 
                                                                                                         
 
 
 
 
 
 
 
 
 
    
Figure 11: IL-6, Osm, Vegf and Egf mRNA levels in vehicle-control and flutamide treated 
tumors. Harvested tumors of mice treated with either vehicle control or Flutamide were prepared 
for RT-PCR. Extracted mRNAs were reverse transcribed to cDNA, quantified by PCR and 
normalized to GAPDH. Bar graph shows IL-6, OSM, VEGF and EGF mRNA levels normalized to 
vehicle control. IL-6 mRNA expression level was performed in triplicates. Error bars represent 
standard deviation. 
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In order to detect potential ligands responsible for STAT3 activation upon 
flutamide administration, mRNA expressions from members of IL-6 type 
cytokines and the growth factor family were analyzed by RT-PCR. Flutamide-
treatment did not affect VEGF or EGF mRNA expression levels considerably. In 
contrast, OSM expression was augmented 2.24 fold in Fl1, but dropped to 1.31 
in Fl2. Relative to vehicle control, mRNA expression of IL-6 was elevated in both 
samples, Fl1 and Fl2 (Figure 11). Thus, IL-6 might be the activator of STAT3 
under anti-androgen treatment. 
3.1.2 STAT3 is relevant for the initiation of prostate cancer. 
In order to evaluate the oncogenic potential of STAT3 and AR in primary 
prostate cancer, knock-downs were engineered in TC1 cells by using shRNAs 
for STAT3, AR as well as a non-silencing control.  
Gene silencing of STAT3 and AR was validated on protein level by western blot 
analysis. Relative to non-silencing control, the knock-down of STAT3 did not 
affect the AR expression level.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conversely, AR-silenced cells revealed elevated levels of total and tyrosine-
phosphorylated STAT3 protein. β-actin was used as a loading control (Figure 
12A). Moreover, relative to non-silencing control TC1 cells, AR knock-down led 
to increased interleukin-6 mRNA expression (3.53 fold) (Figure 12B). This is 
 
Figure 12: Expression levels of STAT3- and AR-protein and IL-6 mRNA in TC1 knock-
down cells. TC1 knock-down cells were engineered by delivering shRNAs for STAT3, AR and 
non-silencing control lentivirally. A: Cell lysates were prepared and analyzed by western blot 
with antibodies raised against pYSTAT3, STAT3, AR and Actin. B: Bar graph shows IL-6 mRNA 
expression of shRNA cell-lines quantified by RT-PCR in triplicates and normalized to mRNA 
levels of TC1 cells expresseing non-silencing control. Error bars represent standard deviation.  
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consistent with previous studies showing that AR represses the IL-6 promoter 
[193, 194]. Therefore, up-regulation of phosphorylated STAT3 and STAT3 
protein might be a result of increased IL-6, correlating with previous results 
shown in figure 10 and 11. There, anti-androgen treatment by flutamide revealed 
diminished AR protein expression, followed by up-regulation of the IL-6/STAT3 
signaling pathway. Thus, TC1-ARshRNA cells might represent prostate cancer 
cells in hormone deprivation state. In STAT3-silenced TC1 cells, mRNA 
expression of IL-6 decreased to 0.52-fold induction compared to non-silencing 
control. This might be a result of an improper induction of the IL-6 promoter by 
NFB. NFB induced IL-6 expression has been suggested to be promoted by 
STAT3 [195] (Figure 12B).  
To further investigate the impact of STAT3 on prostate tumorigenesis in vivo, 
immunocompromised NSGNOD mice lacking B-, T- and natural killer (NK) cells 
were engrafted with TC1 cells expressing shRNAs for STAT3, AR or non-
silencing control. Tumor growth was observed for 29 days. Growth kinetics 
revealed that knock-down of AR did not influence tumor progression compared 
to control tumors. On the 29th day,  AR-silenced tumors reached a mean volume 
of 649 mm3 in comparison to a mean volume of 627 mm3 for control tumors. 
Conversely, knock-down of STAT3 resulted in growth delay with tumors 
obtaining a median volume of 161 mm3 after 29 days (Figure 13A). In order to 
validate gene silencing of AR and STAT3 in vivo, sections of frozen tumor tissue 
were stained for tyrosine phosphorylated STAT3 and AR. Confocal images 
revealed decreased fluorescence intensities of phosphorylated STAT3 and AR 
protein in their respective shRNA tumors (Figure 13B). Additionally, mean 
fluorescence intensities of pYSTAT3 or AR from images acquired at the confocal 
microscope confirmed decreased expression of either pYSTAT3 (1.9 fold) or AR 
(10.4 fold) in TC1STAT3shRNA or TC1ARshRNA tumors compared to MFIs in TC1 
tumors expressing non-silencing control shRNAs. Moreover, the fluorescence 
intensity of phosphorylated STAT3 was elevated 1.38-fold in tumors silenced for 
AR  compared to control tumors, confirming in vitro results shown by western 
blot in figure 12A (Figure 13C). Interestingly, as shown by immunofluorescent 
staining, expression of CD31 was down-regulated in STAT3 shRNA tumors 
(Figure 13B). CD31 or PECAM-1 is a member of the cell adhesion family of 
 Results  
54 
 
proteins and is predominantly expressed by endothelial cells. Therefore, it is 
used as a marker for vascularization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To further evaluate evidence of diminished vascularization upon STAT3 knock-
down in tumor tissue, intra-vital multiphoton microscopy (IVMPM) was performed 
on living animals. Tumor-bearing mice were anesthesized and injected with a 
mixture of Hoechst33342 and dextran-rhodamine. Subsequently, tumors were 
exposed for imaging purposes. IVMPM was performed at the Prairie microscope 
using a 2-photon laser. 
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Figure 13:  Analysis of STAT3 and AR knock-down in TC1 tumors in vivo. A: 2 x 10
6
 TC1 
cells virally transfected with shRNAs for STAT3, AR or non-silencing control were injected s.c. 
into 3 groups of NSGNOD mice with n = 7. Graphs show quantified tumor volumes over time (n 
= 6). B: After 29 days excised tumors were prepared for immunofluorescent staining using 
antibodies raised against pYSTAT3 or AR and secondary antibodies conjugated to Cy2 (green). 
Additionally, CD31 was immunostained with a specific primary and AF555-conjugated secondary 
antibody (red). Hoechst33342 was added to stain the nuclei. Scale: 100 µm. C: Fluorescence 
intensities of phosphorylated STAT3 (left) or AR (right) were acquired at the confocal 
microscope. Bar graphs show quantified mean fluorescence intensities (MFI) (n = 3). Error bars 
represent standard deviation. 
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Figure 14: Analysis of STAT3- or AR- knock-down on angiogenesis, proliferation and 
apoptosis. A: Intra vital multiphoton microscopy (IVMPM) on living animals. Tumor bearing mice 
as indicated were retro-orbitally injected with a mixture of dextran-rhodamine [100 µg/200 µl] and 
Hoechst33342 [250 µg/200 µl]. Then, tumors were exposed. Imaging was performed using a 
two-photon laser with λ = 730 nm for detection of Hoechst, and λ = 860 nm for Rhodamine. 
Scale bar represents 200 µm. B: Frozen sections of excised tumors were immunostained with 
fluorophore-conjugated secondary antibodies recognizing specific primary antibodies raised 
against Ki-67 and CD31. Hoechst was added to stain the nuclei. Scale: 100 µm. C: Single-cell 
suspensions of excised tumors were prepared for FACS analysis. Cells of non-silencing control 
tumors were either stained with AnnexinV-FiTC or left unstained as a blank control. Tumor cells 
silenced for STAT3 or AR were stained with AnnexinV-FiTC. Five min later, cell suspensions 
were analyzed by flow cytometry. D: Tumor sections were immunostained for cleaved caspase 3 
and CD31 with specific primary and AF488- or AF555-conjugated secondary antibodies. 
Hoechst33342 was added 1:500 to stain the nuclei. Scale: 100 µm.    
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Acquired images revealed a proper and functional vasculature in both non-
silencing control and AR-silenced tumors. In contrast, no vascularization was 
detectable in tumors silenced for STAT3. Here, blood vessels were either leaky 
or collapsed, because the dextrane-rhodamine appeared to be distributed 
ubiquitously in the tissue and was not constrained to the vasculature. Nuclear 
staining with Hoechst was used as a tissue marker (Figure 14A).  
Furthermore, tumor sections were stained for the proliferative marker Ki-67. Ki-
67 is a nuclear protein and not expressed in non-proliferating, G(0) resting cells. 
It turned out that Ki-67 was present in both, non-silencing control and AR shRNA 
tumors, but was diminished in tumors silenced for STAT3. Additional staining for 
CD31 showed decreased fluorescence intensity in STAT3 knock-down tumors, 
which is consistent with previous results as shown in figures 14B and 15A 
(Figure 14B). 
To determine apoptosis induced by knock-down of either AR or STAT3 in vivo, 
single cell suspensions of excised tumors were stained with AnnexinV 
conjugated to fluorescein isothiocyanate (FITC) and analyzed by flow cytometry 
(FACS). The FACS analysis revealed slightly increased apoptotic events in 
tumors silenced for AR as compared to non-silencing control tumor cells. 
However, knock-down of STAT3 resulted in the highest detectable apoptotic 
events. The increase of stained non-silencing control tumor cells versus non-
stained cells (blank) is considered to be background fluorescence (Figure 14C).  
To confirm flow cytometry results, sections of frozen tumor tissue were stained 
for cleaved caspase 3. Caspase 3 is a central protein of apoptosis. For its 
activation, caspase 3 is cleaved into activated p17 and p12 fragments. It turned 
out that cleaved caspase 3 was elevated in tumors silenced for STAT3. It was 
mainly located in the cytoplasm of tumor cells and appeared in patches in the 
tumor tissue.  
To determine the impact of STAT3 and AR on gene induction, gene expression 
profiles were analyzed by qPCR arrays that represent the angiogenic and IL-
6/STAT3 signaling pathways. TC1 cells silenced for STAT3 or AR were 
compared to non-silencing control cells. While STAT3-silenced TC1 cells 
showed decreased mRNA expression of inflammatory genes, knock-down of AR 
led to elevated levels of α2M (α2-Macroglobuline), CRP (C-reactive protein) and 
IL-6. Since α2M and CRP are target genes of STAT3, the increase of these 
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inflammatory genes might be a result of up-regulated STAT3 activity upon AR 
gene silencing. Moreover, since SOCS3 is induced by STAT3, SOCS3 mRNA 
was down-regulated in TC1 cells silenced for STAT3 (- 7.32). SOCS3 mRNA 
level was reduced in AR knock-down cells as well (- 5.35). The decrease in 
SOCS3 expression favors the IL-6/STAT3 signaling pathway. Moreover, knock-
down of STAT3 resulted in decreased expression of metastatic (MMP2) and 
angiogenic (HIF1α, FGF1, FGF2) factors (Table 7).  
 
 
 
 
 
 
 
 
 
 
In summary, STAT3 seems to be important for the initiation and progression of 
primary prostate cancer. RNAi-induced knock-down of STAT3 resulted in 
decreased proliferation, angiogenesis, and anti-apoptosis. Conversely, knock-
down of AR had no effect on progression of tumor growth, but rather promoted 
the IL-6/STAT3 signaling pathway. 
3.1.3 STAT3 signal-transduction impacts angiogenesis and metastasis in 
prostate cancer. 
To further determine the role of STAT3 in angiogenic and metastatic processes 
in prostate cancer,  TC1 cells were stably reconstituted with STAT3-YFP or 
STAT3-YFP. The functionality of STAT3α fused to YFP has been demonstrated 
previously [196]. The fusion protein STAT3β-YFP was cloned by excising 
STAT3α from the pcDNA5/FRT/TO-STAT3α-YFP vector and inserting STAT3β. 
STAT3β is a splicing isoform of STAT3α, and is considered to act dominant-
negative on STAT3 target-gene induction [42].  
 ARshRNA STAT3shRNA 
A2m 5.98 - 3.28 
Crp 5.98 - 3.28 
Il6 2.01 - 4.7 
Socs1 1.38 2.34 
Socs3 - 5.35 - 7.32 
 
  
   
   
   
   
   
 
 ARshRNA STAT3shRNA 
Mmp2 1.01 - 7.75 
Mmp9 1.45 - 1.38 
Hif1a 1.13 - 2.5 
Fgf1 1.09 - 5.33 
Fgf2 1.23 - 3.85 
 
  
   
   
   
   
   
 
Table 7: QPCR arrays to measure mRNAs of the IL-6/STAT3 signaling pathway and 
angiogenic pathway. Total RNA of TC1 cells expressing shRNAs for STAT3, AR, or non-
silencing control was isolated, converted to cDNA, and then analyzed by qPCR using SYBR 
Green. Relative gene expression was normalized to GAPDH. Expression levels above + 2 or 
below – 2 were considered to be regulated.   
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To evaluate the impact of STAT3α on angiogenesis, endothelial cells (EC) 
derived from prostate were cultured on collagen to mimic the natural 
environment. Cells were cultured with conditioned medium (CM) of TC1 cells 
expressing either STAT3α- or STAT3β-YFP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tube formation of EC cells was imaged and quantified after one and two days. It 
turned out that factors secreted by TC1-STAT3β-YFP cells decreased tube 
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Figure 15: Impact of STAT3α and STAT3β on angiogenic processes A: Endothelial cells 
derived from prostate (ECs) were labeled with CMTMR, plated on collagen, and covered with 
conditioned medium (CM) of TC1-STAT3α-YFP or STAT3β-YFP cells. Tube formation was 
analyzed by confocal microscopy (left) and quantified per field of view (FOV) after 24 and 48 h 
(right). Error bars represent standard deviation. B: ECs labeled with CMTMR were co-cultured 
with TC1 cells stably expressing STAT3α-YFP or STAT3β-YFP on collagen-containing CM of 
TC1-STAT3α-YFP or STAT3β-YFP cells. Tube formation was analyzed by confocal microscopy. 
C: 3 groups of NSGNOD mice (n = 8) were injected subcutanously with 2 x 10
6
 TC1 cells, or 
TC1 cells stably expressing STAT3α-YFP or STAT3β-YFP. Tumor growth was observed for 33 
days. Graph shows quantified tumor volume [mm
3
] (n = 6) over time. Error bars represent 
standard deviations. D: To record vascularization, anesthesized mice were injected with 
Dextran-rhodamine [100 µg/200 µl] and exposed tumors were analyzed by IVMPM, ECM is 
shown by second-harmonic generation (2HG) (blue). Scale bar represents 200 µm.   
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formation of ECs considerably compared to cells expressing STAT3α-YFP as 
shown by confocal images (left) and quantifications (right) (Figure 15A). 
Moreover, in co-cultures of CellTracker Orange (CMTMR) -labeled ECs and TC1 
cells expressing STAT3α or STAT3β revealed that TC1-STAT3α-YFP cells 
seemed to support the tube formation of ECs. Here, TC1-STAT3α-YFP cells 
showed branches and formed tubes. Conversely, STAT3β-YFP cells were 
distributed homogenously and did not seem to promote tube formation (Figure 
15B). To determine the impact of STAT3 protein on vascularization in vivo, 
parental TC1 cells, TC1-STAT3α-YFP or TC1-STAT3β-YFP were injected into 
NSGNOD mice s.c.. Tumor growth kinetic revealed that STAT3α enhances 
tumor progression compared to control TC1 tumors. In contrast, the presence of 
over-expressed STAT3β resulted in considerable tumor growth delay (Figure 
15C). Furthermore, in vivo imaging of the vasculature stained by dextran-
rhodamine showed no detectable vascularization in TC1 STAT3β-YFP tumors as 
compared to tumors over-expressing STAT3α-YFP. The extracellular matrix 
(ECM) consists of collagen and fibrinogen and represents stromal stability. The 
ECM was used as a tissue marker and was visualized by second harmonic 
generation (2HG). Second harmonic generation describes a non-linear optical 
phenomenon where photons interact with a non-linear material such as the 
collagen fibers in the ECM. By using a two-photon laser with λ = 890 nm the 
autofluorescence of the collagen fibers is detectable (Figure 15D).  
 
To assess the role of STAT3 protein in metastasis of prostate cancer cells, 
conditioned medium of TC1 cells and TC1 cells expressing STAT3α-YFP or 
STAT3β-YFP was analyzed by zymography. Secretory factors MMP2 and 
MMP9, which are produced and secreted in metastatic tumor cells, were 
measured. MMP2 and MMP9 are gelatinases and are important for ECM 
degradation as one of the first steps in metastatic processes [197]. MMP2 and 
MMP9 are secreted as inactive pro-proteins and get activated through cleavage 
by extracellular proteinases. Zymography analysis revealed no detectable MMP9 
or MMP2 in CM of TC1 control and TC1 cells stably expressing STAT3β-YFP. 
Conversely, active MMP2 and MMP9 were secreted by TC1 cells expressing 
STAT3α-YFP.  
 
 Results  
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TC1 
STAT3
CM 
TC1 
STAT3
CM 
TC1 
control 
CM 
Figure 16: Role of STAT3 in prostate cancer metastasis A: TC1, TC1-STAT3α- or TC1-
STAT3β-YFP cells were cultured with 4 ml medium for 48 h. 30 µl conditioned medium (CM) was 
subjected to Zymography using a gelatin-gel. B: Boyden chamber assay was performed with 
TC1cells, TC1-STAT3α- and TC1-STAT3β-YFP cells. 250,000 cells were cultured on collagen-
covered cell-culture inserts with 8 µm pores (n = 3). After 48 h, migrated cells were quantified. 
Error bars represent standard deviation. C: TC1-STAT3α-YFP and TC1-STAT3β-YFP cells were 
stained with APC-conjugated specific antibodies as indicated. The expression of CD44, Galectin-
3 and integrin β1 was analyzed using fluorescence-activated cell sorting (FACS). The YFP 
positive cell population was gated. D: TC1-STAT3α-YFP and TC1-STAT3β-YFP cells were 
injected into NSGNOD mice intravenously (i.v.). Two mice each were prepared for imaging on 
day 1, 3, 5 and 7. Lung colony formation was visualized by 2-photon imaging using a laser for 
YFP (λ = 860 nm). ECM is shown by 2HG with λ = 890 nm and depicted in blue. Scale bar 
represents 200 µm.  
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Since only cleaved MMP2 and MMP9 among the matrix metallopeptidases exert 
collagenase activity, any additional detected band is considered to be artificial 
(Figure 16A). 
In order to assess migration as part of the metastatic processes, parental TC1 
cells, TC1 cells expressing STAT3α- or STAT3β-YFP were analyzed in a boyden 
chamber assay for 48 h. It turned out that considerably more TC1-STAT3α-YFP 
cells (4704) migrated to the bottom of the well as compared to parental TC1 cells 
(1926). In contrast, stably expression of STAT3β-YFP repressed cell migration 
(Figure 16B). In the process of metastasis, tumor cells adhere to distant tissue. 
For that purpose metastatic cells express adhesion molecules such as Galectin-
3, CD44, or integrin β1 to modulate cell-to-cell and cell-to-extracellular matrix 
interaction. To determine protein regulation of adhesion molecules, TC1 cells 
expressing STAT3α-YFP or STAT3β-YFP were stained with specific APC-
conjugated antibodies for integrin β1, Galectin-3 and CD44. Cell-suspensions 
were analyzed by flow cytometry (FACS). The results demonstrated that protein 
expression of integrin β1, Galectin-3 and CD44 was elevated in TC1 cells 
expressing STAT3α-YFP compared to STAT3β-YFP TC1 cells, suggesting that 
inhibiting STAT3 activity led to decreased expression of adhesion molecules 
(Figure 16C). To further evaluate the effect of STAT3 on metastasis in vivo, TC1 
cells expressing STAT3α- or STAT3β-YFP were injected intravenously into 
immunocompromised Rag1-/- mice. In this assay, tumor cells with metastatic 
activity will infiltrate the lungs. In a time dependent manner, lungs were extracted 
and subsequently imaged using 2-photon microscopy. Acquired images revealed 
that TC1 STAT3α-YFP cells infiltrated the lungs already after 24 h. Moreover, 
overexpression of STAT3α resulted in nodule formation after 3-5 days, and 
colonies expanded up to day 7. Conversely, TC1 cells expressing STAT3β-YFP 
did not infiltrate the lungs before day 5. No colony formation was detectable up 
to day 7 (Figure 16D).  
In summary, inhibition of STAT3α action seems to repress angiogenic and 
metastatic processes in prostate cancer.     
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3.2 Targeting the IL-6/STAT3 Signaling Pathway using the IL-6 Receptor 
Fusion Protein (IL-6RFP) 
3.2.1 Functional characterization of the IL-6 receptor fusion protein. 
Previous experiments have shown that the IL-6/STAT3 signaling pathway might 
be important for the initiation and progression of prostate cancer. On the one 
hand, the IL-6/STAT3 signaling pathway was up-regulated upon anti-androgen 
treatment or knock-down of AR (Figure 10, 11, 12). This is consistent with 
previous studies demonstrating that IL-6 was elevated in patients with advanced 
prostate cancer or HRPC [188, 189]. On the other hand, gene silencing of 
STAT3 reduced tumor growth of prostate cancer cells considerably (Figure 13A). 
Therefore, IL-6/STAT3 signaling seemed to be a promising target for prostate 
cancer therapy. In order to determine a possible therapeutic agent, the efficiency 
of the IL-6 receptor fusion protein (IL-6RFP) as an inhibitor of the IL-6 signaling 
pathway was assessed.  The IL-6RFP competes with cognate transmembrane 
receptors for IL-6-binding. IL-6RFP consists of the three extracellular domains of 
murine IL-6R and three N-terminal domains of murine gp130 (IL-6R) fused by 
an artificial, flexible peptide linker. C-terminally, a histidine tag (His-tag) is fused 
to the murine IL-6RFP [102, 198] (Figure 17A). To produce soluble IL-6RFP, HEK 
cells were stably transfected with the IL-6RFP. Assessing the expression and 
secretion of IL-6RFP in HEKIL-6RFP cells, CM and lysates of parental HEK and 
HEKIL-6RFP cells were compared by western blot analysis as indicated in figure 
17B. Two protein bands were detectable in lysates of HEKIL-6RFP using antibodies 
against His and gp130. The detection of two IL-6RFP protein isoforms might be a 
result of glycosylation processes. Furthermore, secreted IL-6RFP was detectable 
in CM of HEKIL-6RFP cells as a single band. Here, the protein band of IL-6RFP was 
slightly shifted compared to cellular receptor fusion protein which is assumingly a 
result of glycosylation as well. In lysates and CM of non-transfected HEK cells no 
protein was measurable using His antibody. Actin was used as a loading control 
(Figure 17B). To evaluate concentrations of secreted IL-6RFP, HEKIL-6RFP cells 
were cultured with 4 ml Medium for two days. IL-6RFP concentration of HEKIL-6RFP 
CM was quantified by ELISA and amounted to 196.54 ng/ml (Figure 17C).  
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Figure 17: Functional characterization of IL-6
RFP
 in vitro. A: Domain structure of murine IL-
6
RFP
. B: Lysates and conditioned medium (CM) of HEK cells expressing IL-6
RFP
 (HEK
IL-6RFP
) and 
parental HEK cells were subjected to western blot and analyzed with antibodies as indicated. C: 
HEK
IL-6RFP 
and HEK cells were cultured with 4 ml DMEM medium for 48 h. Bar graph shows 
concentrations of mIL-6Rα in HEK
IL-6RFP 
CM and HEK
CM
 quantified by ELISA. Error bars 
represent standard deviation. D: For 4 h HEK
IL-6RFP 
CM [0.071 pmol] was incubated with IL-6 
[4.54 pmol] and two crosslinkers, DSS [5 mM] or DTSSP [5 mM], as indicated. Mixtures were 
subjected to western blot and analyzed with antibodies against His-tag and IL-6.  
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Moreover, the IL-6 binding capability of IL-6RFP was determined in vitro by adding 
recombinant IL-6 to IL-6RFP-conditioned medium. As shown in figure 17D, IL-6 
was detectable in complex with IL-6RFP by irreversible crosslinking with DSS 
(lane 3). Two protein bands were detectable using His-tag antibodies 
representing free and IL-6 bound to the receptor fusion protein. Since the lower 
protein band runs on the same height as plain IL-6RFP (lane 2), the upper band 
represents the complex of IL-6 and IL-6RFP. Western blotting with antibodies 
raised against IL-6 detected protein band at about 130 kDa (lane 3). This band 
represented IL-6RFP crosslinked to IL-6. The slight shift of the IL-6 band in lane 4 
compared to lane 5 is probably a result of reversible crosslinking between IL-6 
and IL-6RFP by DTSSP (Figure 17D).  
In order to assess the inhibition of IL-6 downstream events by administration of 
IL-6RFP, TC1 cells were stimulated with either conditioned medium (TCM) of 
murine fibrosarcoma cells (MFib) that secrete high amounts of IL-6 (600 pg/ml, 
data not shown) or left unstimulated. Stimulation of TC1 cells with MFibTCM 
containing 27.27 pM IL-6 led to augmented levels of phosphorylated STAT3. 
Conversely, stimulated cells that were treated with a 65-fold molar surplus of IL-
6RFP CM (1.787 nM) showed reduced STAT3 tyrosine phosphorylation. 
Expression of STAT3 total protein was augmented in MFibTCM-stimulated cells, 
but was not affected upon IL-6RFP administration (Figure 17E). 
To analyze nuclear accumulation of phosphorylated STAT3, TC1 cells were 
stimulated with 25 % MFibTCM and treated with ascending concentrations of IL-
6RFP CM for 24 h, as indicated. Cells were then fixed and immunostained against 
tyrosine-phosphorylated STAT3. Recorded images showed dose-dependent 
decrease of phosphorylated STAT3 colocalized with Hoechst, which was used to 
stain the nuclei (Figure 17F).  Nuclear fluorescence intensity profiles were 
E: TC1 cells were stimulated with CM derived from murine fibrosarcoma cells (MFib) [600 pg/ml] 
or left unstimulated. Additionally, cells were treated with an equal amount HEK
IL-6RFP 
CM [196.54 
ng/ml] or left untreated as indicated. 24 h later lysates were analyzed by western blot with 
antibodies raised against pYSTAT3, STAT3, and β-actin. F: TC1 cells stimulated with 25 % 
MFib
TCM
 were treated with HEK
IL-6RFP 
CM dose dependently (0, 25, 50, 75 %). After 24 h cells 
were fixed and immunostained with antibodies for pYSTAT3 and analyzed by confocal 
microscopy. Hoechst was added to stain the nuclei. (Scale: 10 µm). G: Quantified and 
normalized fluorescence intensity profiles of nuclear pYSTAT3 are shown in bar graph. Error 
bars represent standard deviation. H: TC1 cells were stimulated with 25 % MFib
CM
 and 
incubated with IL-6
RFP
 CM for 24 h as indicated. Nuclear extracts were prepared and analyzed 
by EMSA using a radiolabeled probe (SIE) specifically bound by activated STAT3 and STAT1. 
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acquired at the confocal microscope. Relative fluorescence intensities were 
averaged and normalized with a fluorescence intensity profile of unstimulated 
cells. Quantified and normalized nuclear fluorescences are depicted in a graph 
to support recorded images showing diminished nuclear translocation of 
activated STAT3 upon IL-6RFP administration (Figure 17G). Finally, DNA-binding 
ability of STAT3 was analyzed after treatment with IL-6RFP. Therefore, nuclear 
extracts of TC1 cells stimulated with MFibTCM (25 %) and treated with increasing 
concentrations of IL-6RFP CM (0 %, 25 %, 50 %) were prepared and subjected to 
EMSA analysis. Administration of IL-6RFP resulted in a dose dependent decrease 
of STAT3 DNA-binding. Supershift analysis was performed with a STAT3 
specific antibody (Figure 17H).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to compare the inhibitory activities of IL-6RFP to a neutralizing antibody 
(MP5-20F3), IL-6 induced tyrosine phosphorylation of STAT3 was determined. 
TC1 cells were stimulated with IL-6 and treated with 1.78 nM IL-6RFP or varying 
concentrations of anti-IL-6 antibody. Staining for GAPDH was used as a loading 
Figure 18: Comparison of the IL-6 inhibitory activity of IL-6
RFP
 to a neutralizing antibody.  
TC1 cells were treated with HEK
IL-6RFP 
CM [1.78 nM], or an anti-IL-6 antibody with increasing 
concentrations (0.17, 1.78, 17.8, 178, and 1780 nM) as indicated, or left untreated for 2 h. 90 
min after treatment started, cells were stimulated with IL-6 [10 ng/ml] or left unstimulated for 30 
min. A: Lysates were analyzed by western blot with antibodies raised against pYSTAT3 and 
GAPDH. B: The intensity of pYSTAT3 bands were quantified with ImageQuant, corrected with 
background and normalized with the intensities of stimulated, untreated cells in lane 2. 
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control. The western blot analysis revealed that 1.78 nM IL-6RFP diminished IL-6 
induced activation of STAT3 considerably. Moreover, application of a 
neutralizing antibody resulted in a dose-dependent decrease of tyrosine 
phosphorylated STAT3. However, similar concentrations of IL-6RFP and anti-IL-6 
antibody showed different inhibitory activities on STAT3 phosphorylation (Figure 
18A). The quantification of pYSTAT3 band-intensities revealed a 3.5 fold 
increased IL-6 inhibitory activity of IL-6RFP relative to the neutralizing antibody 
using concentrations of 1.78 nM (Figure 18B). 
Taken together, the IL-6RFP is properly processed and secreted, exerts the 
desired biological activity of capturing interleukin-6, and therefore reduces IL-6-
induced STAT3 activation. The inhibitory activity of IL-6RFP is 3.5 fold increased 
compared to a neutralizing antibody.   
3.2.2 Determination of the best delivery route of IL-6RFP in vivo. 
In order to assess the best delivery route of IL-6RFP in vivo it seemed necessary 
to first evaluate the biostability of the receptor fusion protein in mouse serum. 
For this purpose IL-6RFP-conditioned medium was incubated with an equal 
volume of mouse serum for different times. The mixture was analyzed by 
western blot with antibodies raised against His-tag.  
 
 
 
 
 
 
 
 
Relative to IL-6RFP at 0 min, the receptor fusion protein amount decreased time 
dependently. After 24 h, IL-6RFP protein was barely detectable. Additional protein 
bands that were detectable 1 min after mixing the receptor fusion protein with 
mouse serum seemed to hint at proteolytic degradation of IL-6RFP in mouse 
serum (Figure 19).  
0’ 1’ 5’ 15’ 30’ 2h 4h 24h 
130 
Mr [kDa] 
100 His 
Figure 19: Biostability of IL-6
RFP
 in mouse serum. IL-6
RFP
 CM was incubated with the same 
volume mouse serum in a time-dependent manner as indicated. Mixture was subjected to 
western blot and analyzed with antibodies raised against His-tag. 
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Since the IL-6RFP protein seemed to be degraded within 24 h, IL-6RFP-conditioned 
medium (CM) was injected into tumor bearing mice with a concentration of 1.8 
µg/kg twice daily (3.6 µg/kg per day).  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
To determine the best biological efficiency of the IL-6RFP in vivo, 
immunocompromised Rag1-/- mice were injected with TC1 cells s.c.. Upon 
palpable tumors reached a volume of about 350 mm3, 3 cohorts of mice were 
injected with either IL-6RFP CM, CM of parental HEK cells or blank medium. 
HEKCM and medium in the absence of antibiotics and bovine serum were used 
as vehicle control. The injections were placed either subcutaneously peritumoral, 
intraperitoneal or intravenously. IL-6RFP treatment started 27 days after tumor cell 
engraftment. Growth kinetics revealed that peritumoral (s.c.) administration of IL-
6RFP resulted in the most significant tumor growth inhibition. Intravenous 
treatment of IL-6RFP by retro-orbital injections delayed tumor growth kinetics, and 
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Figure 20: Delivery routes of IL-6
RFP
 in 
vivo. 2 x 10
6
 TC1 cells were injected into 
3 groups of Rag1-/- mice s.c. (n = 8). 27 
days after cell engraftment, tumors were 
treated with IL-6
RFP
 CM [1.8 µg/kg], 
HEK
CM
, or blank medium. Injections were 
placed either A: i.p., B: s.c., C: or i.v. 
(indicated by the black arrows). Tumor 
growth was observed for 37 days. On 
day 37, tumor tissue was excised and 
prepared for necroptic analysis. Error 
bars represent standard deviation. 
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intraperitoneal administration of the receptor fusion protein had the least effect 
on tumor growth. On day 37, in all three different delivery routes, mice treated 
with vehicle (HEKCM or blank medium) reached tumor volumes between 700 – 
900 mm3. Intraperitoneal IL-6RFP administration resulted in mean tumor sizes of 
572 mm3; i.v. injected mice obtained mean tumor volumes of 417 mm3, and 
peritumoral injections led to mean tumor sizes of 316 mm3 (Figure 20).  
After 37 days, tumor-bearing mice from s.c., i.p., and i.v. injected mice were 
euthanized two hours after last treatment to perform necroptic analysis. Tyrosine 
phosphorylation of STAT3 and STAT3 total protein was analyzed by western 
blot. Relative to vehicle-treated mice, administration of IL-6RFP reduced 
phosphorylated STAT3 and total STAT3 protein considerably when tumors were 
injected subcutaneously.  
 
 
 
 
 
 
 
 
 
 
Decrease in total STAT3 expression might be a result of diminished STAT3 
activation upon IL-6RFP treatment, because phosphorylated STAT3 induces its 
own promoter. Systemic, intravenous administration of IL-6RFP appeared to result 
in reduced expression and phosphorylation of STAT3 as well, but not as 
effective as in s.c. injected mice. Conversely, intraperitoneal administration of IL-
6RFP had no considerable impact on STAT3 expression or phosphorylation which 
seemed consistent with the tumor growth kinetic. β-actin was used as a loading 
control (Figure 21). Taken together, subcutaneous, peritumoral administration of 
IL-6RFP twice daily had significant impact on tumor growth of primary prostate 
cancer cells. Moreover, efficient IL-6RFP treatment correlates with diminished 
tyrosine phosphorylated STAT3 and total STAT3 expression. Hence, reduced 
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Figure 21: Inhibition of STAT3 phosphorylation by IL-6
RFP
 in vivo. Tumors of i.p., s.c., or i.v. 
injected mice either treated with blank medium (M), HEK
CM 
(CM), or IL-6
RFP
 CM (IL-6
RFP
)were 
harvested. Tumor tissue of each group was pooled and frozen in liquid nitrogen. Lysates were 
prepared and subjected to western blot analysis. STAT3, pYSTAT3  and Actin were stained with 
specific primary antibodies and HRP-conjugated secondary antibodies. 
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tumor growth might be due to inhibition of IL-6 signal transduction and 
decreased STAT3 activity. 
3.2.3 The IL-6 receptor fusion protein decreases prostate cancer progression by 
inhibiting tumorigenic processes. 
The IL-6/STAT3 signaling pathway is known to induce a number of oncogenic 
factors which are involved in proliferation, survival, angiogenesis, and anti-
apoptosis. Therefore, the impact of IL-6RFP on tumor promoting processes in 
primary prostate cancer was determined. Peritumoral injections of IL-6RFP 
appeared the most promising delivery route to affect tumor growth of TC1 
engrafted cells. Therefore, tumor tissue was excised from subcutaneous 
administered HEKCM and IL-6RFP groups of mice for immunofluorescent 
stainings.  
To evaluate the infiltration of IL-6RFP and occurrence of IL-6 in the tumor, frozen 
sections were dried, fixed and immunostained with antibodies against His-tag 
and IL-6. Hoechst was used for nuclear staining and as a tissue marker. As 
shown by immunofluorescent staining, IL-6 is expressed ubiquitously in the 
tumor tissue of vehicle- (HEKCM) treated mice. Here, staining for IL-6RFP by His-
tag antibodies was negative. In IL-6RFP treated mice, tumor infiltration of 
administered IL-6RFP as well as IL-6 staining turned out to be confined. The 
strongest IL-6RFP fluorescence appeared at the edge of the IL-6-positive area 
and seemed partly co-localized with IL-6 as indicated by the circles. Moreover, 
areas lacking IL-6, but partly positive for IL-6RFP revealed porous Hoechst 
staining, possibly indicating instability of the tissue (indicated by the arrows). In 
contrast to vehicle treated tumors, occurrence of porous Hoechst staining and 
lack of IL-6 was observed at the edge of the tumor. The edge of the tumor is 
marked by a dot. Since IL-6RFP administration was performed peritumoral, 
porous Hoechst and lack of IL-6 at the tumor edge might be a result of the 
inhibitory activity of the IL-6 receptor fusion protein, infiltrating the tumor from the 
edge to the center, presumably causing tissue instability (Figure 22A).  
To assess activation of STAT3 upon IL-6RFP tumor infiltration, tissue sections 
were stained for tyrosine phosphorylated STAT3 and His-tag. Similar to IL-6, 
activated STAT3 is distributed ubiquitously in vehicle-treated tumor sections 
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while equal fluorescence intensities of pSTAT3 were locally restricted upon IL-
6RFP treatment as indicated by the arrows. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 22: Tumor infiltration of IL-6
RFP
. Frozen sections of isolated tumors from subcutaneous 
IL-6
RFP
 treated tumor-bearing mice were prepared for immunofluorescent stainings. A: Tumor 
sections were stained with fluorophore-conjugated secondary antibodies recognizing specific 
primary antibodies raised against IL-6 and His-tag. B: Sections of isolated tumors were stained 
for tyrosine phosphorylated STAT3 and His-tag by fluorophore conjugated secondary antibodies. 
Edge of tumor tissue is indicated by the dot. C: Mean fluorescence intensities (MFI) were 
obtained from images recorded at the confocal microscope; MFI bars represent average of 3 
different tumor sections. D: AR was stained in sections by specific primary and AF488 
conjugated secondary antibodies. Hoechst was used as nuclear staining (left). Fluorescence 
intensities of AR were quantified and depicted in the graph (right). Scale: 100µm. Error bars 
represent standard deviation. 
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Images of phosphorylated STAT3 and IL-6RFP revealed that activated STAT3 is 
reduced in all areas positive for IL-6RFP. This confirms the biological activity of IL-
6RFP in vivo (Figure 22B). Quantified mean fluorescence intensities of activated 
STAT3 supported depicted images by revealing a 4.16-fold decrease of tyrosine 
phosphorylated STAT3 upon IL-6RFP injection, relative to vehicle control (Figure 
22C).  
Furthermore, locally constrained peritumoral treatment with IL-6RFP did not affect 
protein expression of AR as shown by immunofluorescent staining and quantified 
MFIs (Figure 22D). This indicates that in vivo IL-6RFP specifically inhibits 
signaling events downstream of the IL-6 receptor complex.  
To evaluate the impact of IL-6RFP on proliferative activity of engrafted TC1 
tumors, Ki-67 was stained in frozen tumor sections of isolated tumor tissue. 
Immunofluorescent staining revealed that Ki-67 was mainly localized in the 
nucleus. Moreover, the marker for proliferation was decreased upon IL-6RFP 
administration (Figure 23A, left). Additional quantifications of mean fluorescence 
intensities from three different tumor sections supported representative images 
showing an inhibitory effect of IL-6RFP on proliferation (Figure 23A, right).  
Furthermore, administration of IL-6RFP resulted in reduced vascularization as 
shown by immunofluorescent staining of CD31, an endothelial marker. Hoechst 
dye stained the nuclei and was used as a marker for the tissue (Figure 23B, left). 
Manual calculation of CD31 stained blood vessels revealed a diminished number 
of blood vessels upon IL-6RFP treatment (Figure 23B, right).  
Finally, in vivo imaging by 2-photon microscopy was performed to analyze 
apoptosis in living, animals. For this purpose, two mice of each, the vehicle- and 
the IL-6RFP treated group were anesthesized, injected with AnnexinV-FiTC, and 
then prepared for imaging. AnnexinV staining occurred in tumors injected with IL-
6RFP. Imaging of the extracellular matrix (ECM) was performed as a tissue 
marker. The ECM indicates tissue stability whereby disarranged ECM hints to 
instable tissue. Relative to vehicle control, IL-6RFP administration resulted in 
decreased organization of ECM, indicating tissue instability (Figure 23C). 
Additionally, staining of tumor sections from vehicle- and IL-6RFP treated mice 
showed elevated levels of cleaved Caspase 3 upon inhibition of the IL-6/STAT3 
signaling pathway (Figure 23D).   
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Hence, immunoflurescent stainings could demonstrate the infiltration of IL-6RFP 
into the tumor tissue, in which it partially co-localized with IL-6. Locally confined 
IL-6RFP resulted in diminished tyrosine phosphorylation of STAT3, but did not 
affect expression levels of AR, indicating biological specificity in vivo. Moreover, 
inhibition of the IL-6/STAT3 signal transduction pathway by IL-6RFP reduced 
tumorigenic processes such as proliferation, angiogenesis and anti-apoptosis.  
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Figure 23: Impact of IL-6
RFP
 on proliferation, angiogenesis and apoptosis. Tumors of either 
IL-6
RFP
 or HEK
CM
 injected mice were harvested and prepared for immunofluorescence. A: 
Sections of isolated tumors were stained with Ki-67 specific primary and AF488-conjugated 
secondary antibodies. Hoechst was added to stain nuclei. Images were recorded at the confocal 
microscope (left). Fluorescence intensities of Ki-67 were quantified and depicted in a graph (n = 
3) (right). B: Tumor sections were stained for CD31 and Hoechst. 3 x 3 tile scans were obtained 
with a 20x objective, no zoom (left). CD31 stained blood vessels were counted and quantified in 
a graph (n = 3) (right). C: Tumor-bearing mice were injected with AnnexinV-FiTC and analyzed 
by intra-vital multi photon microscopy (IVMPM). ECM is shown by 2HG. D: Tumor sections were 
stained for cleaved Caspase 3 with specific primary and fluorophore-conjugated secondary 
antibodies. Nuclei were stained with Hoechst. Scale: 100 µm. Error bars represent standard 
deviation. 
Scale bars: 100 µm. Error bars represent standard deviation. 
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3.3 STAT3 promotes Cancer Stem Cell Phenotype Development 
3.3.1 Hormone deprivation therapy promotes cancer stem cell phenotype. 
Cancer stem cells (CSCs) are a subpopulation of tumor cells. They possess the 
ability of self-renewal and differentiation and they are characterized by the 
expression of overlapping markers with normal stem cells from the same tissue. 
Among others, CSC markers that have been identified for prostate cancer are 
CD44, Sox2, MSI-1, Nanog and integrin α2β1 [158, 173]. Based on the CSC 
theory, conventional cancer therapy results in tumor regression initially, but since 
CSCs seem to be highly drug resistant, tumor relapse frequently occurs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As most cancer cells, TC1 cells generally express the established CSC marker. 
Therefore, the focus of the investigations laid on the regulation of CSC marker 
C 
A B 
Figure 24: Impact of flutamide treatment 
on CSC marker expression. Tumors of 
either flutamide or vehicle injected mice 
were excised and prepared for immune-
fluorescence. Sections of isolated tumors 
were stained with specific primary and 
AF488 conjugated secondary antibodies. 
Hoechst was added to stain nuclei. Images 
were obtained at the confocal microscope 
(left). Mean fluorescence intensities were 
quantified and depicted in a graph (n = 3) 
(right). A: Staining and quantifications for 
Sox2. B: CD44. C: MSI-1. 
Scale bars: 100 µm. Error bars represent 
standard deviation. 
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expression under different conditions such as anti-androgen treatment, gene 
silencing of STAT3 or AR, and treatment with IL-6RFP. Since hormone deprivation 
therapy most often results in tumor recurrence, the impact of flutamide on CSC 
phenotype development was assessed. Therefore, the expression of various 
biomarkers putatively related to the cancer stem cell phenotype was determined.  
Tumors of vehicle and flutamide treated groups of mice were excised and 
prepared for immunofluorescent staining. Images and mean fluorescence 
intensities of Sox2 staining revealed an increase of the stained CSC marker 
upon flutamide treatment. Sox2 turned out to be ubiquitously expressed in 
flutamide injected tumor tissue and its cellular localization was equally detectable 
in the cytoplasm and the nucleus (Figure 24A). Similar results were achieved by 
staining of tumor sections with antibodies raised against CD44 and MSI-1. 
Immunofluorescent stainings and quantifications of mean fluorescence 
intensities of both cancer stem cell markers, CD44 and MSI-1, were elevated in 
flutamide administered tumor bearing mice relative to vehicle treated mice 
(Figure 24B and 24C).  
These results demonstrated that hormone deprivation therapy by flutamide 
treatment resulted in elevated expression of three cancer stem cell markers, 
Sox2, CD44, and MSI-1. This might indicate that hormone deprivation therapy 
triggers the development of cancer stem cell phenotype which might be the 
reason for cancer recurrence. 
3.3.2 Knock-down of STAT3 resulted in decreased cancer stem cell phenotype 
Since hormone deprivation therapy led to the development of a CSC phenotype, 
the impact of STAT3 and AR on the up-regulation of CSC markers was 
determined. For this purpose, TC1 cells expressing shRNAs for STAT3, AR or 
non-silencing control were plated in conditions enhancing tumor-sphere 
formation.  
It has been shown that undifferentiated multipotent tumor cells could be grown 
and maintained in suspension using the tumor sphere assay.  The tumor sphere 
assay measures the ability of tumor cells to form stem cell colonies and enriches 
tumor cells with stem-like properties. Thus, sphere formation enables to isolate, 
enrich and to enumerate the potential CSC subpopulations.  
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Figure 25: Effect of STAT3 and AR knock-down on CSC development. A: TC1 cells 
expressing STAT3 or AR shRNA, or non-silencing were cultured in tumor sphere medium for 6 
days. Every other day sphere formation was counted at a brightfield microscope. B: On the 6
th
 
day, lysates of tumor spheres were prepared, subjected to western blot and analyzed with 
antibodies as indicated. C/D: Tissue of TC1 tumors silenced for STAT3, AR or non-silencing 
control tumors were excised and prepared for immunofluorescence. Sections were stained with 
specific primary antibodies for Sox2, MSI-1 (C), CD44 or Nanog (D) and fluorophore-conjugated 
secondary antibodies (AF488). Images were obtained at the confocal laserscanning microscope. 
Scale bars: 100 µm. (left). Mean fluorescence intensities of Sox2, MSI-1 (C), and CD44 or 
Nanog (D) were averaged from 3 different sections. Error bars represent standard deviation 
(right). 
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As shown, relative to non-silencing control (32), AR knock-down cells formed 
significantly more tumor-spheres (109) while cells silenced for STAT3 did not 
show considerable sphere formation capability (7) after six days (Figure 25A). 
Lysates of tumor-spheres subjected to western blot and analyzed with antibodies 
as indicated supported the results from the  sphere formation assay. This more 
detailed analysis demonstrated that TC1 cells generally express the established 
CSC markers such as MSI-1 and Sox2. More importantly, expressions of MSI-1 
and Sox2 were elevated in tumor spheres formed by AR-silenced cells relative to 
non-silencing control or TC1 cells silenced for STAT3. The up-regulation of MSI-
1 and Sox2 correlated with elevated tyrosine phosphorylated and total STAT3 
expression in TC1 cells upon knock-down of AR (Figure 25B).  
To investigate the role of STAT3 and AR in the up-regulation or development of 
cancer stem cell markers in vivo, mice were injected with TC1 cells silenced for 
STAT3, AR, or non-silencing control. Palpable tumors were excised and 
prepared for necroptic analysis.  
Sox2, MSI-1, CD44, and Nanog were stained in tumor sections, and 
fluorescence intensities obtained from confocal microscopy were quantified. 
Representative images and MFIs revealed diminished expression levels of the 
mentioned cancer stem cell markers in STAT3 silenced tumors compared to TC1 
tumors silenced for AR or non-silencing control. Consistent to the tumor sphere 
formation assay and the subsequent western blot analysis, fluorescence 
intensities of CSC markers were slightly elevated in AR silenced tumors relative 
to non-silencing control. However, increased CSC marker expression did not 
turn out to be as dramatic as in vitro analysis (Figure 25C, D).  
Taken together, knock-down of AR by RNAi resulted in enhanced CSC 
phenotype development. Conversely, gene silencing of STAT3 led to diminished 
expression of CSC markers such as Sox2, MSI-1, CD44, and Nanog, indicating 
that STAT3 impacted CSC phenotype development. Thus, increased CSC 
phenotype upon AR inhibition might be a result of elevated interleukin-6 
expression (Figure 11 and12B) and subsequent enhanced STAT3 activity.  
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3.3.3 Inhibition of the IL-6/STAT3 signaling pathway by IL-6RFP leads to reduced 
cancer stem cell phenotype. 
Since the IL-6/STAT3 signaling pathway might be critical for the development of 
cancer stem cell phenotype, the IL-6 receptor fusion protein seemed a promising 
inhibitor to target CSCs. In order to determine inhibitory effects of IL-6RFP on 
prostate cancer stem cells, TC1 cells were cultured in tumor sphere-promoting 
conditions.  
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Figure 26: Impact of IL-6
RFP
 on CSC development in vitro. A: TC1 cells were cultured in 
tumor sphere medium for 6 days. Cells were treated with either IL-6
RFP
 CM or HEK
CM
 every other 
day. Formed tumor sphere were counted at a brightfield microscope. B: Lysates of tumor 
spheres were prepared, subjected to western blot and analyzed with antibodies as indicated. 
Exposure time was adjusted to avoid blackshield effect. C: On the 6
th
 day of the sphere 
formation assay cells treated with either HEK
CM
 or IL-6
RFP
 CM were incubated with an APC-
conjugated CD44 antibody and prepared for flow cytometry. D: TC1 cells treated as indicated 
were incubated with a CD44 antibody conjugated to APC. 30 min later cells were analyzed at the 
confocal microscope. Formed tumor spheres are indicated by a black circle. Scale: 100 µm.    
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Relative to vehicle control (HEKCM) (754 spheres), application of IL-6RFP resulted 
in decreased sphere formation (325 spheres) (Figure 26A). Reduced tumor 
sphere formation upon IL-6RFP application was associated with reduced Sox-2 
and diminished levels of pYSTAT3 and STAT3 expression as detected by 
western blot analysis (Figure 26B). Assessing CD44 expression, TC1 tumor 
spheres treated with either HEKCM or IL-6RFP were stained with specific 
antibodies conjugated to APC and analyzed by flow cytometry and live cell 
imaging. Quantifications by FACS analysis showed a decrease in CD44 
expression from 34.2 % to 23.3 % upon IL-6RFP administration (Figure 26C). 
Furthermore, inhibition of IL-6/STAT3 signaling reduced CD44 expression 
visualized in living cells by confocal microscopy. Acquired images of vehicle 
treated cells showed non-adherent tumor spheres as indicated by the circles. 
These spheres revealed up-regulation of CD44. In contrast, IL-6RFP treatment 
resulted in no detectable tumor sphere formation accompanied by diminished 
CD44 expression (Figure 26D).  
To evaluate the impact of IL-6/STAT3 signaling inhibition on CSC phenotype 
development in vivo, Rag1-/- mice were injected with TC1 cells and treated with 
either HEKCM or IL-6RFP twice daily. Once vehicle treated tumors reached a 
volume of about 800 mm3, tumor tissues were excised and prepared for 
necroptic analysis. Lysates were subjected to western blot and analyzed with 
antibodies as indicated. Western blot analysis revealed that vehicle treated TC1 
tumors expressed the CSC markers MSI-1 and Sox2. IL-6RFP administration 
demonstrated inhibitory effects on Sox2, and MSI-1 expression. Moreover, 
decreases in CSC marker expression correlated with reduced levels of 
phosphorylated STAT3. In addition, a weak reduction in STAT3 expression was 
detectable. Actin was used as a loading control (Figure 27A).  
To confirm CSC marker expression, frozen sections of isolated tumor tissue 
were prepared for immunofluorescent staining. Representative images as well as 
mean fluorescence intensities (MFIs)v showed reduced expression of Sox2 upon 
IL-6RFP administration. Here, Sox2 expression was distributed ubiquitously, 
similar to vehicle control (Figure 27B). In contrast, MSI-1 appeared to be 
expressed in distinct areas of IL-6RFP treated tumors only. Fluorescence 
intensities of MSI-1-positive areas were not decreased when compared to 
vehicle control (indicated by the circle). The distribution of IL-6RFP in the tumor 
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tissue was not ubiquitously as well, similar to previous results shown in figures 
22A and 22B. However, tumor areas infiltrated by IL-6RFP revealed reduced MSI-
1 fluorescence as indicated by the arrows (Figure 27C, left). Quantifications of 
MSI-1 fluorescence intensities showed decreased CSC marker expression upon 
IL-6RFP treatment (Figure 27C, right). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 1.45-fold decrease of MSI-1 fluorescence intensity upon IL-6RFP treatment 
seemed moderate in comparison to the diminished expression of MSI-1 shown 
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Figure 27: Impact of IL-6
RFP
 on CSC development in vivo. TC1 tumor-bearing mice were 
injected subcutaneously with either IL-6
RFP
 CM or HEK
CM
 (vehicle control). When control tumors 
reached tumor volumes of about 800 mm
3
, tissue was excised for necrotpic analysis. A: Lysates 
were prepared and subjected to western blot using antibodies against pYSTAT3, STAT3, MSI-1, 
Sox2 and Actin. B: Sections of isolated tumor tissue were stained with antibodies raised against 
Sox2 and an AF488-conjugated secondary antibody. For nuclear staining, Hoechst was added 
(left). Mean fluorescence intensities of Sox2 were determined from images acquired at the 
confocal microscope (right). C: Tumor sections of vehicle and IL-6
RFP
 treated mice were 
incubated with specific primary antibodies for MSI-1 and His-tag and stained with fluorophore-
conjugated secondary antibodies. Hoechst was added to stain nuclei (left). Quantifications of 
MSI-1 fluorescence intensities were averaged using 3 different sections and are shown in the 
graph (right). Scale bars: 100 µm. Error bars represent standard deviation. 
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by western blot analysis in figure 27A. MSI-1 expression was detected as a 
locally confined event in immunofluorescent stainings, but up-regulation of the 
CSC marker in few areas of the tumor tissue might not have been sufficient 
enough to show a signal in the westen blot analysis.  
Moreover, fluorescence staining of Nanog was similar to that of MSI-1. While 
Nanog-fluorescence was distributed homogenously in vehicle treated tumors, IL-
6RFP administration resulted in decreased fluorescence intensity of Nanog in 
areas infiltrated by the receptor fusion protein (Figure 28A, left).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MFIs showed overall decrease (2.71 fold) of Nanog fluorescence intensity in IL-
6RFP treated mice relative to vehicle injected tumors (Figure 28A, right). The 
fluorescence intensity of the CSC marker CD44 was 2.28 fold decreased upon 
IL-6RFP administration when compared to vehicle control, as shown by 
immunofluorescence and quantifications of MFIs (Figure 28B). In summary, 
inhibition of STAT3 activity using IL-6RFP in vitro and in vivo resulted in 
diminished CSC phenotype as shown by decreased expression of Sox2, MSI-1, 
CD44 and Nanog. 
Figure 28: Protein regulation of CD44 and Nanog upon IL-6
RFP
 administration in vivo. A: 
Tumor sections were incubated with primary antibodies against Nanog and His-tag, and stained 
with fluorophore conjugated secondary antibodies. Hoechst was used for nuclear staining (left). 
Mean fluorescence intensities of Nanog were quantified and depicted in graph (right). Scale: 100 
μm B: Sections were stained for CD44 and Hoechst was added to stain nuclei (left). 
Quantifications of CD44 fluorescence intensities were depicted in the graph (right). Scale bars: 
100 µm. Error bars represent standard deviation. 
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3.3.4 Up-regulated STAT3 activity coincides with CSC marker expression in 
advanced prostate cancer cells. 
Since CSCs are believed to drive tumor progression and posses enhanced 
metastatic potential, AR and STAT3 expression levels were correlated with the  
expression levels of CSC markers in primary and advanced or metastatic 
prostate cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
While murine TC1 cells represent early stage prostate cancer, TRAMP-C2 (TC2) 
cells correspond to advanced prostate cancer cells. TC1 and TC2 cells were 
established from a 32-week-old prostatic adenocarcinoma of a C57BL/6 male 
TRAMP mouse. The cell lines were generated based on different growth rates 
and cell morphology [199].  
To evaluate the expression of AR and STAT3 in both cell lines, AR mRNA 
expression was determined by RT-PCR initially. AR mRNA level was decreased 
in TC2 (0.97 fold) cells compared to TC1 cells (6.22 fold) (Figure 29A). 
Comparing lysates of TC1 and TC2 cells by western blot analysis, no expression 
of AR protein was decteted. Importantly, detection of tyrosine-phosphorylated 
STAT3 revealed elevated STAT3 activation in TC2 cells relative to TC1 cells. 
Conversely, STAT3 total protein was reduced in TC2 cells. Actin was used as a 
loading control (Figure 29B). In order to compare cells representing primary and 
advanced prostate cancer in vivo, TC1 and TC2 cells were injected into 
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Figure 29: Expression of AR, STAT3 and pYSTAT3 in TC1 and TC2 cells. A: Total RNA of 
TC1 and TC2 cells was isolated and analyzed by RT-PCR with primers for the AR gene. Relative 
mRNA expression was normalized to GAPDH. RT-PCR was performed in triplicates. B: Lysates 
of TC1 and TC2 cells were subjected to western blot and analyzed with antibodies raised against 
AR, pYSTAT3, STAT3 and β-Actin. 
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NSGNOD mice. Growth kinetics revealed significantly increased tumor growth of 
TC2 cells. While TC1 tumors reached mean tumor volumes of 1332 mm3 after 
45 days, TC2 tumors obtained a volume of 1314 mm3 already after 14 days 
(Figure 30A). When palpable tumors reached volumes of about 1300 mm3, 
tissue was excised and prepared for immunofluorescent stainings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to determine proliferation, tumor sections were stained for Ki-67. It 
turned out that Ki-67 fluorescence was elevated in TC2 tumor sections relative to 
TC1 tumors, which correlated with the growth kinetic. CD31 staining did not 
show considerable differences between TC1 and TC2 tumor sections (Figure 
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Figure 30: Comparison of TC1 and TC2 cells in vivo. A: 1.5 x 10
6
 TC1 and TC2 cells were 
injected into 2 groups of 7 NSGNOD mice s.c.. Tumor growth was observed for 45 days. Graph 
shows mean tumor volumes (n = 6) over time. Once tumors reached a tumor volume of about 
1300 mm
3
, tumor tissue was harvested and prepared for necroptic analysis. B: Sections of 
isolated tumor tissue were stained for Ki-67 and CD31. Hoechst was added to stain nuclei C: 
Tumor sections were stained with specific primary antibodies raised against AR (left) or 
pYSTAT3 (right) and AF488-conjugated secondary antibodies. Nuclei were stained by Hoechst. 
Scale bars: 100 µm.  
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30B). Moreover, similar to in vitro experiments (Figure 29B), down-regulation of 
AR and elevated STAT3 phosphorylation was detectable in tumor sections of 
TC2 tumors (Figure 30C). 
 
 
 
 
 
 
 
 
 
 
 
To evaluate and compare the expression of cancer stem cell markers in TC1- 
and TC2-tumors, sections of excised tumors were stained with antibodies raised 
against Sox2 and MSI-1. Stainings revealed up-regulated CSC marker 
expression of Sox2 (left) and MSI-1 (right) in TC-2 tumors relative to TC1 tumor 
sections (Figure 31). 
Taken together, advanced prostate cancer cells expressed elevated levels of 
activated STAT3, but not AR, and proliferated significantly faster than primary 
prostate cancer cells in vivo. This might correlate with the enhanced expression 
of CSC markers such as MSI-1 and Sox2 in metastatic TC2 tumors. 
3.3.5 Inhibition of STAT3 causes CSC phenotype reduction in human prostate 
cancer cells. 
Similar to TC-2 cells, many advanced human prostate cancer cells are AR-
negative but express high levels of tyrosine-phosphorylated STAT3, such as 
DU145, and PC-3 cells. DU145 cells express an IL-6 autocrine loop and it has 
been shown that targeting the IL-6/STAT3 signaling pathway was promising for 
cancer therapy [93].  
Assessing the impact of STAT3 inhibition on human prostate cancer cells by IL-
6RFP, binding of murine IL-6RFP to human IL-6 was determined by western blot 
Sox2 
Hoechst 
TC1 TC2 
MSI-1 
Hoechst 
TC1 TC2 
Figure 31: CSC marker expression in TC1 and TC2 tumors. Tumor sections of isolated 
tumors with a mean tumor volume of 1300 mm
3
 were incubated with specific primary antibodies 
raised against Sox2 (left) and MSI-1 (right) and stained with fluorophore-conjugated secondary 
antibodies. Hoechst was used for nuclear staining. Scale: 100 µm. 
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analysis first. For this purpose, conditioned medium of HEKIL-6RFP cells was 
incubated with 20 ng/µl murine or human IL-6 and the non-cleavable crosslinker 
DSS or the cleavable crosslinker DTSSP. 
 
 
 
 
 
Western blot analysis revealed that mIL-6RFP binds to murine as well as human 
IL-6, since in samples incubated with DSS a second band representing IL-6 
covalently bound to IL-6RFP was detectable (Figure 32).  
To determine the impact of IL-6RFP on CSC-indicating marker expression in 
human prostate cancer cells, DU145 cells were cultured in tumor sphere 
condition medium and treated with either HEKCM as vehicle control or murine IL-
6RFP. Indeed, relative to vehicle control (326 spheres), application of IL-6RFP 
resulted in decreased number of tumor spheres (95 spheres) (Figure 33A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Live cell imaging of formed tumor spheres in vehicle control compared to IL-6RFP 
treated cells confirmed the results obtained by the tumor sphere formation 
assay. In vehicle treated cells, distinct spheres were detectable consisting of at 
least 20 cells that were detached from the cell culture dish. Conversely, inhibition 
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murine human Figure 32: Binding of IL-6RFP to murine or human 
IL-6. Conditioned medium of HEK
IL-6RFP 
cells were 
incubated with 20 ng/µl murine or human IL-6 and 5 
mM DSS or DTSSP for 4 h at 4
o
C. Mixture was 
subjected to western blot and analyzed with 
antibodies raised against His-tag.  
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Figure 33: Impact of IL-6
RFP
 treatment on CSC phenotype development in human DU145 
cells. A: Parental HEK cells and HEK
IL-6RFP 
cells were covered with 4 ml tumor sphere medium 
for 48 h. For 6 days, DU145 cells were cultured in 50 % tumor sphere medium and 50 % tumor 
sphere CM of either HEK
IL-6RFP 
or parental HEK cells (vehicle). Tumor spheres were quantified 
every other day. B: On day 6, tumor spheres of vehicle or IL-6
RFP
 treated cells were imaged at a 
brightfield microscope. C: Lysates of tumor spheres were subjected to western blot and 
analyzed with antibodies raised against pYSTAT3, STAT3, MSI-1, Sox2 and GAPDH. 
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of the IL-6/STAT3 signaling pathway resulted in settled, single cells (Figure 33B). 
More detailed analysis of formed spheres by western blot analysis revealed that 
MSI-1, Sox2 as well as pYSTAT3 and total STAT3 expression is decreased 
upon IL-6RFP treatment. GAPDH was used as a loading control (Figure 33C). 
Thus, inhibiting IL-6/STAT3 signal transduction in metastatic DU145 cells by IL-
6RFP resulted in diminished CSC phenotype development.  
To confirm that suppression of CSC phenotype predominantly was a result of 
STAT3 inhibition, and not due to inhibition of other pathways stimulated by IL-6, 
such as the MAP kinase pathway, DU145 cells were stably transfected with a 
STAT3 shRNA or non-silencing control. DU145 cells silenced for STAT3 or non-
silencing control cells were cultured in conditions enhancing tumor sphere 
formation and analyzed regarding their sphere formation ability for six days. 
STAT3-silenced cells formed significantly less tumor spheres (68 spheres) than 
non-silencing control DU145 cells (178 spheres) (Figure 34A). Furthermore, 
Sox2 and MSI-1 expression were abolished in lysates of these tumor spheres, 
as analyzed by western blot. Knock-down of STAT3 in DU145 cells was 
validated by staining for tyrosine phosphorylated STAT3 and STAT3 total 
protein. Actin was used as a loading control (Figure 34B).  
 
 
 
 
 
 
 
 
 
 
 
 
In summary, inhibition of STAT3 in DU145 cells either by gene silencing or IL-
6RFP delivery resulted in decreased development of a CSC phenotype, as 
B A 
Figure 34: Gene silencing of STAT3 reduces expression of CSC markers in tumor 
spheres. A: DU145 cells expressing a STAT3 shRNA or non-silencing control were culture in 
tumor sphere medium for 6 days. Sphere formation was quantified every other day. Error bars 
represent standard deviation. B: After 6 days, lysates of tumor spheres were analyzed by 
western blot using antibodies against pYSTAT3, STAT3, MSI-1, Sox2 and β-Actin.  
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determined by reduced CSC marker expression such as MSI-1 and Sox2. 
Hence, targeting STAT3 by administration of IL-6RFP seemed to be a promising 
treatment for the CSC populaation in metastatic human prostate cancer as well.    
3.3.6 CSC phenotype occurs in areas with activated STAT3 in human prostate 
cancer. 
To further assess the correlation between the IL-6/STAT3 signaling pathway and 
increased CSC phenotype development, human prostate cancer tissues were 
analyzed. The tumor tissue represents primary prostate cancer of human 
patients. 
 
 
 
 
 
 
 
 
 
 
In order to evaluate the impact of IL-6 signal transduction in human prostate 
cancer, malignant tissue was stained for IL-6 and STAT3 phosphorylation. 
Distribution of phosphorylated STAT3 and IL-6 was constrained to few areas in 
the tissue. Areas positive for phosphorylated STAT3 revealed elevated levels of 
IL-6 suggesting interleukin-6 as the upstrem ligand responsible for STAT3 
activation. Nuclear staining with Hoechst was used as a tissue marker (Figure 
35, left). IL-6 appeared to be mainly located in the cytoplasm and interstitially of 
stromal cells as indicated by the circle. Tyrosine phosphorylated STAT3 was 
exclusively detectable in the nucleus of stromal cells and glandular cells. 
Glandular cells are indicated by the arrows (Figure 35, right).  
In order to assess the expression of CSC markers in a STAT3-dependent 
manner, human prostate cancer sections were stained for MSI-1, Sox2, CD44, 
integrin α2β1, or Nanog. Sections were co-stained for pYSTAT3, and Hoechst 
Figure 35: Phosphorylated STAT3 is up-regulated in IL-6 positive areas of human prostate 
cancer tissue. Shown are representative images of human prostate cancer tissue, that was 
immunostained for pYSTAT3 (green) and IL-6 (red). Hoechst was added to stain the nuclei, as a 
tissue marker. Tissue sections were analyzed by confocal microscopy. Circle indicates stromal 
cells, arrows indicate glandular cells. Scale bar: 100 µm 
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dye was used as a tissue marker. Tyrosine-phosphorylated STAT3 was not 
detectable ubiquitously, but was confined in areas of the prostatic tissue as 
shown in the left panels of figure 36. Moreover, in areas with high levels of 
phosphorylated STAT3, expression of CSC-indicating markers like CD44, 
integrin α2β1, MSI-1, Sox-2, and Nanog were elevated as well. Areas positive for 
tyrosine phosphorylated STAT3 and the corresponding CSC marker are 
indicated by the arrows (Figure 36, left panels). 
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Interestingly, most cells with  up-regulated CSC marker expression revealed 
increased tyrosine-phosphorylated STAT3 as shown by magnified field of views 
in the double-positive areas (Figure 36, right panels). MSI-1 and CD44 were 
mainly localized in the cytoplasm (Figure 36A, 36C). MSI-1 expression coincided 
with pYSTAT3 up-regulation in stromal (indicated by the circle) and glandular 
cells (indicated by the arrows) of the malignant tissue (Figure 36A, right image). 
CD44 was predominatly expressed in stromal cells and to a lesser extent in 
glandular cells, as indicated by the arrows in figure 36C (right image). While 
integrin α2β1 was detected at the cell membrane (Figure 36D, right image), the 
transcription factors Sox2 and Nanog were located in the cytoplasm and the 
nucleus as indicated by the arrows. Moreover, Sox2 and Nanog did not seem to 
be expressed in the stroma (Figure 36B, 36E, right images). A quantitative 
Figure 36: Activated STAT3 and CSC markers were up-regulated in same areas of human 
prostate cancer tissue. Shown are representative images of tissue sections from patients with 
prostate cancer (n = 3). Sections were stained with specific primary antibodies for pYSTAT3 and 
CSC marker, and fluorophore-conjugated secondary antibodies. Hoechst was added to stain the 
nuclei, as a tissue-marker (left). Double- and single positive cells were manually counted and 
quantified from 3 different patients (right) A: MSI-1, B: Sox2, C: CD44, E: Integrin α2β1, F: 
Nanog. Scale: 100 µm. Error bars represent standard deviation. 
D 
pYSTAT3 
Integrin α2β1 
Hoechst 
pYSTAT3
+
/α2β1
+
 
pYSTAT3
+
/α2β1
-
 
pYSTAT3
-
/α2β1
+
 
 
C
e
ll 
c
o
u
n
t 
[%
] 
30 
20 
10 
0 
40 
50 
60 
E 
pYSTAT3 
Nanog 
Hoechst 
pYSTAT3
+
/Nanog
+
 
pYSTAT3
+
/Nanog
-
 
pYSTAT3
-
/Nanog
+
 
 
C
e
ll 
c
o
u
n
t 
[%
] 60 
30 
20 
10 
0 
40 
50 
70 
 Results  
89 
 
approach by calculating cells single-positive for either pYSTAT3 or CSC-
indicating marker, or double-positives showed that STAT3 activity is primarily 
associated with the expression of CSC markers. Tyrosine phosphorylated 
STAT3 could also be found as an isolated event in human prostate cancer 
sections, but to a lower extend than double-positives, as shown in the bar graphs 
(Figure 36, right). Moreover, the number of tumor cells testing positive for the 
expression of CSC markers alone were significantly decreased. Taken together, 
human prostate cancer tissue revealed elevated CSC marker expression of 
Sox2, MSI-1, integrin α2β1, CD44 and Nanog coincided with those cells 
exhibiting high STAT3 activity. 
3.3.7 Elevated CSC marker expression does not coincide with AR positive tumor 
cells. 
In order to determine the role of the androgen receptor on the expression of 
CSC-indicating markers, CD44 expression was analyzed in frozen sections of 
TC1 tumors stained for AR or tyrosine phosphorylated STAT3. Tissue areas with 
a partial up-regulation of pYSTAT3 or AR were picked, and cells single positive 
for CD44, pYSTAT3, or AR and double positive cells were quantified.  
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Figure 37: Comparison of CD44 expression in pYSTAT3 positive and AR positive murine 
tumor cells. A: Shown is a representative image of a murine TC1 prostate cancer section 
stained for AR (green) and CD44 (red); Hoechst was used for nuclear staining (left). Double- and 
single-positive cells were quantified from 3 different tumor sections (right). B: Representative 
image of TC1 tumor tissue section stained for CD44 (red) and pYSTAT3 (green). For nuclear 
staining Hoechst was added (left). Quantifications of double and single- positive cells are shown 
(right). Error bars represent standard deviation.  Scale bar: 100 μm.  
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Similar to human prostate cancer slides, CD44 was detected at the cell 
membrane while the two transcription factors, STAT3 and AR, were located in 
the nucleus (Figure 37).  Magnified field of views of immunofluorescent stainings 
revealed that CD44 expression was mainly up-regulated in AR negative tumor 
cells (Figure 37A, left). Quantifications of single- and double-positive cells 
showed that the minority of tumor cells (9%) were double positive for AR and 
CD44. The CSC marker and AR expressions were primarily found as solitary 
events (Figure 37A, right). In contrast, tyrosine phosphorylated STAT3 correlated 
with CD44 expression in immunofluorescent stainings (Figure 37B, left), which 
was supported by quantifications of double and single positive cells. The majority 
of tumor cells were positive for both, CD44 and tyrosine phosphorylated STAT3 
(68%) (Figure 37B, right). 
To determine a correlation of AR and CSC marker expression in human 
samples, tumorigenic tissue from patients was stained for AR and two CSC 
markers, CD44 and Sox2. 
Similar to murine TC1 tumors, AR was detected in the nucleus suggesting that 
the hormone receptor is transcriptionally active. CD44 and Sox2 were mainly 
localized in the cytoplasm. In contrast to the co-staining of CD44 and 
phosphorylated STAT3, the highest detectable fluorescence intensity of CD44 
did not overlap with areas positive for AR (indicated by arrows, Figure 38A, left). 
Instead, AR and CD44 positive areas seemed to exclude each other, except in 
few regions as indicated by the circle (Figure 36A, left). As shown in the bar 
graph of quantified double- and single-positive cells, 17.2 % of CD44 and AR 
double-positive cells  were detected in representative regions of  the tissue 
(Figure 38A, right). Moreover, tumor sections stained for AR and Sox2 revealed 
a similar distribution. Beside regions with upregulated AR and Sox2, single-
positive areas were predominantly detectable for Sox2 as indicated by the 
arrows (Figure 38B). In a more detailed analysis, magnified field of views from 
double-positive areas were examined regarding the expression level of AR and 
Sox2, and compared to tissue sections stained for STAT3 and Sox2. The protein 
expression level is relative to the fluorescence intensity, which was depicted in 
the rainbow-colours. In the rainbow-colour mode blue represents low 
fluorescence intensity and red indicates high fluorescence intensity. Acquired 
images revealed that Sox2 was highly expressed in cells negative for AR 
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suggesting a negative correlation between AR and Sox2 expression (Figure 
38C, upper panel).  Conversely, cells with elevated levels of tyrosine 
phosphorylated STAT3 showed high Sox2 fluorescence intensity (Figure 38C, 
lower panel).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, while tumor cells that tested negative for the androgen receptor 
revealed elevated levels of CSC marker expression, tyrosine-phosphorylated 
STAT3 is accompanied with the expression of CSC markers, providing further 
evidence that STAT3 might be a promising target for CSC phenotype deprivation 
in prostate cancer. 
 
Figure 38: CSC markers are up-regulated in cells with diminished AR expression. A: 
Shown is a representative image of a human prostate cancer section stained for AR (green) and 
CD44 (red). Hoechst was used for nuclear staining (left). Double- and single-positive cells were 
quantified from 3 different patients (right). Error bars represent standard deviation.  B: Tissue 
sections from patients with primary prostate cancer were immunostained with specific primary 
antibodies for AR and Sox2 and fluorophore-conjugated secondary antibodies. For nuclear 
staining Hoechst was added. C: Detailed analysis of Sox2 and AR stained tumor sections. 
Fluorescence intensities of AR, Sox2 and pYSTAT3 are depicted in the rainbow colours as 
indicated (left). Original image with stainings for AR or pYSTAT3 (green) and Sox2 (red) are 
depicted (right). Hoechst was added to stain the nuclei. Scale bar: 100 μm.  
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3.4 Treatment of TC1 Tumors with a Combined Therapy using Bicalutamide 
and IL-6RFP. 
3.4.1 The impact of combining bicalutamide and IL-6RFP on tumor growth. 
So far, treatment of prostate cancer relies on targeting the androgen receptor 
signaling with considerable primary effect on tumor growth. However, anti-
androgen therapy leads to recurring prostate cancer. In chapter 3.1, down-
regulation of AR upon application of anti-androgens or gene silencing of AR has 
been shown to result in up-regulation of the IL-6/STAT3 signaling pathway. 
Since STAT3 is an oncoprotein, up-regulation of the IL-6/STAT3 signaling 
pathway might be a potential reason for tumor relapse. In order to reduce tumor 
growth and prevent recurring prostate cancer, a combined therapy targeting AR 
and IL-6/STAT3 signaling pathway was applied in mice. Instead of flutamide as 
used in previous experiments (Chapter 3.1), the anti-androgen bicalutamite was 
administered to evaluate whether the mode of action of anti-androgens on AR 
and IL-6/STAT3 signaling pathway is universally applicable. Both anti-androgens 
have similar mechanistical inhibitory activity, but bicalutamide is used in the 
clinics due to reduced side effects.  
Four groups of immunocompromised Rag1-/- mice were engrafted with TC1 
cells. Once TC1-tumors were palpable and reached a volume of 100 – 200 mm3, 
mice were injected with either vehicle control, 50 mg/kg bicalutamide, 1.8 μg/kg 
IL-6RFP, or a combination of bicalutamide and IL-6RFP. While the anti-androgen 
bicalutamide was injected intraperitoneally every other day, conditioned medium 
of HEKIL-6RFP cells was administered subcutaneously, in close proximity to the 
tumor twice daily. Drug delivery started after 18 days. While IL-6RFP treatment 
delayed tumor growth compared to vehicle control, administration of 
bicalutamide had no considerable impact on tumor growth. However, the 
combination of IL-6RFP and bicalutamide improved tumor growth delay (Figure 
39A).  
Tumors were resected 34 days after tumor cell engraftment. The excised tumors 
were prepared for western blot analysis and indirect immunofluorescent. 
Moreover, one mouse per group was used for IVMPM as shown in figure 40A. In 
order to determine tumor cell death, lysates of tumor tissue were subjected to 
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western blot and analyzed with antibodies raised against pro- and anti- apoptotic 
proteins. PARP (poly (ADP-ribose) polymerase) is involved in DNA repair. 
Cleavage of PARP is mainly performed by cleaved caspase 3 and results in its 
inactivation. Cleaved PARP facilitates cellular disassembly and is therefore 
involved in cell death.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pro-apoptotic proteins cleaved caspase 3 and cleaved PARP were down-
regulated upon IL-6RFP administration and mice treated with IL-6RFP and 
bicalutamide combined relative to vehicle control. No significant change in 
cleaved caspase 3 and cleaved PARP expression was detected in bicalutamide 
Ki67 
Hoechst 
B A 
C 
Figure 39: Combining IL-6
RFP
 and bicalutamide improves tumor growth delay. A: 4 groups 
of Rag1-/- mice (n = 6) were injected with 2 x 10
6
 TC1 cells subcutaneously (s.c.). Treatment 
with vehicle control (10% EtOH in corn oil and CM of parental HEK cells), 50 mg/kg 
bicalutamide, 1.8 μg/kg IL-6
RFP
 or IL-6
RFP
 and bicalutamide (bic) combined started on day 18 
(indicated by the black arrow). Injections of bicalutamide were performed intraperitoneally ( i.p.) 
every other day. IL-6
RFP
 was administered s.c. twice daily. Mean tumor volumes are shown in 
graph (n = 5). 34 days after cell engraftment, tumors were harvested 2 hours after last treatment.   
B: Tissue lysates were subjected to western blot and analyzed with antibodies against cleaved 
PARP, cleaved caspase 3, Bcl-2, Bcl-xL and GAPDH. C: Sections of frozen tumor tissue were 
stained with Ki-67 (green). Secondary antibodies conjugated to AF488 were used for 
immunodetection and quantifications of MFIs. Hoechst dye was added for nuclear staining and is 
depicted in blue. Scale: 100 μm (left). Bar graphs show quantified mean fluorescence intensities 
(MFI) of Ki-67 (n = 3). Error bars represent standard deviation (right). 
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injected in comparison to vehicle treated mice. In contrast, expression of the 
anti-apoptotic proteins Bcl-2 and Bcl-xL was decreased upon IL-6RFP and the 
combined IL-6RFP/bicalutamide treatment relative to vehicle control. Bcl-2 and 
Bcl-xL as a member of the Bcl-2 family exert pro-survival activity. They inhibit 
caspase activity through inhibition of mitochondrial cytochrome c release and by 
binding of APAF-1 (apoptosis-activating factor 1). Both anti-apoptotic proteins 
were up-regulated in mice treated with bicalutamide compared to vehicle control.  
The inverse expression of pro- and anti- apoptotic proteins correlated with the 
levels of tyrosine phosphorylated STAT3. While phospho-tyrosine STAT3 was 
increased upon bicalutamide injection, diminished STAT3 activity was detected 
in tumor bearing mice treated with IL-6RFP or a combination of bicalutamide and 
the IL-6RFP. Total STAT3 protein was not changed considerably upon drug 
delivery. GAPDH was used as a loading control (Figure 39B).  
In order to determine proliferative activity in the tumor tissue, frozen sections 
were stained for Ki-67. Immunofluorescent stainings and quantifications of mean 
fluorescence intensities revealed that Ki-67 was up-regulated in vehicle and 
bicalutamide administered tumor sections, but was decreased in sections from 
mice treated with IL-6RFP and IL-6RFP/bicalutamide (Figure 39C). 
These results demonstrated that, similar to flutamide, application of the anti-
androgen bicalutamide resulted in increased tyrosine phosphorylation of STAT3 
which correlated with decreased apoptosis. Inhibition of the IL-6/STAT3 signaling 
pathway using IL-6RFP lead to decreased proliferation, but elevated apoptosis. 
The combination of IL-6RFP and bicalutamide revealed similar effects on 
apoptosis and proliferative activity of tumor cells as IL-6RFP administration. 
Moreover, combining the IL-6 and AR inhibitor resulted in a slight improvement 
of tumor growth delay compared to the mono-therapy using IL-6RFP. 
3.4.2 CSC marker expression upon combined treatment of IL-6RFP and 
bicalutamide. 
In order to evaluate the impact of a combined treatment including bicalutamide 
and IL-6RFP on the expression of CSC markers such as CD44, MSI-1 and Sox2, 
tumor bearing mice were prepared for IVMPM and indirect immunofluorescent 
34 days after tumor cell engraftment (Figure 39A). 
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Mice were injected i.v. with a mixture of CD44-FiTC and iRGD peptide 30 min 
before surgical preparation for IVMPM. The iRGD peptide was added to improve 
tissue penetration of CD44-FiTC. Two-photon microscopy on living animals and 
quantifications of CD44 positive cells per field of view revealed that few cells in 
vehicle treated mice were CD44 positive (17.75). Compared to vehicle control, 
the CSC marker expression of CD44 was reduced in TC1 tumor-bearing mice 
treated with IL-6RFP (8.5) and IL-6RFP/bicalutamide (4.25). In contrast, 
bicalutamide injections resulted in elevated CD44 positive cells (29.75). The 
ECM was detected as a tissue marker (Figure 40A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lysates of tumor tissue were subjected to western blot and analyzed with the 
indicated antibodies. Similar to the expression profile of tyrosine phosphorylated 
STAT3 as shown in figure 39B, the CSC markers MSI-1 and Sox2 were 
diminished in tumors treated with IL-6RFP and a combination of IL-6RFP and 
bicalutamide. In contrast, MSI-1 and Sox2 expression was up-regulated in 
bicalutamide injected mice compared to vehicle control (Figure 40B).  
In summary, the combined treatment of IL-6RFP and bicalutamide resulted in 
decreased expression of the CSC markers CD44, Sox2 and MSI-1, similar to the 
Figure 40: CSC phenotype is inhibited upon combining IL-6
RFP
 and bicalutamide. A:  
Tumor-bearing mice treated with vehicle, bicalutamide, IL-6
RFP
 or bicalutamide and IL-6
RFP
 
combined were injected with 50 μg CD44-FiTC per mouse. CD44-FiTC was in complex with an 
iRGD peptide for better tissue infiltration. 30 min after injection, mice were prepared and 
analyzed by intra-vital multi photon microscopy (IVMPM). ECM is shown by 2HG. Scale bar: 200 
μm.B: Lysates from tissue were subjected to western blot analysis and analyzed with antibodies 
against MSI-1, Sox2 and GAPDH. 
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mono-therapy using IL-6RFP. Inversely, bicalutamide application leads to up-
regulation of a CSC phenotype confirming results as shown in figure 24 using 
the anti-androgen flutamide. 
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4 Discussion 
 
4.1 The IL-6/STAT3 Signaling Pathway as a Target for Prostate Cancer 
Therapy 
The prostate is not dependent on androgens alone, but also on cytokines and 
growth factors, mainly secreted by stromal and basal cells [200]. The cytokine 
interleukin-6 is involved in cellular processes regulating inflammation, 
proliferation, anti-apoptosis, angiogenesis, differentiation and immune responses 
[201]. IL-6 is expressed and secreted by fibroblasts, endothelial and mesothelial 
cells, keratinocytes, B- and T- cells, macrophages, monocytes, and certain tumor 
cells such as prostate cancer cells [202]. In immunohistochemical studies 
interleukin-6 and its receptor was predominantly expressed in basal cells of the 
benign prostate. In prostate cancer tissue, IL-6 is up-regulated in all cell types, 
stromal cells and basal as well as luminal cells of the prostatic epithelium, which 
has been shown by immunostainings of sections from human patients  [200]. 
Clinical studies demonstrated elevated levels of IL-6 in blood plasma and blood 
serum of patients with hormone refractory prostate cancer (HRPC) or metastatic 
prostate cancer compared to earlier stages such as benign prostate hyperplasia 
(BPH), prostatic intraepithelial neoplasia (PIN), or non-malignant forms [203]. 
Thus, high IL-6 expression (> 7 pg/ml) has been correlated with poor prognosis 
in human patients [204]. However, approaches of targeting IL-6 signal 
transduction in prostate cancer are rare. The monoclonal IL-6 antibody 
siltuximab (CNTO 328) has been used in vivo and clinical studies [205, 206]. 
Other approaches involve IL-6 antisense oligonucleotides or IL-6 antagonists like 
Sant-7, a modified IL-6 which binds to the IL-6Rα, but does not induce 
recruitment of gp130 [207]. 
The goal of this study was to evaluate the IL-6/STAT3 signaling pathway in 
prostate cancer as a potential target for therapeutic agents such as the IL-6 
receptor fusion protein (IL-6RFP). In this context, one focus laid on influences of 
the androgen receptor and the IL-6/STAT3 signal transduction on proliferative, 
apoptotic, angiogenic, and metastatic processes. Furthermore, since tumor 
relapse upon AR down-regulation by hormone deprivation therapy might be a 
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result of cancer stem cell (CSC) survival, the impact of IL-6 induced STAT3 
activation on CSC development was determined in prostate carcinogenesis. 
Finally, in order to prevent tumor relapse the effect of a combined therapy using 
anti-androgens and the IL-6RFP was evaluated in regard to tumor growth and 
CSC phenotype development.  
4.1.1  IL-6/STAT3 Signaling in Prostate Cancer. 
In order to evaluate the impact of IL-6/STAT3 signaling on tumor relapse, the 
connection between elevated levels of IL-6 and HRPC had to be confirmed by 
establishing a murine tumor model. For this purpose murine TRAMP-C1 cells 
(TC1) of luminal origin were used. Similar to the course of hormone deprivation 
therapy in patients, flutamide treatment of TC1 tumor bearing mice resulted in 
initial tumor growth delay, but tumors progressed and grew out. Analyzed tumors 
revealed down-regulation of AR and elevated levels of IL-6 as well as total and 
phosphorylated STAT3 upon flutamide administration. Thus, the suggested up-
regulation of the IL-6/STAT3 signaling pathway in the transition from androgen-
dependent to HRPC was confirmed and established with the TC1 tumor model. 
Hence, increased IL-6 induced STAT3 tyrosine phosphorylation seemed to be 
important for tumor progression upon anti-androgen treatment. 
Besides its role in tumor relapse, STAT3 was crucial for the initiation of prostate 
cancer. Tumors silenced for STAT3 showed considerable tumor growth delay. 
Reduced tumor growth correlated with decreased proliferation, angiogenesis and 
increased apoptosis. Interestingly, gene silencing of AR did not affect tumor 
growth compared to non-silencing control. This was accompanied by elevated 
proliferative activity, a proper vascularization, and reduced apoptotic events. 
Similar to recurring prostate cancer upon anti-androgen treatment, knock-down 
of AR favored the IL-6/STAT3 signaling pathway. Up-regulation of the STAT3 
signal transduction as a result of AR silencing was supported by the finding that 
SOCS3 was down-regulated in AR negative TC1 cells. Since SOCS3 is a STAT3 
target gene, this result was unanticipated. However, one could imagine that gene 
methylation of SOCS3 might be a result of AR knock-down. Epigenetic silencing 
of SOCS3 has been described in several tumors including prostate cancer [208, 
209]. 
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The reduction of the androgen receptor by either hormone deprivation therapy or 
gene silencing was accompanied by the up-regulation of CSC indicating markers 
such as Sox2, MSI-1, Nanog and CD44 in TC1 tumors. Since cancer stem cells 
have been implicated to be the major cause for tumor relapse, the over-
expression of CSC markers upon anti-androgen treatment seemed to indicate 
one possible reason for recurring prostate cancer. Interestingly, CSC phenotype 
development was a result of the synergistic effect of decreased AR expression 
and elevated IL-6/STAT3 signaling. Indeed, knock-down of STAT3 by RNAi 
resulted in decreased CSC phenotype development as indicated by down-
regulation of the previous mentioned CSC markers in immunofluorescent 
stainings of tumor sections and in vitro tumor spheres. It has not been addressed 
yet how and whether AR and STAT3 affect gene-regulation of these CSC 
markers in prostate cancer.  
However, STAT3 activity correlated with CSC phenotype development, as 
constitutively active STAT3 in cells with diminished AR expression resulted in the 
overexpression of CSC markers, and lack of STAT3 activity led to down-
regulated CSC markers. The correlation between up-regulated IL-6/STAT3 
signaling pathway and CSC marker expression was confirmed in human prostate 
cancer tissue derived from patients. Tissue-areas positive for tyrosine-
phosphorylated STAT3 revealed elevated expression of IL-6 and CSC-indicating 
markers. On the other hand, CSC markers seemed to overlap with up-regulated 
AR as well. However, magnified field of views from tissue regions positive for AR 
and Sox2 showed that AR-negative cells revealed considerable increased Sox2 
expression, which suggests an inverse correlation between AR expression and 
the regulation of CSC-indicating markers. Similar results were achieved by 
staining murine TC1 tumors for CD44 and AR or tyrosine phosphorylated 
STAT3. While expressions of CD44 coincided with phospho-tyrosine STAT3, AR 
positive cells did not reveal CD44 up-regulation.  
Based on these observations, the following hypothesis was proposed: In the 
normal prostate, STAT3 signaling is tightly regulated and the transcription factor 
acts as an inflammatory response factor exclusively. The androgen receptor is 
responsible for differentiation and the secretion of seminal fluid components. 
Initiation of prostate cancer by genetic alterations or microenvironmental 
changes is promoted by overactive AR. However, prostate cancer initiation might 
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not necessarily depend on AR activity, but is as well a result of aberrant STAT3 
activity. Hormone ablation therapy inhibits AR activity which results in decreased 
expression of AR (Figure 41A, 41B). Diminished AR protein activity leads to the 
up-regulation of the IL-6/STAT3 signaling pathway suggesting a counter-
regulatory process between AR- and IL-6/STAT3-signaling (Figure 41C). 
 
 
 
   
 
 
 
 
 
 
Elevated STAT3 activity is associated with the development of a CSC phenotype 
(Figure 41B). CSC phenotype development is a result of CSC survival or altered 
gene-expression which might be induced by IL-6/STAT3 signal transduction. 
Constitutive activation of STAT3 and CSC phenotype development results in the 
recurrence of prostate cancer upon hormone ablation therapy (Figure 41A, 41B).  
4.1.2 STAT3 in Prostate Cancer Metastasis 
Since HRPC might exert a similar phenotype as metastatic prostate cancer, the 
impact of STAT3 on metastasis was determined by using metastatic TC2 cells 
Figure 41: Hypothesis about the regulation of the AR- and the IL-6/STAT3 signaling 
pathways in prostate cancer progression. A: Shown is a scheme of the development of 
hormone refractory prostate cancer starting with a normal prostate, primary prostate cancer (PC) 
followed by an invasive carcinoma as a result of hormone ablation therapy as indicated. Tumor-
heterogeneity is indicated by different colors of cancer cells. CSCs are indicated in green. B: 
Expressions of STAT3 and AR in correlation to the occurrence of CSCs are summarized in the 
different stages. While ‘–‘ represents downregulation, ‘+’ and ‘++’ represent the grade of 
upregulation. C: Depicted is a suggested signaling network representing the crosstalk of AR and 
STAT3 in primary PC and HRPC or Metastasis. The changes in the transition from androgen 
dependent to androgen-independent prostate cancer are summarized by down-regulation of AR 
and up-regulation of the IL-6/STAT3 signaling pathway as a counter-regulating process (middle). 
Abbreviations: PC-prostate cancer; HRPC-hormone refractory prostate cancer.  
 
A 
B 
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and primary TC1 cells in which the STAT3 signaling pathway was enhanced by 
stable over-expression of STAT3α-YFP. STAT3 has been demonstrated to play 
a role in angiogenesis and metastasis in a variety of tumors promoting neo-
vascularization, extravasation and invasion of meastatic cells into target tissue 
[27]. A gene-expression profile of TC1 cells silenced for either STAT3 or AR 
revealed, that knock-down of AR promoted IL-6 induced inflammatory response 
as shown by up-regulated STAT3 target genes α2-Macroglobuline and CRP. 
Interestingly, AR did not impact STAT3 target genes involved in angiogenesis 
(HIF-1α, FGF1, FGF2) and metastasis (MMP2, MMP9) (Table 7). Particularly 
MMP2, which has been described as an AR target-gene, was not regulated upon 
AR gene silencing. The lack of MMP2 down-regulation in AR knock-down cells 
might be a result of up-regulated STAT3 which compensates MMP2 gene 
regulation by AR. However, down-regulation of angiogenic and metastatic 
factors upon STAT3 gene silencing suggested a role of STAT3 in neo-
vascularization and metastasis in prostate cancer.  
In order to assess the impact of STAT3 on angiogenesis and metastatic 
processes, TC1 cells stably expressing STAT3α-YFP were compared with cells 
stably transfected with the dominant-negative form STAT3β fused to YFP.  
The induction of secretory factors that induce neo-vascularization is partially 
regulated by STAT3 signaling. The STAT3 target gene HIF1α encodes a 
transcription factor essential for oxygen homeostasis. HIF1α is activated by 
hypoxic conditions and promotes VEGF induction [210]. The soluble factors 
VEGF as well as FGF bind to endothelial cells and promote sprouting, migration 
and microvascular tube formation [211, 212].  
In this study, STAT3β, as a negative regulator of STAT3α, inhibited 
microvascular tube formation of endothelial cells considerably. As another 
consequence, overexpression of STAT3β resulted in significantly decreased 
tumor growth. The tumors revealed no detectable vascularization compared to 
TC1 tumors stably expressing STAT3α-YFP. Since STAT3α enhances different 
cellular processes important for tumor growth, other target genes beside 
angiogenic factors might be responsible for STAT3β induced tumor growth delay 
as well. 
In the course of cell metastasis neo-vascularization of the tumor is essential. 
Metastasis involves the migration of tumor cells to blood vessels, invasion, 
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circulation of tumor cells in blood vessels, adherence at secondary organ sites, 
and finally the evasion of host immune defense [197]. Migratory processes of 
prostate cancer cells were assessd by detecting STAT3 dependent secretion of 
gelatinases MMP2 and MMP9, and a boyden chamber assay. Since STAT3α 
induces gene expression of MMP2 and MMP9, it was consistent that TC1 cells 
stably expressing STAT3α-YFP migrate faster. Conversely, STAT3β reduced 
induction of these matrix metalloproteases that are important for ECM 
degradation which resulted in decreased migratory activity of TC1-STAT3β-YFP 
cells compared to parental TC1 cells. Moreover, the expression of adhesion 
proteins such as integrin 1, Galectin3, and CD44 were elevated in prostate 
cancer cells expressing STAT3α-YFP compared to STAT3β-YFP expressing 
cells. In vivo, the metastatic activity was assessed by retro-orbital injection of 
TC1 cells expressing STAT3α-YFP or STAT3β-YFP. Lung-infiltration of STAT3α-
YFP cells was already observed one day after injection. Colony formation started 
on day 3, expanded on day 5, and seven days after tumor cell challenge a 
nodule outgrowth was observed. Conversely, overexpression of STAT3β-YFP 
inhibited this process considerably, indicating that STAT3α plays a substantial 
role in metastasis of prostate cancer cells.  
This might explain the observation that several metastatic prostate cancer cells 
such as DU-145 and PC-3 express high levels of tyrosine phosphorylated 
STAT3. Since prostate tumor metastasis seems to develop similar as recurring 
prostate cancer, these results underline the importance of targeting STAT3 to 
prevent aggressive tumor progression.  
Similar results to recurring prostate cancer upon hormone deprivation therapy 
were observed in metastatic TC2 cells. In comparison to TC1 cells, tumors 
derived from TC2 cells grew considerably faster due to increased proliferative 
activity. These TC2 cells showed no AR protein expression, but elevated levels 
of tyrosine phosphorylated STAT3 which was associated with up-regulation of 
the CSC markers MSI-1 and Sox2. These observations correlate with HRPC 
showing a potential counter-regulation between AR- and IL-6/STAT3-signaling 
pathways. 
 Discussion  
103 
 
4.1.3 Targeting the IL-6/STAT3 Signaling Pathway with the IL-6 Receptor Fusion 
Protein 
Since hormone ablation therapy has shown to enhance IL-6 induction in this 
study, the IL-6/STAT3 signaling pathway is a promising target for recurring 
prostate cancer. The IL-6 receptor fusion protein (IL-6RFP) has been engineered 
and tested in vitro. It revealed high specificity and potency towards IL-6 [101, 
102]. In order to assess the IL-6RFP as a potential therapeutic agent for prostate 
cancer, the IL-6RFP plasmid was stably introduced into HEK293-FRT cells. The 
expression and secretion of the receptor fusion protein from HEKIL-6RFP cells was 
confirmed, and the concentration of IL-6RFP in conditioned medium was about 
200 ng/ml. The functionality was assessed using TC1 cells revealing inhibitory 
effects of IL-6RFP on tyrosine-phosphorylation, nuclear translocation, and DNA-
binding of STAT3 suggesting that the IL-6RFP exerts the desired activity by 
binding IL-6 and inhibiting STAT3 activity. Moreover, comparing the IL-6RFP with 
a commercially available neutralizing IL-6 antibody on the inhibition of STAT3 
activity revealed a 3.5 fold higher inhibitory efficiency of the IL-6 receptor fusion 
protein. 
The subcutaneous, peritumoral administration of IL-6RFP in TC1 tumor bearing 
mice resulted in the most efficient tumor growth delay. Reduced tumor growth 
was associated with decreased total and tyrosine-phosphorylated STAT3 
protein, but did not affect AR protein level. A more detailed analysis by 
immunofluorescent staining of phosphorylated STAT3 and IL-6RFP showed a 
locally confined distribution of the receptor fusion protein in the tumor tissue. 
While tissue-areas negative for IL-6RFP revealed tyrosine-phosphorylated STAT3, 
tumor tissue infiltrated by IL-6RFP showed reduced levels of activated STAT3 
indicating proper functionality in vivo. Diminished STAT3 activity was 
accompanied by reduced proliferation, vascularization and elevated apoptosis.  
Since up-regulated IL-6/STAT3 signaling correlated with CSC phenotype 
development, the inhibitory impact of IL-6RFP on CSC-indicating marker 
expression was analyzed in tumor sections and tumor spheres. In fact, inhibition 
of the IL-6/STAT3 signaling pathway by IL-6RFP resulted in decreased levels of 
CSC markers such as Sox2, CD44, MSI-1 and Nanog in vitro and in vivo. 
Additionally, the impact of IL-6RFP on CSC marker expression in human prostate 
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cancer cells was confirmed in human DU145 cells. Tumor sphere formation of 
DU145 cells was considerably reduced upon IL-6RFP treatment. This was 
accompanied by decreased MSI-1 and Sox2 expression. The inhibition of CSC 
marker expression by IL-6RFP was STAT3 dependent, as DU145 cells silenced 
for STAT3 revealed a down-regulation of MSI-1 and Sox2 as well.  
Despite HRPC might be a result of AR down-regulation coinciding with CSC 
development and up-regulated IL-6/STAT3 signaling, targeting AR results in 
reduced tumor growth initially. Prostate cancer has been shown to be AR 
dependent [116]. A combined therapy including the anti-androgen bicalutamide 
and the IL-6RFP resulted in improved tumor growth delay compared to a mono-
therapy using IL-6RFP. Decreased proliferation and survival upon IL-6 and AR 
inhibition was similar to IL-6RFP treated tumor tissue. Moreover, IL-6RFP mono-
therapy and the combined treatment resulted in decreased CSC phenotype 
development. The anti-androgen bicalutamide led to elevated CSC phenotype. 
Thus, additional application of IL-6RFP seemed to overwrite the bicalutamide 
induced CSC marker up-regulation in the combined therapy suggesting that the 
development of CSCs is an IL-6/STAT3 dependent process.  
Taken together, the inhibition of the IL-6/STAT3 signaling pathway in prostate 
cancer did not affect expression of AR, but reduced tumor growth and CSC 
phenotype development. Hence, the IL-6RFP is a promising agent for therapeutic 
intervention in prostate cancer by targeting the proliferative tumor cells as well as 
the CSC population.    
4.2 Crosstalk of STAT3 and AR 
In the ligand-independent activation of the androgen receptor in HRPC, STAT3 
has been implicated to promote AR regulated gene-induction in an IL-6 
dependent manner [155]. AR activation by phosphorylation through the 
Ras/MAPK and PI3K/AKT pathways has been reported, though the occurrence 
of direct phosphorylation by MAP kinases is still unclear. In this context, it has 
been shown that STAT3 physically interacts with AR at the N-terminal region 
(234-558) in an IL-6 dependent but androgen-independent manner in human 
prostate adenocarcinoma cells (LNCaP) [151]. Additionally, the IL-6 induced 
activation of STAT3 was required for IL-6 to activate AR in LNCaP cells. STAT3 
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has been shown to enhance AR-mediated gene expression and AR 
transcriptional activity in prostate cancer cells [213]. It has been suggested that 
activated STAT3 can act synergistically with other coactivators such as CBP, 
p300 and SRC-1 to enhance AR transcriptional activity [214]. This crosstalk of 
STAT3 and AR by direct interaction and the subsequent enhancement of AR-
target genes in the course of ligand-independent signaling in HRPC is the 
prevalent opinion, but remains controversial.  
 
 
 
 
 
 
   
 
 
 
 
In an artificial cell-model using STAT3 deficient MEF cells, nuclear translocation 
of AR which is critical for target gene induction was determined upon either 
stimulation with IL-6, R1881 or overexpression of v-Src. The agonist R1881 is a 
synthetic derivate of testosterone, and v-Src has been suggested to 
phosphorylate STAT3 at Y705 and AR at Y534 to promote STAT3- and AR-
signal transduction [20, 127]. MEFSTAT3cells were transiently transfected with 
GFP-AR and STAT3-DsRed or co-transfected with v-Src as indicated in figure 
42. Transfected cells were stimulated with IL-6, R1881 or left unstimulated. 
Nuclear translocation of both transcription factors was analyzed by confocal 
microscopy. STAT3-DsRed was mainly localized in the nucleus after IL-6 
stimulation and in v-Src co-transfected cells. The testosterone derivate R1881 
did not result in nuclear localization of STAT3-DsRed, but led to translocation of 
GFP-AR to the nucleus. Interestingly, neither IL-6 stimulation nor v-Src co-
transfection resulted in a nuclear localization of AR (Figure 42). Hence, these 
results did not support the hypothesis of IL-6 induced AR activation.  
Figure 42: Nuclear translocation of STAT3-DsRed and GFP-AR upon different activators.  
STAT3 deficient MEF cells were transfected with GFP-AR, STAT3-DsRed or v-Src. After 24 h 
cells were stimulated with IL-6 [20 ng/ml], sIL-6R [250 ng/ml], R1881 [1 nM] or left unstimulated. 
30 min later, cells were fixed, mounted with Mowiol and analyzed by confocal microscopy. Cells 
co-transfected with v-Src were left unstimulated and immunostained with Src-specific antibodies 
and Alexa Fluor 633 secondary antibodies. Scale: 10 μm. 
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A possible explanation for AR activation might involve an IL-6-induced promotion 
of AR signal transduction by phosphorylation in an androgen poor environment 
in which androgens stimulate nuclear translocation and DNA-binding of AR 
homo-dimers.  
On the other hand, Keller et al. pointed out that the androgen receptor represses 
NFB dependent IL-6 induction [215, 216], which would rather underline a 
crosstalk in which AR and STAT3 inversely-regulate each other. This was 
supported by the finding in TC1 cells which were stimulated with IL-6 or R1881 in 
a time-dependent manner as indicated in figure 43.  
 
 
 
 
 
 
 
 
 
The western blot analysis revealed an increase of tyrosine-phosphorylated and 
total STAT3 protein upon IL-6 stimulation, while protein-level of AR decreased 
time-dependently (Figure 43A). In contrast, testosterone stimulation resulted in 
an up-regulation of AR protein, but decreased levels of phosphorylated and total 
STAT3 protein (Figure 43B). The connection between decreased AR expression 
and elevated IL-6 levels in many advanced prostate cancers seems to contribute 
to the hypothesis of an inverse regulation between the AR- and STAT3- 
signaling pathways. However, since a tumor is heterogeneous one could 
imagine that both, the interaction of STAT3 and AR to enhance AREs and a 
counter-regulation between AR- and STAT3-signaling, might play a role in tumor 
progression and HRPC. Therefore, the TC1-tumor-model might not fully display 
the heterogeneity in patients, but rather shows the situation in a subpopulation of 
tumor cells.  
Moreover, Heisler et al. indicated that AR might as well function as a tumor 
repressor. They demonstrated, that stable expression of AR in androgen-
pYSTAT3 
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Figure 43: Counter-regulation of STAT3 and AR. A: TC1 cells were stimulated with IL-6 in a 
time-dependent manner (0, 0.5, 1, 2, 4, 8, 24 h). Lysates were prepared for western blot 
analysis. B: Shown is a western blot analysis of TC1 cells stimulated with R1881 [1 nM] in a 
time-course as indicated. Membranes were stained with anitbodies against pYSTAT3, STAT3, 
AR and β-Actin. 
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independent and AR-negative prostate cancer cells called PC-3 revealed 
reduced proliferation and invasion [217, 218]. Moreover, it has been 
demonstrated that IL-6 acted as an autocrine growth and survival factor in 
androgen-independent DU-145 and PC-3 cells [219]. Thus, reduced IL-6 
induction followed by decreased pYSTAT3 might be a potential reason for 
reduced proliferation and invasion upon AR overexpression.  
                         
 
 
 
 
On the contrary, androgen sensitive LNCaP cells did not secrete detectable 
amounts of IL-6. Interestingly, LNCaP cells were derived from lymph node 
metastasis, which is usually the first site metastasis in prostate cancer. 
Conversely, androgen-independent PC-3 cells were derived from bone and 
DU145 from brain metastasis which represent second or late stage metastasis 
(Figure 44). Since LNCaP, DU145, and PC-3 cells were originated from different 
tissue, it is to be expected that these cancer cells exert altered gene expression 
profiles. Thus, one could imagine that prostate cancer cells loose AR function, 
and lack of AR might lead to a more aggressive cell phenotype which results in 
metastasis to secondary sites due to growth advantage.  
 
4.3 Limitations of IL-6RFP Treatment 
The binding of IL-6 to its cytokine receptor results in the activation of intracellular 
signaling cascades including JAK/STAT and MAPK [24]. The activation of the 
Figure 44: Metastatic sites in prostate cancer progression. Shown is the scheme of a human 
body with metastatic sites of prostate cancer including lymphnode, bone, spine bone, liver, lung 
and brain with the correlating cells that were isolated from human patients depicted in red. 
Lymph node represents a first site metastasis, while brain and bone metastasis are secondary or 
tertiary sites. The location of the prostate is indicated by the black rectangle, (modified from 
http://www.dilipraja.com/prostate-cancer.html) 
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PI3K/AKT pathway has been suggested to be activated by IL-6 stimulation as 
well [220]. Both pathways, the MAPK and the PI3K/AKT signal transduction, 
have been demonstrated to be dysregulated in a variety of cancers. Similar to 
the STAT3 signaling pathway, they play critical roles in the promotion of 
proliferation, survival, and anti-apoptosis (Figure 45). Thus, inhibition of the IL-6 
signaling pathway using IL-6RFP lacks STAT3 specificity, but prevents activation 
of three oncogenic pathways, which might be advantageous for cancer therapy.  
        
High levels of autocrine and paracrine acting IL-6 were measured in conditioned 
medium of androgen-independent prostate cancer cells [221]. Increases in IL-6 
expression have been associated with several regulatory processes. TGFβ, 
which is up-regulated in advanced prostatic tumors, loss of Rb, and the AP-1 
complex consisting of c-Jun and c-fos have been suggested to play a role in the 
induction of IL-6 [222]. Moreover, the androgen receptor has been observed to 
repress NFB mediated IL-6 induction [191, 215]. The dysregulation of IL-6 
expression in prostate cancer suggests that the cytokine might be a target for 
therapy in this disease, but therapeutic agents are rare and revealed mixed 
effects. The anti-IL-6 antibody siltuximab (CNTO328) has been applied in 
patients with recurring prostate cancer. Tumor growth had progressed beyond 
several chemotherapeutical treatments. Siltuximab administration showed limited 
clinical efficiency, despite achieved IL-6 inhibition [223]. Since tumors are 
heterogeneous, especially in advanced disease, it seems unlikely that a single 
agent would be effective. Application of a combined therapy using IL-6RFP and 
Figure 45: Activation of the MAPK, 
STAT3, and PI3K signaling pathways 
via IL-6. Upon IL-6 binding to its receptor 
complex, receptor associated JAKs 
activate SHP2, STAT3 or the PI3 kinase. 
The MAPK signaling cascade results in 
the activation of the transcription factor 
Erk. Erk translocates to the nucleus and 
activates Elk, which induces target genes 
involved in proliferation and mitogenic 
proteins (cell cycle). STAT3 promotes 
expression of genes important for 
proliferation, anti-apoptosis, angiogenesis 
and metastasis. The PI3 kinase cascade 
results in the induction of genes involved 
in survival and anti-apoptosis. 
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the anti-androgen bicalutamide in this study resulted in improved tumor growth 
delay compared to IL-6RFP mono-therapy. However, inhibition of the IL-6/STAT3 
and AR signaling pathway did not lead to tumor rejection and an entire cure of 
the disease. Hence, administration of different inhibitor combinations might be 
valuable to determine. 
Despite the inhibition of STAT3, MAPK and PI3K signaling by IL-6RFP, these 
pathways can get activated by receptor tyrosine kinases as a response to EGF 
or VEGF and non-receptor tyrosine kinases such as v-Src as well.  
 
 
 
 
 
 
 
 
 
Interestingly, comparing TC1 cells which represent primary prostate cancer with 
advanced TC2 cells, differences in IL-6 and Src expression were observed. The 
RT-PCR analysis revealed that IL-6 mRNA levels were 34-fold increased in TC1 
cells compared to TC2 cells (Figure 46A). Instead, a different tyrosine kinase 
was responsible for elevated activation of STAT3 in TC2 cells. Src expression 
was considerably increased in TC2 tumor sections. Hoechst and CD31 were 
used as markers for the tissue (Figure 46B). These results indicate that in the 
transition from primary (TC1) to metastatic (TC2) tumors, cell phenotypes 
change due to altered gene-expression. When tumor cells change their 
intracellular signal transduction network in the course of metastasis, 
therapeutical intervention becomes challenging. Thus, targeting the IL-6 
signaling pathway might not be sufficient for tumor rejection and therefore, tumor 
relapse of selected cancer clones might occur. Instead of a mono-therapy, poly-
therapies combining anti-IL-6 therapy such as IL-6RFP with tyrosine kinase 
inhibitors (i.e. dasatininb) might be more promising.  
This observation seems to be consistent with the IL-6RFP treatment in this study, 
which did not result in complete tumor rejection, but tumor growth delay. 
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Figure 46: Counter-regulation of IL-
6 and Src in TC1 and TC2 cells. A: 
Shown is a RT-PCR of TC1 and TC2 
cells analyzed for IL-6 mRNA 
induction. IL-6 mRNA induction of 
TC1 cells was normalized to TC2 IL-6 
mRNA levels. Error bars represent 
standard deviations.   B: Tumor 
sections of TC1 and TC2 tumor 
bearing mice were immunostained for 
pSrc (green) and CD31 (red). Hoechst 
dye was used to stain the nuclei. 
Scale: 100 µm. 
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However, lack of tumor rejection might be a result of too low IL-6RFP 
concentrations. IL-6RFP was injected into tumor bearing mice in a concentration 
of 1.8 nM. TC1 tumors showed IL-6 concentrations of approximately 3.2 pM per 
1x106 tumor cells. To determine intratumoral IL-6 concentrations, TC1 tumors 
were excised, single cell suspensions were prepared and 1x106 tumor cells were 
cultured on a 12 well plate for 24 h. Then, conditioned medium was subjected to 
a murine IL-6 ELISA (data not shown). 
Considering that each molecule IL-6RFP can bind one molecule IL-6, 
approximately 560-fold more IL-6RFP molecules were given daily to prevent IL-6 
action in a tumor consisting of 1x106 cancer cells. In vitro analysis revealed that 
a 65-fold molar surplus was sufficient to reduce tyrosine phosphorylated STAT3 
in IL-6 stimulated TC1 cells (Figure 17E). A 560-fold molar surplus of IL-6RFP in 
vivo led to tumor growth delay, but not tumor rejection. The distribution of 
peritumoral injected IL-6RFP was locally confined and IL-6RFP negative areas 
revealed up-regulated STAT3 activity (Figure 22B). Thus, IL-6RFP concentrations 
might have been too low to reach complete inhibition of the IL-6 signaling 
pathway. However, used concentrations resulted in tumor regression, and 
application of increased IL-6RFP concentrations after proper purification might 
lead to tumor rejection and prevention of tumor relapse. 
 
4.4 STAT3 in Cancer Stem Cells 
One critical aspect for the evaluation of CSC phenotype development is the 
identification of CSC markers such as CD44, Sox2, MSI-1, Nanog, and integrin 
α2β1. However, probably all of these markers are expressed in a variety of 
cancer stem cells. As summarized in table 6, CSC markers have more functions 
than maintaining pluripotency and self-renewal. CD44, for instance, is involved in 
cell-adhesion, and is therefore also used as a marker for metastasis. This 
involvement in cancer functionality might explain why these CSC-indicating 
markers were up-regulated in many cells in this study, instead of only few cells 
as proposed in the cancer stem cell theory. Hence, it is important to determine 
the up-regulation of several CSC markers (>3) to make conclusions regarding 
the development of a CSC phenotype.   
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In the course of prostate CSC development it has been proposed that somatic 
stem cells, progenitor cells and differentiated prostate cancer cells can evolve 
into CSCs upon genetic alterations or microenvironmental influences (Figure 7). 
In turn, CSCs have the ability to differentiate into a variety of tumorigenic cells 
that promote tumor growth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
The de-differentiation of cancer cells to CSCs and their subsequent 
differentiation to tumor cells with a changed phenotype might have been 
observed in the following experiment: TC1-STAT3α-YFP and TC1-STAT3β-YFP 
cells were cultured on collagen mixed with CM of STAT3α or STAT3β-YFP 
expressing cells for 48 h. Live cell imaging was performed via confocal 
microscopy and revealed that TC1-STAT3α-YFP cells were able to form tubes 
similar to endothelial cells, while cells over-expressing the dominant-negative 
form STAT3β-YFP were distributed homogenously (Figure 47A). In a further 
analysis by flow cytometry, YFP positive cells revealed that CD31 expression is 
elevated in STAT3α-YFP expressing cells relative to TC1-STAT3β-YFP cells. 
CD31 is a marker for endothelial cells that is indicating blood vessels (Figure 
47B). One could imagine that STAT3 drives de-differentiation of luminal prostate 
cancer cells to CSCs, due to up-regulation of CSC markers such as Sox2, MSI-
1, CD44, Nanog, and integrin α2β1. Hypothetically, CSCs differentiated then 
STAT3 dependently into tumor cells with endothelial features. These endothelial 
cells might either stabilize or promote neo-vascularization in tumors. 
Figure 47: Over-expression of STAT3α-YFP promotes an endothelial phenotype of TC1 
cells. A: TC1 cells stably expressing STAT3α-YFP or STAT3β-YFP were cultured on collagen 
containing CM of TC1-STAT3αYFP or –STAT3β-YFP cells. After 48 h cells were analyzed at the 
confocal microscope at 37
o
C and 5% CO2. Scale: 100 µm. B: TC1-STAT3α-YFP and TC1-
STAT3β-YFP cells were incubated with an APC-conjugated CD31 antibody for 30 min. Then, 
cells were prepared for FACS analysis. YFP-positive cells were gated and analyzed for APC 
fluorescence. 
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Furthermore, one could imagine that tumor cells need to adapt endothelial 
features temporary in the course of angiogenesis during metastasis and tumor 
growth.  
The STAT3 dependent up-regulation of CD31 and the ability of TC1-STAT3α-
YFP cells to form tubes might be a result of the microenvironment induced by 
collagen or secreted autocrine acting soluble factors. Hence, it may be possible 
that over-activation of signaling pathways such as the STAT3 signaling pathway 
results in phenotypical changes of cells that might not only include 
transformation, but de-differentiation to CSCs, and a subsequent induction of 
genes that enhance an endothelial phenotype as well. Moreover, one could 
imagine that, in a different microenvironment, CSCs could differentiate into 
phenotypically changed tumor cells i.e. luminal or basal prostate cancer cells, 
tumor cells with endothelial features, or even osteoblasts or astrocytes in the 
course of metastasis (Figure 48A).  
 
 
 
 
 
 
 
In this context, STAT3 might be important due to the following reasons: on the 
one hand, STAT3 has been suggested to play a role in CSC phenotype 
development in glioblastomas by promoting self-renewal and maintaining 
pluripotency (Figure 48B) [224]. On the other hand, STAT3 has been 
Figure 48: Potential role of STAT3 in de-differentiation and differentiation of tumor cells. 
A: Prostate cancer cells can de-differentiate to CSCs (indicated by 1). CSCs may differentiate 
into various tumor cells with different phenotypes: Basal, luminal, endothelial, and metastatic 
prostate cancer cells (indicated by 2). B: STAT3 dependent de-differentiation and CSC 
development due to the up-regulation of CSC markers such as Sox2, CD44, MSI-1, Nanog and 
Integrin α2β1, as well as Bcl-2 and FGF2. C: Role of STAT3 in differentiated tumor cells 
including the up-regulation of c-myc, Cyclin D1, D2, HIF1α, VEGF, MMP2,9, BclXL, Bcl-2, and 
FGF2.  
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demonstrated to play a critical role in tumor growth by inducing genes involved in 
proliferation, anti-apoptosis, angiogenesis and metastasis (Figure 48C).  
The differences in STAT3 function in CSCs and differentiated tumor cells, 
probably due to altered gene expression profiles, could be a result of changes in 
secreted soluble factors by the microenvironment, epigenetic alterations and 
mutations. Posttranslational modifications of STAT3 or the crosstalk with other 
signaling pathways might play a role as well. For instance, it has been shown 
that STAT3 interacts with Nanog in embryonic stem cells to maintain 
pluripotency [225]. 
Whether the STAT3 dependent balance between CSC development and 
tumorigenic processes in differentiated cancer cells is mechanistically and/or 
temporally excluded is unclear. Since the STAT3 target genes Bcl-2 and FGF2 
have been implicated to be important in CSC maintenance [181], as well as anti-
apoptosis and angiogenesis, one could imagine that the processes involved in 
de-differentiation and differentiation of tumor cells are inter-connected and rather 
fluent than chronologically excluded (Figure 48). 
In the context of cancer treatment, the prevalent drug-resistance and the 
potential ability of CSCs to avoid treatment by adapting differentiation processes 
to microenvironmental changes make tumor targeted therapy challenging. Thus, 
treatment of the cancer stem cell population seems critical to prevent recurring 
tumors.  
In prostate cancer, the expression of AR in CSCs is controversially discussed, 
but most evidence hints to an AR negative phenotype [181]. Thus, androgen 
ablation therapy which affects AR positive cells results in the survival of CSCs. 
Immunotherapy targets differentiated cells, but CSCs are undifferentiated. 
Radiotherapy as well as most chemotherapies target rapidly dividing cells, but 
CSCs usually show low proliferative activity during self-renewing processes 
[226]. Since STAT3 plays a critical role in differentiated, highly proliferative tumor 
cells, as well as in de-differentiated CSCs, the STAT3 signaling pathway seems 
to be a promising target. Moreover, IL-6 has been implicated in the maintenance 
of stem-like cancer cells. In gene-expression profiles of CD44 positive breast 
CSCs, IL-6 has been demonstrated to be up-regulated [227].  
Thus, targeting the IL-6/STAT3 signaling pathway seems to be a promising 
therapy to abolish tumor cells and CSCs in prostate cancer.  
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5 Synopsis 
 
Prostate cancer is the most common cause of male cancer-related deaths in 
Western countries. Current treatment relies on targeting the androgen receptor 
(AR) signaling by hormone deprivation therapy. However, hormone depletion 
results in the selection of drug resistant, highly metastatic tumor cells that 
survive targeted therapy. Hence, the initial response to treatment is almost 
always followed by tumor relapse, which is called hormone refractory prostate 
cancer (HRPC) [142]. The development of HRPC is not well understood and 
remains a challenge for prostate cancer therapy. One model to explain HRPC 
development proposes the survival of so called cancer stem cells (CSC). CSCs 
share phenotypical features with embryonic stem cells, are highly drug resistant, 
and have been suggested to resupply the highly proliferative tumor cell 
population.  
STAT3 has been shown to maintain the pluripotent state of glioblastoma stem 
cells. Moreover, the IL-6/STAT3 signaling pathway has been emphasized to play 
a critical role in the progression of prostate tumors [27].  
In this study, the role of the IL-6/STAT3 signaling pathway in the initiation, 
progression and recurrence of prostate cancer upon hormone ablation therapy 
was determined. It was demonstrated that down-regulation of AR by either 
hormone deprivation therapy or gene-silencing results in the up-regulation of IL-
6/STAT3 signaling. Overactive IL-6/STAT3 signal transduction coincided with 
CSC phenotype development. CSC marker expressions were up-regulated in 
tumors treated with anti-androgens, metastatic tumor cells as well as human 
prostate cancer. In human prostate cancer tissues, elevated cancer stem cell 
markers coincided with those cells exhibiting high STAT3 activity and low AR 
expression, supporting an opposing role of AR and STAT3 in prostate cancer 
stem cell development.  
Targeting the IL-6/STAT3 signaling pathway by gene silencing or using an IL-6 
receptor fusion protein (IL-6RFP) resulted in significantly reduced tumor growth 
which was associated with decreased proliferation, angiogenesis and anti-
apoptosis. It was found that overexpression of STAT3β, a dominant-negative 
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form of STAT3α, resulted in diminished prostate tumor growth, reduced 
angiogenesis and metastasis.  
Moreover, STAT3 inhibition by either using IL-6RFP or gene-silencing resulted in 
decreased CSC phenotype development in vitro and in vivo. Application of a 
combined therapy using the IL-6RFP and the anti-androgen bicalutamide 
improved tumor growth delay compared to the respective mono-therapies. In 
addition, IL-6 inhibition by IL-6RFP overwrote the anti-androgen induced CSC 
phenotype development. 
More specifically the following results were obtained: 
 The up-regulation of the IL-6/STAT3 signaling pathway upon hormone 
ablation therapy was determined by using the TC1-tumor model. Anti-
androgen treatment with flutamide resulted in decreased AR protein 
expression, but increased IL-6 mRNA levels, total and tyrosine 
phosphorylated STAT3. Since growth factor expression levels were not 
affected by flutamide administration, IL-6 seemed to be the trigger for 
elevated STAT3 activation. Moreover, hormone ablation therapy using 
flutamide led to up-regulated CSC marker expression of Sox2, CD44 and 
MSI-1. 
 Gene silencing of STAT3 in TC1 cells diminished the initiation of prostate 
cancer and resulted in considerable tumor growth delay and decreased 
CSC phenotype development in vitro and in vivo. Western blot analysis of 
tumor spheres and tumor sections stained for CSC markers revealed 
reduced expression of Sox2 and MSI-1. CD44 and Nanog were down-
regulated in immunofluorescent stainings of frozen tumor sections as well. 
Conversely, AR knock-down did not affect tumor growth, but rather 
enhanced the IL-6/STAT3 signaling pathway by up-regulation of IL-6 
mRNA, elevated levels of total and tyrosine-phosphorylated STAT3 
protein and down-regulation of SOCS3, the feedback inhibitor of STAT3. 
Moreover,  CSC phenotype was up-regulated in tumor sections and tumor 
spheres of TC1 cells silenced for AR. 
 Tissue sections from human prostate cancer patients were stained for 
CSC markers such as Sox2, MSI-1, CD44, integrin α2β1 or Nanog and 
tyrosine phosphorylated STAT3. Those cells with elevated pYSTAT3 
coincided with increased IL-6 and cancer stem cell marker expression. In 
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contrast, despite co-expression of AR and CSC markers in cancerous 
tissue, up-regulated AR was associated with decreased CD44 and Sox2 
expression in murine and human tumorigenic tissue.  
 In order to achieve tumor growth reduction and diminished CSC 
phenotype development, the IL-6 receptor fusion protein was evaluated 
as a potential therapeutic agent for prostate cancer. The functionality of 
IL-6RFP was characterized in vitro showing a proper binding of secreted IL-
6RFP to murine and human IL-6. The IL-6RFP inhibits phosphorylation of 
STAT3 and prevents nuclear translocation as well as DNA-binding of 
STAT3 in a dose-dependent manner. The IL-6RFP was 3.5 fold more 
efficient in inhibiting STAT3 phosphorylation relative to a neutralizing 
antibody. 
 In the course of a functional characterization in vivo, 1.8 µg/kg IL-6RFP 
was injected into TC1-tumor bearing mice twice daily. Peritumoral 
administration of IL-6RFP revealed the highest inhibitory impact on tumor 
growth. The IL-6RFP did not affect expression of AR, but reduced 
activation of STAT3, which was accompanied by decreased proliferation, 
vascularization and enhanced apoptosis.  
 IL-6RFP treatment of TC1 tumor spheres and tumor bearing mice showed 
decreased expression of MSI-1, CD44, Nanog and Sox2 which was 
associated with reduced total and tyrosine phosphorylated STAT3. 
Application of IL-6RFP on human, metastatic DU145 cells inhibited tumor 
sphere formation as well, and was associated with Sox2 and MSI-1 down-
regulation. 
 Combining IL-6RFP and an anti-androgen bicalutamide resulted in 
improved tumor growth delay relative to monotherapies including IL-6RFP 
or bicalutamide. Increased apoptosis, and reduced proliferation and CSC 
marker expression was observed upon IL-6RFP and IL-6RFP/bicalutamide 
treatment. Similar to flutamide, bicalutamide application resulted in 
increased proliferation and anti-apoptosis accompanied by elevated levels 
of CSC marker expression. 
 Gene-silencing of STAT3 in TC1 cells resulted in decreased proliferation 
and increased apoptosis of tumor bearing mice. The neo-vascularization 
was impaired upon knock-down of STAT3 as well. This was associated 
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with decreased mRNA levels of HIF1α, FGF1 and FGF2. MMP2 and 
MMP9, which are involved in metastatic processes, were down-regulated 
in STAT3 silenced cells as well. To support the impact of STAT3 on 
angiogenic and metastatic processes TC1 cells stably expressing 
STAT3α-YFP or STAT3β-YFP were developed. Overexpressed STAT3β-
YFP diminished tube-formation of endothelial prostate cancer cells and 
reduced tumor growth considerably, which was associated with no 
detectable vascularization. Moreover, STAT3β-YFP decreased STAT3α-
YFP induced expression of MMP2 and MMP9, repressed migration and 
the expression of adhesion molecules such as integrin β1, CD44 and 
Galectin3. Finally, STAT3β-YFP reduced infiltration and colony formation 
of murine prostate cancer cells in a time-dependent manner. 
 Similar to recurring prostate cancer upon hormone ablation therapy and 
tumor cells silenced for AR, metastatic TC2 cells revealed decreased AR 
expression, but elevated levels of phosphorylated STAT3. Mice injected 
with TC2 cells showed considerable enhanced tumor growth, which 
correlated with increased proliferation as compared to TC1 tumor 
development. Moreover, the expression of CSC indicating markers was 
elevated in advanced TC2 tumor sections stained for MSI-1 and Sox2.  
 
In summary, it was found that down-regulation of AR mediates activation of 
STAT3 signaling through increasing IL-6 expression, which coincided with 
increased CSC phenotype development, and that the IL-6RFP is a potential 
therapeutical agent for prostate cancer to reduce tumor growth and to prevent 
recurring prostate cancer by targeting the CSC population.    
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6 Future Directions 
 
In this study, the importance of the IL-6/STAT3 signaling pathway in prostate 
cancer development was determined and treatment using the IL-6 receptor 
fusion protein was successful to reduce tumor growth and CSC development.  
Since the TC1 tumor model does not represent the heterogeneity of tumor cells 
in human patients, it would be preferable to include more tumor models to 
confirm general validity of the shown critical role of IL-6 induced STAT3 signal 
transduction in prostate cancer. As such, DU145 and PC-3 cells might be 
appropriate tumor models, as they show high STAT3 activity and are of human 
origin. Usage of DU145 and PC-3 cells in a xenograft model would strengthen 
the hypothesis developed in this study, due to their improved clinical relevance. 
In addition, the usage of primary prostate cancer cells derived from human 
patients might be preferable as well.  
To generate a clinical study using the IL-6 receptor fusion protein, it seems 
necessary to purify the IL-6RFP. Purified IL-6RFP would give the advantage to 
adjust concentrations and avoid unwanted side-effects potentially induced by 
conditioned medium of HekIL-6RFP cells. In this context, it might be preferable to 
improve the stability of the IL-6RFP. Modifications of the IL-6RFP C-terminus such 
as the fusion to peptide IG might be an approach to improve protein stability. If 
inhibitors reveal high stability and pharmacokinetic it might be necessary to 
evaluate the organ distribution of the IL-6RFP upon continuous treatment to avoid 
undesired side-effects. Therefore, the occurrence of IL-6RFP in liver and kidney 
as possible organs for degradation or secretion of the IL-6RFP needs to be 
determined.  
Moreover, it might be possible to expand the application of the IL-6RFP on other 
tumorigenic diseases. Solid tumors i.e. breast, brain and ovarian cancer have 
been shown to secrete high levels of IL-6. Multiple myeloma is highly IL-6 
dependent and might be therefore a promising cancer model for IL-6RFP therapy. 
Since many tumors are not strictly IL-6 dependent, STAT3 might get activated by 
other tyrosine kinases such as the EGFR or Src kinases as well. Considering the 
complexity of cancer therapy a mono-therapy might not be sufficient to reject 
tumors. Mono-therapy targeting STAT3 might still result in CSC survival followed 
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by recurring tumor growth due to other signaling pathways compensating for 
inhibition of STAT3. Therefore, it might be considerable to investigate a 
combined therapy (poly-therapy) including the IL-6RFP and i.e. tyrosine kinase 
inhibitors (TKIs). Dasatinib might be a good candidate, as it predominantly 
inhibits the Src kinase which is up-regulated in several tumors such as prostate 
and breast cancer [228].  
Furthermore, it might be interesting to evaluate whether the de-differentiation of 
cancer cells to CSCs as well as the differentiation of CSCs to tumor cell subsets 
with changed phenotypes is a STAT3 dependent process. In order to further 
investigate the role of STAT3 in CSC phenotype development, it might be 
interesting to determine cellular mechanisms involving the crosstalk between 
constitutive active STAT3 and up-regulated CSC indicating markers. So far, it 
has been shown, that HA (hyaluronic acid) which is probably secreted by 
endothelial cells, binds to CD44. Activation of CD44 promotes STAT3-Nanog 
interaction which leads to nuclear translocation of the interaction partners. In the 
nucleus, the transcription factors induce gene expression which results in the 
maintenance of pluripotent CSCs. It has been suggested, that STAT3 does not 
induce Nanog, but they may have common targets [229]. Moreover, STAT3 has 
been shown to induce Sox2 to regulate differentiation processes [230]. On the 
other hand, a STAT3 dependent crosstalk and regulation of other CSC indicating 
markers such as integrin α2β1 and Musashi-1 remains unclear. 
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7 Abbreviations 
 
A 
A     adenosine 
Aa     amino acid 
Abl     Abelson leukemia protein 
AF     AlexaFluor 
α2M     α2macroglobuline 
AKT     proteinkinase B 
ALDH-1    aldehyde dehydrogenase 1 
AIPC     androgen independent prostate cancer  
APC     allophycocyanin 
APRF     acute phase response factor 
APS      ammoniumperoxodisulfat 
AR     androgen receptor 
ARA     androgen receptor activator 
ARE     androgen responsive element 
ATP     adenosine triphosphate   
 
B 
Bcl-2     B-cell-lymphoma 2 
Bcl-xL     B-cell-lymphoma protein-xL 
BCR-Abl  fusion of the breakpoint cluster region (BCR) 
and Abl 
BSA bovine serum albumine 
 
C 
C     cytosine 
C-terminal     carboxy-terminal 
CBP      CREB binding protein 
CD31 (PECAM-1)   Platelet Endothelial Cell Adhesion Molecule 1 
CIS      cytokine-inducible SH2-containing protein 
CM     conditioned medium 
CML      chronic myeloid leukemia 
CMTMR    Orange-fluorescent tetramethylrhodamine 
CNTF     ciliary neurotrophic factor 
CR     cytokine receptor 
CRP     c reactive proteine 
CSC     cancer stem cell 
CT-1      cardiotrophin 1 
Ctrl     control 
Cy      cyanine-dye 
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D 
ddH20     double distilled water 
DHT     5α-dihydrotestosterone 
DIC     differential interference contrast 
DMEM    Dulbeccos modified Eagle medium 
DMSO    dimethylsulfoxide 
DNA      deoxyribonucleic acid 
dNTP      deoxyribonucleoside triphosphate 
dsRed     discosoma spec red fluorescent protein  
DSS     disuccinimidyl suberate 
DTSSP    3,3´-dithiobis[sulfosuccinimidylpropionate] 
DTT      dithiotreitol 
 
E 
ECL      enhanced chemiluminescence 
ECM     extracellular matrix 
EDTA     ethylendiaminetetraacetate 
EGF      epidermal growth factor 
EPO     erythropoietin 
EtOH     ethanol 
 
F 
F      phenylalanine 
FACS     fluorescent activated cell sorter 
FBS      fetal bovine serum 
FGF     fibroblast growth factor 
FRT      flp recombination target sequence 
FSC     forward scatter 
 
G 
G     guanosine 
G-CSF     granulocyte colony stimulating factor 
GAPDH     glycerinaldehyde-3-phosphate-dehydrogenase 
GAS      ×-interferone activated sequence 
GFP      green fluorescent protein 
GF      growth factor 
GFR     growth factor receptor 
GM-CSF  granulocyte macrophage colony stimulationg 
factor 
GnRH gonadotropin releasing hormone 
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H 
h      hour 
HBSS     hank’s balanced salt solution 
HDAC     histone deacetylase 
HIF1α     hypoxia inducible factor 1α 
HGF     hepatocyte growth factor 
HRP      horseradish peroxidase 
HRPC     hormone refractory prostate cancer 
HSP     heat shock protein 
HTLV-1    human T-lymphotrophic virus-1 
 
I 
IgG      immunoglobulin of the subclass G 
IF      immunofluorescence 
IFN      interferon 
IL      interleukin 
IL-R     interleukin-receptor 
IGF      insulin growth factor 
i.p.     intraperitoneal 
iPSC     inducible pluripotent stem cell 
i.v.     intravenous 
IVMPM    intra-vital multiphoton microscopy 
ISG      interferon-stimulated gene 
 
J 
JAK      Janus Kinase 
 
K 
kDa      kilo Dalton 
KGF     keratinocyte growth factor 
 
L 
LB      lysogeny broth 
LIF      leukemia inhibitory factor 
LSM     laser scanning microscope  
 
M 
MAPK     mitogen-activated protein-kinase 
MEF      murine embryonic fibroblasts 
MFI     mean fluorescence intensity 
MFib     murine fibrosarcoma cells 
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min      minute 
mm     millimeters 
MMP     matrix metalloprotein 
MUC-1    mucin 1 
MSI-1     musashi-1 
 
N 
N-terminal     amino-terminal 
NFB  nuclear factor kappa-light-chain-enhancer of 
activated B-cells 
 
O 
OD      optical density 
o.n.     over night 
OSM      oncostatin M 
 
P 
p53      tumor-suppressor 53 
PAGE     polyacrylamide-gel electrophoresis 
PAP     prostate specific acid phosphatase 
PARP     poly (ADP-ribose) polymerase 
PBS      phosphate buffered saline 
PBS-T    phosphate buffered saline/Tween-20 
PCa     prostate cancer 
PCR      polymerase chain reaction 
PDGF     platelet-derived growth factor 
PI3K      phosphatidylinositol-3-kinase 
PIAS      protein inhibitor of activated STAT 
PIN     prostatic intraepithelial neoplasia 
PMSF     phenylmethylsulfonylfluoride 
PSA     prostate specific antigen 
PVDF     polyvinylide-difluoride 
 
Q 
Q     glutamine 
 
R 
R     arginine 
R1881    synthetic testosterone 
Rag-1     recombination activating gene 
Rb     retinoblastoma protein 
RFP     receptor fusion protein 
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RIPA      radioimmune precipitation assay 
RNA      ribonucleic acid 
RNAi     RNA interference 
mRNA     messenger RNA 
shRNA    short hairpin RNA 
siRNA     small interfering RNA 
rpm      rounds per minute 
RPMI     roswell park memorial institute 
RT      room temperature 
RTK     receptor tyrosine kinase 
qRT-PCR     quantitative real-time-PCR 
 
S 
s      second 
S      serine 
s.c.     subcutaneous 
SDS      sodium-dodecylsulfate 
SH     src-homology  
SOCS     suppressors of cytokine signaling 
Src      rous sarcoma virus 
SRC     steroid receptor coactivator 
SSC     side scatter 
STAT      signal transducer and activator of transcription 
 
T 
T     thymidine 
TAE      tris-acetate/EDTA 
TCM     tumor conditioned medium 
TEMED     N, N, N’, N’-Tetramethylethylenediamine 
TGF     transforming growth  factor 
TKI     tyrosine kinase inhibitor 
TPO      thrombopoietin 
Tris      tris hydroxymethyl aminomethane 
 
U 
U      unit 
 
V 
VEGF     vascular endothelial growth factor 
v-Src      viral sarcoma kinase 
 
Abbreviations 
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W 
wt      wildtype 
 
X 
X      random amino acid 
 
Y 
Y      tyrosine 
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